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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease 
characterised by degeneration of the upper and lower motor neurons. Cognitive 
impairment in ALS is common and as such ALS and frontotemporal dementia 
(FTD) now constitute a spectrum of disorders ranging from pure ALS through to 
pure FTD. The hallmark of these diseases is the presence of neuronal 
cytoplasmic inclusions immunoreactive for a range of cellular proteins, 
suggesting defective protein clearance may contribute to disease. Indeed, 
damage to the cellular degradation pathway of autophagy, and disrupted protein 
clearance, is a potential causative mechanism in many familial inherited cases 
of ALS.  
 
The most common genetic cause of ALS and FTD is a hexanucleotide repeat 
expansion of GGGGCC within the first intron of C9orf72. How this repeat 
expansion causes disease is unknown but it has been shown to correlate with 
reduced expression of C9orf72. Thus, loss of functional C9orf72 protein could 
contribute to disease pathogenesis. As C9orf72 codes for two conserved, but 
uncharacterised, protein isoforms this thesis set out to investigate the cellular 
function of C9orf72. C9orf72 was found to interact with FIP200, ULK1 and 
ATG13, all of which are members of the autophagy initiation complex. In line 
with this, C9orf72 protein levels were found to modulate autophagy initiation by 
regulating Rab1a dependent trafficking of the ULK1 autophagy initiation 
complex. Knockdown of C9orf72 by targeted siRNA resulted in defective 
autophagy initiation, which led to the accumulation of p62, similar to the 
inclusion pathology specifically associated with C9orf72 ALS/FTD. Furthermore, 
iNeurons derived from C9orf72 ALS/FTD patient induced neural progenitor cells 
were shown to have a basal autophagy deficit, which correlated with reduced 
expression of C9orf72.  
 
Thus haploinsufficiency of C9orf72, leading to reduced C9orf72 protein levels 
and defective autophagy, could lead to the accumulation of protein aggregates, 
such as p62, and the development of ALS/FTD. This thesis has therefore 
identified a possible cellular mechanism by which reduced levels of C9orf72 




I am indebted to a number of people who have helped me throughout the 
preparation of this thesis. Firstly I would like to thank my parents and family for 
all their support and encouragement, especially my elder brothers, whose 
appreciation and experience of the lab and research process has been 
priceless. 
 
I would like to send a huge thank you to my supervisors Dr Alexander Whitworth 
and Dr Kurt De Vos for their continual guidance and support throughout my 
project. I would like to thank Alex for giving me the opportunity to work in his lab 
prior to starting my PhD and all his help since that time. I thank Kurt for his 
unfailing optimism, encouragement and enthusiasm, which have kept me 
motivated and focussed over the past four years. I wish to extend a special 
thank you to Miss Emma Smith for her truly invaluable help with many sections 
of this thesis, and Dr Annekathrin Möller for her advice and open ear. A big 
thank you also goes to all other members of the De Vos and Grierson groups, 
as well as everyone within B10, past and present, who are too numerous to 
mention by name, for scientific discussion, friendship and support. I thank Dr 
Mathew Walsh and Dr Guillaume Hautbergue for their help and advice with in-
vitro binding assays, and Miss Monika Myszczynska and Dr Laura Ferraiuolo for 
their help with the preparation of the iNeurons. My thanks also extend beyond 
the walls of SITraN to all the friends who have given advice and support 
whenever needed. 
 
I wish to thank the Moody Endowment who funded my project and made this 
research possible, as well as Professor Dame Pamela Shaw for making this 
funding available. This thesis was also supported, in part, by funding from The 
Thierry Latran Foundation and the MRC. 
 
Finally, and last but by no means least, I thank my fiancée Emma, whose 
tolerance and understanding of late nights and weekends, as well as her 
reassurance and support, has made the whole experience so much more 
manageable. I assure you it’s all been worthwhile.  
  
 iv 
ABSTRACT	  ....................................................................................................................	  ii	  
ACKNOWLEDGEMENTS	  ..........................................................................................	  iii	  
List	  of	  Figures	  ............................................................................................................	  ix	  
List	  of	  Tables	  ..............................................................................................................	  xi	  
Abbreviations	  ..........................................................................................................	  xii	  
1	   Introduction	  .........................................................................................................	  1	  
1.1	   Motor	  Neuron	  Disease	  and	  Amyotrophic	  Lateral	  Sclerosis	  .....................	  1	  
1.2	   Clinical	  and	  pathological	  feature	  of	  ALS	  .........................................................	  2	  
1.3	   Genetics	  of	  ALS	  ........................................................................................................	  4	  
1.4	   Mechanisms	  of	  Disease	  in	  ALS	  ...........................................................................	  7	  
1.4.1	   Oxidative	  Stress	  ..............................................................................................................	  7	  
1.4.2	   Mitochondrial	  dysfunction	  ........................................................................................	  8	  
1.4.3	   Glutamate	  Excitotoxicity	  .............................................................................................	  9	  
1.4.4	   Axonal	  Transport	  Defects	  ........................................................................................	  10	  
1.4.5	   RNA	  dysregulation	  .....................................................................................................	  13	  
1.4.6	   ER	  stress	  .........................................................................................................................	  14	  
1.4.7	   Protein	  Aggregation	  ...................................................................................................	  18	  
1.5	   Protein	  Degradation	  ...........................................................................................	  20	  
1.5.1	   The	  Ubiquitin	  Proteasome	  System	  ......................................................................	  20	  
1.5.2	   Autophagy	  ......................................................................................................................	  21	  
1.5.2.1	   Initiation	  ................................................................................................................................	  25	  
1.5.2.1.1	   mTOR	  dependent	  autophagy	  ..............................................................................	  25	  
1.5.2.1.2	   mTOR	  independent	  autophagy	  ..........................................................................	  26	  
1.5.2.2	   Vesicle	  formation	  and	  elongation	  ..............................................................................	  29	  
1.5.2.3	   Defining	  the	  cargo	  .............................................................................................................	  30	  
1.5.2.4	   Maturation,	  Transport	  and	  Fusion	  ............................................................................	  30	  
1.5.2.5	   Rab	  GTPases	  and	  autophagy	  ........................................................................................	  31	  
1.6	   Dysfunctional	  autophagy	  in	  ALS	  .....................................................................	  34	  
1.6.1	   Alsin	  ..................................................................................................................................	  36	  
1.6.2	   FIG4	  ...................................................................................................................................	  36	  
1.6.3	   p62	  ....................................................................................................................................	  36	  
1.6.4	   Optineurin	  ......................................................................................................................	  37	  
1.6.5	   VCP	  ....................................................................................................................................	  37	  
1.6.6	   Ubiquilin-­‐2	  .....................................................................................................................	  38	  
 v 
1.6.7	   CHMP2B	  ..........................................................................................................................	  38	  
1.6.8	   Dynactin	  ..........................................................................................................................	  39	  
1.6.9	   TBK1	  .................................................................................................................................	  39	  
1.6.10	   SigR1	  ..............................................................................................................................	  40	  
1.6.11	   Spatacsin	  ......................................................................................................................	  40	  
1.7	   C9ORF72	  and	  ALS	  ................................................................................................	  41	  
1.7.1	   Clinical	  and	  pathological	  features	  of	  the	  C9orf72	  repeat	  expansion	  ....	  41	  
1.7.2	   Pathogenic	  Mechanisms	  in	  C9orf72	  ALS/FTD	  ...............................................	  43	  
1.7.2.1	   RNA	  toxicity	  .........................................................................................................................	  43	  
1.7.2.2	   Dipeptide	  repeat	  protein	  toxicity	  ...............................................................................	  44	  
1.7.2.3	   Haploinsufficiency	  ............................................................................................................	  46	  
1.7.3	   C9orf72	  protein	  ...........................................................................................................	  47	  
1.8	   Hypothesis	  and	  aims	  ..........................................................................................	  51	  
2	   Materials	  and	  Methods	  ..................................................................................	  52	  
2.1	   Materials	  .................................................................................................................	  52	  
2.1.1	   Stock	  Solutions	  .............................................................................................................	  52	  
2.1.2	   Microbiology	  reagents	  ..............................................................................................	  53	  
2.1.2.1	   Plasmids	  and	  vectors	  .......................................................................................................	  53	  
2.1.2.2	   Escherichia	  coli	  growth	  media	  .....................................................................................	  55	  
2.1.2.3	   Reagents	  for	  preparation	  and	  purification	  of	  plasmid	  DNA	  ...........................	  55	  
2.1.2.4	   Reagents	  for	  cloning	  of	  FIP200	  fragments,	  C9orf72S,	  C9orf72L	  and	  
C9orf72L	  K14R	  ......................................................................................................................................	  56	  
2.1.2.4.1	   Primers	  for	  PCR	  generation	  of	  FIP200	  fragments,	  C9orf72S,	  C9orf72L	  
and	  C9orf72L	  K14R	  ........................................................................................................................	  56	  
2.1.2.4.2	   PCR	  amplification	  ....................................................................................................	  57	  
2.1.2.4.3	   Reagents	  for	  cloning	  into	  pCRTM-­‐Blunt	  II-­‐TOPO	  vector	  ..........................	  58	  
2.1.2.4.4	   Reagents	  for	  Transformation	  of	  XL10-­‐Gold	  ultracompetent	  cells	  .....	  58	  
2.1.2.4.5	   Reagents	  for	  restriction	  digest	  of	  DNA	  ...........................................................	  58	  
2.1.2.4.6	   Reagents	  for	  agarose	  gel	  electrophoresis	  .....................................................	  58	  
2.1.2.4.7	   Reagents	  for	  gel	  extraction	  of	  restriction	  digested	  DNA	  ........................	  59	  
2.1.2.4.8	   Reagents	  for	  de-­‐phosphorylation	  of	  linearized	  DNA	  vectors	  ...............	  59	  
2.1.2.4.9	   Reagents	  for	  ligation	  of	  DNA	  vectors	  and	  inserts	  ......................................	  59	  
2.1.2.4.10	   Reagents	  for	  the	  transformation	  of	  Rosetta	  pLysS	  competent	  cells	  59	  
2.1.2.4.11	   Reagents	  for	  bacterial	  production	  of	  GST-­‐tagged	  proteins	  ................	  60	  
2.1.3	   Mammalian	  cell	  culture	  and	  transfection	  .........................................................	  60	  
2.1.3.1	   HeLa	  and	  Human	  embryonic	  kidney	  (HEK)	  293	  cell	  culture	  reagents	  ......	  60	  
2.1.3.2	   Lipofectamine	  2000	  transfection	  reagents	  ............................................................	  60	  
2.1.3.3	   Lipofectamine	  RNAiMax	  siRNA	  transfection	  reagent	  .......................................	  60	  
 vi 
2.1.4	   General	  biochemical	  reagents	  ...............................................................................	  61	  
2.1.4.1	   Cell	  lysis	  buffer	  ...................................................................................................................	  61	  
2.1.4.2	   Bradford	  reagents	  .............................................................................................................	  61	  
2.1.4.3	   Immunoprecipitation	  ......................................................................................................	  61	  
2.1.4.4	   In	  vitro	  binding	  assays	  ....................................................................................................	  61	  
2.1.4.5	   SDS-­‐PAGE	  and	  Immunoblotting	  ..................................................................................	  62	  
2.1.4.5.1	   SDS-­‐polyacrylamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  .............................	  62	  
2.1.4.5.2	   Immunoblotting	  of	  proteins	  onto	  nitrocellulose	  membranes	  .............	  63	  
2.1.4.5.3	   Probing	  of	  nitrocellulose	  membranes	  with	  antibodies	  ...........................	  63	  
2.1.4.6	   RNA	  extraction	  and	  reverse-­‐transcription	  quantitative	  PCR	  (RT-­‐qPCR)	  .	  65	  
2.1.4.6.1	   RNA	  extraction	  ..........................................................................................................	  65	  
2.1.4.6.2	   cDNA	  preparation	  and	  RT-­‐qPCR	  .......................................................................	  65	  
2.1.5	   Microscopy	  ....................................................................................................................	  65	  
2.1.5.1	   Immunofluorescence	  .......................................................................................................	  65	  
2.1.5.2	   Proximity	  Ligation	  Assay	  (PLA)	  ..................................................................................	  66	  
2.1.6	   Drug	  treatments	  ..........................................................................................................	  66	  
2.1.6.1	   Autophagy	  induction	  .......................................................................................................	  66	  
2.1.6.2	   Autophagy	  inhibition	  .......................................................................................................	  66	  
2.1.6.3	   Proteasome	  inhibition	  ....................................................................................................	  66	  
2.1.6.4	   Inhibition	  of	  protein	  translation	  .................................................................................	  67	  
2.2	   Methods	  ..................................................................................................................	  67	  
2.2.1	   General	  molecular	  biology	  methods	  ...................................................................	  67	  
2.2.1.1	   Growth	  and	  storage	  of	  E.coli	  for	  plasmid	  DNA	  preparation	  ...........................	  67	  
2.2.1.2	   Plasmid	  DNA	  purification	  ..............................................................................................	  67	  
2.2.1.3	   Quantification	  of	  plasmid	  DNA	  ....................................................................................	  67	  
2.2.1.4	   Restriction	  enzyme	  digest	  of	  DNA	  .............................................................................	  68	  
2.2.1.5	   Agarose	  gel	  electrophoresis	  of	  DNA	  ..........................................................................	  68	  
2.2.1.6	   Cloning	  of	  FIP200	  fragments,	  C9orf72	  and	  C9orf72	  K14R	  .............................	  68	  
2.2.1.6.1	   PCR	  generation	  of	  FIP200	  fragments,	  C9orf72S,	  C9orf72L	  and	  
C9orf72L	  K14R	  .................................................................................................................................	  68	  
2.2.1.6.2	   Sub	  cloning	  into	  pCRTM-­‐Blunt	  II	  TOPO	  vector	  .............................................	  69	  
2.2.1.6.3	   Transformation	  of	  XL10-­‐Gold®	  ultracompetent	  cells	  ............................	  70	  
2.2.1.6.4	   Screening	  of	  bacterial	  colonies	  ..........................................................................	  70	  
2.2.1.6.5	   Restriction	  digest	  and	  agarose	  gel	  extraction	  of	  inserts	  and	  vector	  .	  70	  
2.2.1.6.6	   De-­‐phosphorylation	  of	  linearized	  vectors	  ....................................................	  72	  
2.2.1.6.7	   Ligation	  of	  purified	  inserts	  and	  linearized	  vectors	  ...................................	  72	  
2.2.1.6.8	   Transformation	  of	  Rosetta	  pLysS	  cells	  with	  ................................................	  73	  
2.2.1.6.9	   Bacterial	  production	  of	  GST-­‐tagged	  proteins	  ..............................................	  73	  
2.2.2	   Mammalian	  cell	  culture	  and	  transfection	  .........................................................	  74	  
 vii 
2.2.2.1	   HeLa	  and	  HEK293	  cell	  culture	  .....................................................................................	  74	  
2.2.2.2	   Induced	  Neural	  Progenitor	  Cell	  (iNPC)	  production	  and	  neuronal	  
differentiation	  ........................................................................................................................................	  74	  
2.2.2.3	   Transient	  transfection	  of	  HeLa	  and	  HEK293	  cells	  with	  plasmid	  DNA	  .......	  75	  
2.2.2.4	   siRNA	  transfection	  of	  HeLa	  and	  HEK293	  cells	  .....................................................	  76	  
2.2.3	   General	  Biochemical	  methods	  ...............................................................................	  77	  
2.2.3.1	   Cell	  lysis	  .................................................................................................................................	  77	  
2.2.3.2	   Bradford	  Assay	  ...................................................................................................................	  77	  
2.2.3.3	   Immunoprecipitation	  ......................................................................................................	  78	  
2.2.3.4	   In	  vitro	  binding	  assays	  ....................................................................................................	  78	  
2.2.3.5	   SDS-­‐PAGE	  and	  Immunoblot	  ..........................................................................................	  79	  
2.2.3.5.1	   SDS-­‐PAGE	  ....................................................................................................................	  79	  
2.2.3.5.2	   Coomassie	  staining	  of	  polyacrylamide	  gels	  ..................................................	  80	  
2.2.3.5.3	   Transfer	  of	  proteins	  to	  nitrocellulose	  membranes	  ...................................	  80	  
2.2.3.5.4	   Antibody	  probing	  of	  nitrocellulose	  membranes	  ........................................	  80	  
2.2.3.5.5	   Densitometry	  of	  bands	  ..........................................................................................	  81	  
2.2.3.6	   Modulation	  of	  autophagy	  ...............................................................................................	  81	  
2.2.3.7	   Inhibition	  of	  protein	  translation	  .................................................................................	  81	  
2.2.3.8	   RNA	  extraction	  and	  RT-­‐qPCR	  .......................................................................................	  82	  
2.2.3.8.1	   RNA	  extraction	  ..........................................................................................................	  82	  
2.2.3.8.2	   RT-­‐qPCR	  .......................................................................................................................	  82	  
2.2.4	   Microscopy	  ....................................................................................................................	  83	  
2.2.4.1	   Immunofluorescence	  .......................................................................................................	  83	  
2.2.4.2	   Proximity	  Ligation	  Assay	  ...............................................................................................	  83	  
2.2.4.3	   Image	  Analysis	  ....................................................................................................................	  84	  
2.2.5	   Statistical	  analysis	  ......................................................................................................	  84	  
3	   Identification	  of	  C9orf72	  binding	  partners	  ............................................	  85	  
3.1	   Introduction	  ..........................................................................................................	  85	  
3.2	   Results	  .....................................................................................................................	  86	  
3.2.1	   Characterization	  of	  C9orf72	  antibodies	  and	  siRNA	  .....................................	  86	  
3.2.2	   C9orf72	  interacts	  FIP200	  ........................................................................................	  96	  
3.2.3	   C9orf72	  interacts	  with	  ULK1	  ...............................................................................	  103	  
3.2.4	   C9orf72	  interacts	  with	  ATG13	  ............................................................................	  108	  
3.2.5	   Unbiased	  mass	  spec	  identification	  of	  C9orf72	  binding	  partners	  .........	  113	  
3.2.6	   Unbiased	  Y2H	  screen	  ..............................................................................................	  119	  
3.2.7	   C9orf72	  interacts	  with	  Cox6C	  .............................................................................	  122	  
3.2.8	   C9orf72	  does	  not	  interact	  with	  OAT	  .................................................................	  126	  
3.2.9	   C9orf72	  interacts	  with	  Synapsin	  III	  ..................................................................	  129	  
 viii 
3.3	   Discussion	  ............................................................................................................	  133	  
4	   C9orf72	  regulates	  the	  initiation	  of	  autophagy	  ....................................	  137	  
4.1	   Introduction	  ........................................................................................................	  137	  
4.2	   Results	  ...................................................................................................................	  137	  
4.2.1	   Loss	  of	  C9orf72	  disrupts	  the	  initiation	  of	  autophagy	  ...............................	  137	  
4.2.2	   C9orf72	  over	  expression	  induces	  autophagy	  ...............................................	  143	  
4.2.3	   C9orf72	  induces	  autophagy	  via	  the	  ULK1	  initiation	  complex	  ...............	  147	  
4.2.4	   Loss	  of	  C9orf72	  does	  not	  affect	  ULK1	  activation	  ........................................	  150	  
4.2.5	   C9orf72	  regulates	  translocation	  of	  the	  ULK1	  initiation	  complex	  to	  the	  
phagophore	  via	  Rab1a	  ...........................................................................................................	  152	  
4.2.6	   C9orf72	  interacts	  with	  Rab1a	  .............................................................................	  158	  
4.2.7	   C9orf72	  mediates	  the	  interaction	  between	  Rab1a	  and	  the	  ULK1	  
initiation	  complex	  ....................................................................................................................	  161	  
4.2.8	   C9orf72	  depletion	  induces	  p62	  accumulation	  .............................................	  167	  
4.2.9	   C9orf72	  ALS/FTD	  patient	  derived	  iNeurons	  show	  defective	  autophagy
	   169	  
4.3	   Discussion	  ............................................................................................................	  172	  
5	   C9orf72	  turnover	  and	  stability	  .................................................................	  177	  
5.1	   Introduction	  ........................................................................................................	  177	  
5.2	   Results	  ...................................................................................................................	  177	  
5.2.1.	   Determination	  of	  the	  half-­‐life	  of	  C9orf72	  ......................................................	  177	  
5.2.2.	   C9orf72	  is	  a	  substrate	  of	  the	  proteasome	  .....................................................	  181	  
5.2.3.	   Mutation	  of	  Lysine	  14	  extends	  the	  half-­‐life	  of	  C9orf72L	  ........................	  184	  
5.2.4.	   C9orf72	  interacts	  with	  USP8	  ..............................................................................	  190	  
5.2.5.	   USP8	  extends	  the	  half-­‐life	  of	  C9orf72L	  ..........................................................	  192	  
5.3.	   Discussion	  ...........................................................................................................	  197	  
6	   Discussion	  ........................................................................................................	  200	  
6.1	   Summary	  ..............................................................................................................	  200	  
6.2	   Defective	  autophagy	  and	  ALS/FTD	  ..............................................................	  201	  
6.3	   Consequences	  for	  the	  treatment	  of	  ALS/FTD	  ...........................................	  211	  
6.4	   C9orf72	  as	  an	  effector	  of	  Rab	  biology	  .........................................................	  212	  
6.5	   C9orf72	  and	  mitophagy	  ...................................................................................	  216	  
6.6	   Future	  directions	  ...............................................................................................	  218	  
7	   References	  .......................................................................................................	  222	  
 ix 
List	  of	  Figures	  


































The Unfolded Protein Response…………………………….. 
Micro, Macro and Chaperone Mediated Autophagy............. 
Macroautophagy……………………………………………….. 
mTOR dependent and mTOR independent autophagy…… 
Autophagy and ALS…………………………………………… 
C9orf72 transcriptional variants……………………………… 
The predicted DENN-like domains of C9orf72……………… 
Commercial anti-C9orf72 antibodies detect transfected 
epitope tagged C9orf72 on immunoblot…………………….. 
Anti-C9orf72 HPA023873 is able to detect endogenous 
C9orf72…………………………………………………………. 
Commercial anti-C9orf72 antibodies detect transfected 
epitope tagged C9orf72 in immunofluorescence…………… 
Commercial antibodies do not detect endogenous C9orf72 
in immunofluorescence……………………………………….. 
C9orf72 interacts with FIP200………………………………... 
C9orf72 directly interacts with the N terminus of FIP200….. 
C9orf72 interacts with ULK1………………………………….. 
C9orf72 directly interacts with ULK1………………………… 
C9orf72 interacts with ATG13………………………………... 
C9orf72 directly interacts with ATG13………………………. 
A number of proteins specifically co-immunoprecipitate 
with C9orf72L……………………………………….………….. 
C9orf72 interacts with SMCR8……………………………….. 
The Cox6C clones identified from the Y2H screen map 
across the transmembrane domain of Cox6C……………… 
C9orf72L interacts with Cox6C………………………………. 
Mapping of the OAT clones identified from the Y2H screen 
to the OAT amino acid sequence……………………………. 
C9orf72 does not interact with OAT………………………… 
The Synapsin III clones identified from the Y2H screen 
map across the conserved C domain of Synapsin III……… 


































































Loss of C9orf72 inhibits autophagy induction………………. 
Loss of C9orf72 inhibits LC3-II formation…………………… 
C9orf72 induces EGFP-LC3-II formation……………………. 
C9orf72 induces autophagy…………………………………... 
C9orf72 induces autophagy via the ULK1 initiation 
complex…………………………………………………………. 
Loss of C9orf72 does not affect activation of ULK1……...... 
C9orf72 regulates translocation of the ULK1 complex…….. 
C9orf72 regulates translocation of the ULK1 initiation 
complex via Rab1a………………………………..…………... 
C9orf72 directly interacts with Rab1a……………………….. 
C9orf72 preferentially binds GTP-bound Rab1a…………… 
C9orf72 regulates the interaction between Rab1a and 
ULK1……………………………………………………………. 
C9orf72 is required for the Rab1a dependent induction of 
autophagy………………………………………………………. 
Loss of C9orf72 induces p62 accumulation………………… 
C9ALS/FTD patient have reduced basal autophagy………. 
Half-life of C9orf7………………………………………………. 
C9orf72S is a substrate of the proteasome……………….... 
C9orf72L is a substrate of the proteasome…………………. 
UbPred predicted ubiquitination sites of C9orf72L…………. 
Mutation of lysine 14 extends the half-life of C9orf72L……. 
C9orf72 interacts with USP8……….………………………… 
USP8 extends the half-life of C9orf72L……………………… 
USP8 extends the half-life of C9orf72S……………………... 
The role of C9orf72 in autophagy initiation…………………. 
Impact of ALS associated genes on the autophagy 
pathway…………………………………………………………. 
















































Subtypes of motor neuron disease…………………………………… 





PCR cycling parameters of Phusion High Fidelity DNA 
polymerase……………………………………………………………… 
DNA transfection with Lipofectamine 2000………………………….. 
siRNA transfection with Lipofectamine RNAiMax…………………... 
siRNA transfection with Lipofectamine 2000………………………... 
Plasmids and TnT quick-coupled transcription/translation kits……. 
Identities of the bands from C9orf72L pulldown…………………….. 
Clones identified from the Y2H screen………………………………. 





































































Amyotrophic lateral sclerosis 
ALS with frontotemporal dementia 
Adenosine monophosphate 
α-amin-3-hydroxy-5-methylisoxazole-4-propionic acid 
AMP-activated protein kinase 
Analysis of variance 
Autosomal recessive 













































Chromosome 9 open reading frame 72 gene 
C9orf72 Long isoform (481 aa) 
C9orf72 Short isoform (222) 
Lysine to arginine substitution at position 14 in C9orf72 
Calcium ion 













Excitatory amino acid transporter 
Enhanced chemiluminescence 
Ethylenediaminetetraacetic acid 
Enhanced Green Fluorescent Protein 
Ethylene glycol-bis (β-aminoethylether) N,N,N’,N’-tetraacetic 
acid 
Endoplasmic reticulum 
ER associated degradation 
Empty vector 
Familial ALS 
Focal adhesion kinase family kinase interacting protein of 200 
kDa 








GTPase activating enzyme 
Glyceraldehyde 3-phosphate dehydrogenase 
Guanosine diphosphate 
































Glutamate receptor 2 
5’-Guanylyl imidodiphosphate 
Guanosine triphosphate 
Genome wide association study 
Human embryonic kidney 293 
4-(2-hydroxyethyl)piperazine-1-ethansulphonic acid 




Induced Neural progenitor cell 
Inositol 1,4,5-triphosphate 
Inositol 1,4,5-triphosphate receptor 
Immunoprecipitation 
Induced pluripotent stem cells 
Isopropyl-1-thio-β-D-galactopyranoside 
Inositol requiring enzyme 1 
Potassium 
PIPES buffered with KOH 
Luria Bertani 
Microtubule-associated protein 1 light chain 3 
Mitochondrial associated membranes 
Motor Neuron Disease 
Messenger RNA 
Mammalian target of rapamycin 
Multivesicular body 
Nicotinamide adenine dinucleotide phosphate 
NIMA-related kinase 1 gene 
Amino terminal 
Optical density 






































Outer mitochondrial membrane 
Preautophagosomal structure 
Phosphate buffered saline 
Polymerase chain reaction 
Protein Disulphide Isomerase 
Power of hydrogen 
Phosphatidylinositol 3-kinase 
Phosphatase and tensin homologue (PTEN)-induced kinase 1 
protein 
Protein tyrosine phosphatase-interacting protein 51 
Ras-related C3 botulinum toxin substrate 1 
Repeat associated non-ATG 
Rat sarcoma 
Retinoblastoma1-induced coiled coil 1 gene 
Really interesting new gene 
Ribonucleic acid 
Ribonuclease 
Reactive oxygen species 
Relative centrifugal force 
Sporadic ALS 
Sodium dodecyl sulphate 
SDS polyacrylamide gel electrophoresis 
Standard error of mean 
Sigma-1 receptor 
Spinal muscular atrophy 
Smith-Magenis Syndrome Chromosome Region, Candidate 8 
Soluble N-ethylmaleimide-sensitive factor-attached protein 
receptor 
Single nucleotide polymorphism 

































Un-coordinated (Unc) 51-like kinase 1 
Unfolded Protein Response 
Ubiquitin proteasome system 
Ubiquitin specific protease 
Volume/volume 
Vesicle associated membrane protein 
Vesicle associated membrane protein-associated protein B 
Valosin containing protein 
Voltage dependent anion channel 
Weight/volume 
X-box-binding protein 1 
 1 
1 Introduction	  
1.1 Motor Neuron Disease and Amyotrophic Lateral 
Sclerosis 
Motor Neuron Disease (MND) is a collective term for a group of neurological 
disorders characterised by degeneration and loss of the motor neurons. The 
subtypes of MND are classified based on the involvement of the upper motor 
neurons or lower motor neurons in disease pathogenesis. Upper motor neurons 
originate in the cortex or brain stem and feed information down to the lower 
motor neurons of the spinal cord, which innervate into the muscle to bring about 
contraction and movement. The different subtypes of MND are detailed in Table 
1.1 
 
Table 1.1 Subtypes of motor neuron disease 




Amyotrophic lateral sclerosis (AL) Yes Yes 
Progressive bulbar palsy (PBP) Yes Yes 
Progressive muscular atrophy (PMA) No Yes  
Spinal muscular atrophy (SMA) No Yes  
Kennedy’s disease No Yes 
Monomelic amyotrophy No Yes 
Brachial amyotrophic diplagia No Yes 
Primary lateral sclerosis Yes No 
Hereditary spastic paraplegia (HSP) Yes No 
 
Amyotrophic Lateral Sclerosis (ALS) is the most common form of MND. ALS is a 
progressive adult onset disease characterised by selective degeneration of 
upper and lower motor neurones, leading to muscle wasting and eventual 
premature death due to respiratory failure and paralysis. The median survival for 
ALS is less than 3 years from diagnosis, but a range of factors appears to 
impact on disease duration. For example, bulbar onset, older age at diagnosis, 
poor motor function at diagnosis and increased weight loss over time are all 
related to a shorter survival (Gordon et al., 2012). 
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The incidence of ALS is approximately 2 per 100,000 people per year (Alonso et 
al., 2009; Logroscino et al., 2010), with incidence rates peaking in the 7th and 
8th decades of life (Alonso et al., 2009). Around 90% of cases are sporadic 
(SALS) with approximately 10% showing a genetic component and familial 
inheritance, termed familial ALS (FALS). The genetic loci associated with FALS 
are listed in Table 1.2, and will be discussed in more detail later. 
1.2 Clinical and pathological feature of ALS 
Sporadic and familial ALS cases are clinically indistinguishable suggesting a 
common disease mechanism. The majority of ALS cases present with upper or 
lower limb onset with aspects of upper and lower motor neuron degeneration, 
including muscle wasting and weakness (Kiernan et al., 2011). Death due to 
respiratory failure usually occurs within 2 to 5 years from diagnosis (Kiernan et 
al., 2011). Cognitive decline has also been linked to ALS, with up to 50% of 
sufferers presenting with cognitive impairment, and the most severe developing 
features of frontotemporal dementia (FTD) (Lomen-Hoerth et al., 2003; Ringholz 
et al., 2005). Indeed, some of the most common genetic causes of ALS, such as 
C9orf72 repeat expansions, which is the topic of this thesis and will be 
discussed in section 1.7, are now known to lead to FTD (Ferrari et al., 2011), 
and up to 25% of ALS patients are clinically diagnosed with FTD (Rippon et al., 
2006). This places ALS and FTD on a spectrum of disorders ranging from pure 
ALS, through ALS with behavioural impairment, ALS with FTD, FTD with motor 
neuron involvement, to finally pure FTD at the other end of the spectrum 
(Swinnen and Robberecht, 2014). 
 
In addition to motor neuron loss, the aggregation and accumulation of 
proteinaceous intraneuronal inclusions are considered a hallmark of ALS 
pathology (Wood et al., 2003). These intraneuronal inclusions are classified into 
three types: 1) ubiquitinated inclusions, 2) Bunina bodies and 3) hyaline 
conglomerate inclusions (Wood et al., 2003).  
 
Nearly all inclusions observed in ALS are positive for ubiquitinated TAR-DNA-
binding protein 43 (TDP-43), as are the accumulations found in FTD, thus 
suggesting a common mechanism for these clinically similar diseases 
(Neumann et al., 2006). These ubiquitinated inclusions (UBIs) are negative for 
proteins found in aggregates of other neurodegenerative disorders, such as tau 
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and α-synuclein, but are the most common inclusions found in both SALS and 
FALS (Wood et al., 2003). The accumulation of these aggregates is the first 
evidence suggesting that defective protein clearance and turnover may play a 
role in the pathogenesis of ALS. Aside from ubiquitin and TDP-43, the 
components of these inclusions have been shown to contain proteins known to 
be involved in the development of other rare cases of FALS, including 
Optineurin, Ubiquilin-2, Ataxin, p62 and FUS (Deng et al., 2011; Elden et al., 
2010; Maruyama et al., 2010; Teyssou et al., 2013; Vance et al., 2009). 
Although mutations to these genes are known to cause FALS, the proteins 
themselves are found as inclusion components in SALS cases, suggesting a 
possible common mechanism of disease. p62 appears to be a relatively 
common component of these intraneuronal UBIs (Arai et al., 2003; Mizuno et al., 
2006a), and is also found in inclusions of other neurodegenerative diseases 
besides ALS, including Alzheimer’s disease and tauopathies (Kuusisto et al., 
2001; Kuusisto et al., 2002). UBIs can also be categorised based on their 
morphology. They can be described as skein-like inclusions, which are 
filamentous in structure, or rounded Lewy body-like inclusions (Kato et al., 1989; 
Leigh et al., 1988; Lowe et al., 1988). 
 
Bunina bodies, originally described by Bunina in 1962 (Bunina, 1962), are 
specific to ALS and are not found in other neurodegenerative disease. They are 
eosinophilic inclusions that are negative for ubiquitin but positive for cystatin-C, 
transferrin and potentially peripherin (Mizuno et al., 2006b; Mizuno et al., 2011; 
Okamoto et al., 1993). The actual origin of Bunina bodies is unclear but they 
may originate from the endoplasmic reticulum or Golgi apparatus (Okamoto et 
al., 1993; Okamoto et al., 2008; Takahashi et al., 1991). The relevance to the 
pathogenesis of ALS is unclear but they may be a cellular response to 
proteinaceous aggregates (Okamoto et al., 2008). 
 
Hyaline conglomerate inclusions are found almost exclusively in FALS cases 
(Murayama et al., 1989). They are comprised of phosphorylated and non-
phosphorylated neurofilaments (Hays et al., 2006; Hirano et al., 1984; Munoz et 
al., 1988). Defective neurofilament transport has been reported in mouse 
models of ALS (Collard et al., 1995). Phosphorylation of neurofilament side 
arms slows their axonal transport, thus potentially leading to accumulations of 
phosphorylated neurofilament and subsequent incorporation into hyaline 
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conglomerate inclusions (Ackerley et al., 2000; Ackerley et al., 2003; Munoz et 
al., 1988). 
 
1.3 Genetics of ALS 
The majority of cases of ALS are sporadic (SALS), but approximately 5-10% of 
cases are familial (FALS) (Byrne et al., 2011). The aetiology of SALS is 
unknown and no single gene has been associated with its development 
(Schymick et al., 2007). Twin studies of SALS cases, where at least one twin 
has been diagnosed with ALS, have shown that the chance of the other 
developing ALS is approximately 61%, suggesting a genetic role in many cases 
of SALS (Al-Chalabi et al., 2010). The clinical presentation is identical between 
SALS and FALS, suggesting the possibility of common pathways leading to 
disease.  
 
A number of gene mutations have been shown to cause FALS, as detailed in 
table 1.2. The majority of FALS is autosomal dominant in inheritance but X-
linked and autosomal recessive forms have been reported (Hadano et al. 2001; 
Deng et al. 2011). The first genetic locus identified was that on chromosome 21 
(Siddique et al., 1991; Siddique et al., 1989), which was later identified as the 
SOD1 gene (Rosen et al., 1993). Over 150 mutations in SOD1 now account for 
approximately 20% of FALS cases (Abel et al., 2012), but mutations have also 
been identified in a minority of SALS cases (Jones et al., 1994).  
 
To date, the most common genetic defect associated with ALS is the GGGGCC 
hexanucleotide repeat expansion within chromosome 9 open reading frame 72 
(C9orf72) (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Prior to 2011, 
a number of genome wide association studies (GWAS) had identified a genetic 
locus on chromosome 9p21 as being associated with familial ALS or FTD 
(Boxer et al., 2011; Gijselinck et al., 2010; Le Ber et al., 2009; Morita et al., 
2006; van Es et al., 2009; Vance et al., 2006). The repeat expansion accounts 
for approximately 40% of FALS cases from white European populations, but is 
less prevalent in Hispanic and Asian populations (DeJesus-Hernandez et al., 
2011; Majounie et al., 2012; Renton et al., 2011). In a Finnish population the 
C9orf72 repeat expansion is causative for 46% of FALS (Renton et al., 2011). 
C9orf72 repeat expansions also account for approximately 5% of total SALS 
cases (DeJesus-Hernandez et al., 2011; Majounie et al., 2012; Renton et al., 
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2011). As C9orf72 is the main topic of this thesis, C9orf72 will be discussed in 
more detail in section 1.7. 
 
Along with C9orf72 and SOD1, mutations to FUS (Kwiatkowski et al., 2009; 
Vance et al., 2009) and TARDPB (Kabashi et al., 2008; Sreedharan et al., 2008) 
are the most common genetic defects associated with ALS. Mutations to FUS 
account for approximately 4% of FALS (Kwiatkowski et al., 2009; Vance et al., 
2009), while mutations to TARDBP account for approximately 4.3% of FALS 
(Millecamps et al., 2010). Tar DNA binding protein of 43 kDa (TDP-43) encoded 
by TARDBP is a nuclear RNA and DNA binding protein involved in several 
aspects of RNA metabolism, including transcriptional repression and splicing 
(Ou et al., 1995; Wang et al., 2004). FUS encodes the FUS protein, which, 
similar to TDP-43, is involved in RNA metabolism (Lagier-Tourenne et al., 
2010). Both mutated proteins are found in abnormal cytoplasmic inclusions, 
which may contribute to disease pathogenesis (Arai et al., 2006; Kwiatkowski et 
al., 2009; Vance et al., 2009). Potential mechanisms of disease associated with 
these genetic mutations will be discussed in section 1.4.  
 
The role of other genetic factors in the development of sporadic ALS is 
uncertain. Multiple genetic screens as well as GWAS have revealed a number of 
susceptibility genes and genetic variants that may contribute to the development 
of ALS (Chio et al., 2009; Gijselinck et al., 2010; Takahashi et al., 2013; van Es 
et al., 2009). However, the majority are yet to be confirmed as definitive disease 
genes. 
 
Association studies of sporadic ALS patients has identified loci on chromosome 
9p21, corresponding to C9orf72, as well as 9p13.3, corresponding to a region 
within UNC13A, as being associated with increased risk of developing ALS 
(Shatunov et al., 2010; van Es et al., 2009). Indeed, C9orf72 and UNC13A are 
considered shared risk loci for ALS and FTD, and thus UNC13A is considered a 
susceptibility gene for these diseases (Diekstra et al., 2014). UNC13A functions 
to prime presynaptic vesicles to bring about correct neurotransmitter release 
(Varoqueaux et al., 2002). Thus, defective neurotransmitter release may be 
implicated in the development of ALS and FTD (Diekstra et al., 2014).  
 
In the same study that identified TANK-binding kinase 1 (TBK1) as a definitive 
ALS gene (Cirulli et al., 2015), a number of other susceptibility genes were 
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identified. Loss of function variants within the NIMA-related kinase 1 (NEK1) 
gene was identified in a number of cases (Cirulli et al., 2015). NEK1 was shown 
to interact with other known FALS associated proteins Alsin (ALS2), a Rab5 
GTPase guanine nucleotide exchange factor, and VAPB. The role of Alsin in the 
development of ALS will be discussed in further detail in section 1.6.1, but the 
interaction of NEK1 with Alsin suggests a common pathway may be involved in 
these ALS cases. 
 
Table 1.2 FALS associated genes 
FALS 
type 
Inheritance Locus Gene Reference 
ALS1 AD 21q22.1 SOD1 (Rosen et al., 1993) 
ALS2 AR 2q33.2 ALS2 (Hadano et al., 2001a) 
ALS3 AD 18q21 Unknown (Hand et al., 2002) 
ALS4 AD 9p34 SETX (Chen et al., 2004) 
ALS5 AR 15q21.1 SPG11 (Orlacchio et al., 2010) 
ALS6 AD 16p11.2 FUS (Kwiatkowski et al., 2009; 
Vance et al., 2009) 
ALS7 AD 20p13 Unkown (Sapp et al., 2003) 
ALS8 AD 20q13.33 VAPB (Nishimura et al., 2004) 
ALS9 AD 14q11.1 ANG (Greenway et al., 2006) 
ALS10 AD 1p36.22 TARDBP (Kabashi et al., 2008; 
Sreedharan et al., 2008) 
ALS11 AD 6p21 FIG4 (Chow et al., 2009) 
ALS12 AR/AD 10p13 OPTN (Maruyama et al., 2010) 
ALS13 AD 12q23-
q24.1 
ATXN2 (Elden et al., 2010) 
ALS14 AD 9p13 VCP (Johnson et al., 2010) 
ALS15 X-linked Xp11.21 UBQLN2 (Deng et al., 2011) 
ALS16 AR/AD 9p13 SIGMAR1 (Al-Saif et al., 2011) 
ALS17 AD 3p12.1 CHMP2B (Parkinson et al., 2006) 
ALS18 AD 17p13.3 PFN1 (Wu et al., 2012) 
ALS19 AD 2q33.3-q34 ERBB4 (Takahashi et al., 2013) 
ALS20 unknown 12q13.1 HNRNPA1 (Kim et al., 2013) 
ALS21 AD 5q31.2 MATR3 (Johnson et al., 2014) 
ALS/FTD1 AD 9p21 C9ORF72 (DeJesus-Hernandez et al., 
2011; Renton et al., 2011) 
ALS AD 2p13.1 DCTN1 (Münch et al., 2004) 
ALS unknown 5q35 SQSTM1 (Fecto et al., 2011) 
ALS AD 12q14.2 TBK1 (Freischmidt et al., 2015) 
AR – autosomal recessive: AD – autosomal dominant: Data were obtained from 
ALSoD (Abel et al., 2012) 
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1.4 Mechanisms of Disease in ALS 
A number of mechanisms have been implicated in the pathogenesis of ALS. 
However, the underlying pathogenic process is incompletely understood in the 
majority of ALS cases. It is possible that a number of the proposed mechanisms 
described could contribute to disease, and unlikely that each mechanism is 
mutually exclusive. There is also evidence that the development of ALS likely 
involves other cell types aside from the motor neurons, such as astrocytes and 
microglia. 
1.4.1 Oxidative Stress 
The main form of oxidative stress in cells arises from the production of reactive 
oxygen species (ROS) during normal cellular metabolism. ROS are mainly 
produced by electron leakage across the electron transport chain leading to the 
reduction of molecular oxygen and production of hydrogen peroxide (H2O2) and 
the superoxide oxygen free radical (O2.) (Cadenas et al., 1977). 
 
Several pieces of evidence suggest oxidative stress may be involved in the 
development of ALS. Firstly, oxidative damage to protein has been found to be 
greater in post mortem spinal cord tissue of sporadic ALS patients compared to 
controls, as has the oxidation to lipids and nuclear DNA (Ferrante et al., 1997; 
Shaw et al., 1995; Shibata et al., 2001). Markers of oxidative stress are also 
elevated in urine, sera and cerebrospinal fluid (CSF) of sporadic ALS patients 
(Mitsumoto et al., 2008; Simpson et al., 2004; Smith et al., 1998). Secondly, 
mutant TDP-43, a known cause of FALS, has also been shown to cause 
oxidative stress when overexpressed in neuronal cell lines (Duan et al., 2010). 
TDP-43 pathology is a hallmark of ALS and it is therefore possible that oxidative 
stress plays a role in many forms of familial, as well as sporadic, ALS. Finally, 
the mouse model of SOD1 ALS shows enhanced oxygen free radical 
production, accompanied by Ca2+ dysregulation and mitochondrial dysfunction 
(Kruman et al., 1999). 
 
The case for the role of oxidative stress as a pathogenic mechanism is further 
strengthened by evidence suggesting that the nuclear erythroid 2-related factor 
2 (Nrf2) pathway may be dysregulated in ALS (Sarlette et al., 2008). Nrf2 is a 
transcription factor regulating the anti-oxidant response (Ma, 2013). In ALS 
spinal cord post mortem tissue, Nrf2 mRNA and protein levels were found to be 
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reduced compared to controls suggesting a dysregulation of the antioxidant 
response (Sarlette et al., 2008). 
 
Activated microglia may also be involved in ROS production in ALS. SOD1 in 
microglia has been shown to bind the GTPase Rac1, inhibiting its GTPase 
activity (Harraz et al., 2008). SOD1 normally dissociates from Rac1 in response 
to increased NADPH oxidase-dependent (Nox-dependent) O2.- production, 
leading to Nox complex inactivation. However, mutant SOD1 in microglia does 
not release Rac1 in response to increased local ROS production and so Nox 
activity is sustained, thereby increasing ROS production (Harraz et al., 2008). 
NADPH oxidase activity has been found to be upregulated in ALS patients and 
mouse models of ALS (Marden et al., 2007; Wu et al., 2006). 
1.4.2 Mitochondrial dysfunction 
There are multiple evidences for the involvement of mitochondrial dysfunction in 
the development of ALS, much of which comes from the study of mouse and 
cellular models of mutant SOD1 ALS. Firstly, mitochondrial morphology defects, 
such as mitochondrial swelling and fragmentation, are seen in both FALS and 
SALS (Menzies et al., 2002; Sasaki and Iwata, 2007; Song et al., 2013). This 
morphology defect is also seen at a pre-symptomatic stage is some mouse 
models of SOD1 ALS, suggesting an early event in the pathogenesis of disease 
(Wong et al., 1995).  
 
Secondly, while mutant SOD1 has been shown to increase oxidative stress, the 
mutant protein has also been shown to accumulate on the outer-mitochondrial 
membrane (OMM) and also in the intermembrane space (IMS) of neuronal 
mitochondria, disrupting mitochondrial biology and function by blocking protein 
import and export from these organelles (Higgins et al., 2002; Liu et al., 2004; 
Pasinelli et al., 2004; Vande Velde et al., 2008).  
 
Thirdly, perturbed energy production, as assessed by the activity of the 
respiratory chain proteins, has been reported in the spinal cord of ALS patients 
as well as SOD1 mouse models (Mattiazzi et al., 2002; Wiedemann et al., 
2002). The effects seen by the expression of mutant SOD1 may be linked to its 
interaction with the voltage-dependent anion channel 1 (VDAC1) on the OMM, 
resulting in reduced ADP import and ATP synthesis (Israelson et al., 2010). This 
could also account for disturbed calcium buffering and homeostasis in models of 
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SOD1 ALS (Damiano et al., 2006; Nguyen et al., 2009), as VDAC1 is involved in 
Ca2+ exchange between mitochondria and the ER (De Stefani et al., 2012). 
Disrupted calcium uptake by mitochondria has also been reported in VAPB 
associated ALS, suggesting a mechanism that may be involved in a wide range 
of ALS cases (De Vos et al., 2012). 
 
Finally, mutant SOD1 has been shown to aggregate the anti-apoptotic protein 
Bcl-2, thereby reducing functional Bcl-2 in neuronal cells, leading to disruption of 
the anti-apoptotic machinery (Pasinelli et al., 2004). This potential disruption to 
the anti-apoptotic machinery may be the cause of increased caspase activation 
and apoptosis in models of SOD1 ALS (Sathasivam et al., 2005) 
1.4.3 Glutamate Excitotoxicity 
Glutamate is the main neurotransmitter involved in signal transduction within the 
central nervous system. The excitatory signal from glutamate is reversed by 
efficient removal of glutamate from the synaptic cleft by a family of glutamate re-
uptake transporters, the most common of which is excitatory amino acid 
transporter 2 (EAAT2) (Danbolt, 2001). Prolonged or excessive neurotransmitter 
excitation has been implicated in neuronal injury in a process called 
excitotoxicity. Excitotoxicity can be caused by reduced removal of glutamate or 
by increased release from the pre-synaptic neuron (Fray et al., 1998; Milanese 
et al., 2011; Rothstein et al., 1992). Several observations indicate glutamate 
excitotoxicity is involved in the pathogenesis of ALS.   
 
Firstly, excitotoxicity is observed at an early and even pre-symptomatic stage of 
disease, with patients showing increased cortical hyperexcitability prior to the 
development of clinical features in SOD1 patients (Vucic et al., 2008).  
Excitotoxicity could therefore be one of the initiating factors for the development 
of ALS. In support of this, FALS patient derived induced pluripotent stem cells 
(iPSCs) are shown to have intrinsic hyperexcitability, which could account for 
the neuronal vulnerability in ALS (Wainger et al., 2014). 
 
Secondly, glutamate levels have been shown to be elevated in the cerebral 
spino fluid (CSF) of ALS patients (Fiszman et al., 2010; Spreux-Varoquaux et 
al., 2002; Yáñez et al., 2011). This may be related to the fact that EAAT2 
expression is down regulated in the spinal cord and motor cortex of ALS 
patients (Fray et al., 1998; Rothstein et al., 1992; Rothstein et al., 1995). This is 
 10 
supported by the mouse models of SOD1 ALS, which exhibit decreased EAAT2 
expression as well as increased glutamate release into the synaptic cleft 
(Boston-Howes et al., 2006; Milanese et al., 2011). 
 
α-amin-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors are a 
class of postsynaptic ionotropic glutamate receptors (Dingledine et al., 1999). 
Motor neurons appear to be particularly susceptible to AMPA receptor mediated 
excitotoxicity, possibly due to their role in calcium uptake into the postsynaptic 
neuron (Carriedo et al., 1996; King et al., 2007). The GluR2 subunit of AMPA 
receptors is the main determinant of calcium permeability of these receptors 
(Hollmann et al., 1991). GluR2 mRNA can be post-transcriptionally edited at Gln 
607 site to produce Arg 607 (the Gln/Arg site) (Melcher et al., 1996) rendering 
the receptor calcium impermeable (Hume et al., 1991). Reduced Gln/Arg editing 
of GluR2 has been reported in ALS patients (Kawahara et al., 2004; Kwak et al., 
2010; Takuma et al., 1999), which may lead to increased calcium influx in ALS 
patients and neuronal vulnerability (Takuma et al., 1999). This calcium influx 
may overload the mitochondrial calcium buffering capacity of the neurons, 
leading increased ROS production (Carriedo et al., 2000). 
 
Finally, the involvement of excitotoxicity in the development of disease is 
strengthened by the fact that the only drug proven to affect disease progression 
and increase patient lifespan is riluzole (Lacomblez et al., 1996), which has 
shown to have anti-excitotoxic effects (Bensimon et al., 1994). However, it is 
worth noting that the actual action of riluzole may extend beyond the ability to 
modulate the glutamate neurotransmitter (Cheah et al., 2010).  
1.4.4 Axonal Transport Defects 
Axonal transport involves the transport and delivery of cellular cargos from the 
cell body to the distal axon and visa versa. Transport from the cell body to the 
distal axon is termed anterograde transport and is mediated by kinesin motor 
proteins. Transport from the distal axon back towards the cell body is termed 
retrograde transport and is mediated by the motor protein cytoplasmic dynein-1. 
These motor proteins move along microtubules, with kinesins moving towards 
the plus end (the “growing” end) and cytoplasmic dynein-1 moving towards the 
minus end (Figure 1.1). Several lines of evidence implicate axonal transport 






Figure 1.1. Axonal Transport. Microtubules are polarised structures with the 
growing, plus end located at the synapse and the minus end located at the cell 
body. Kinesin motor proteins transport cargo along the microtubules in an 
anterograde fashion from the cell body to the synapse. Cytoplasmic dynein 
transports cargo in a retrograde fashion from the synapse to the cell body. 
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Firstly, mutations to the p150 subunit of dynactin are linked to ALS and FTD 
(Münch et al., 2005; Münch et al., 2004; Puls et al., 2003). Dynactin is a large 
protein complex and also a component of the cytoplasmic dynein motor protein 
(Gill et al., 1991). Mutant dynactin may disrupt the dynein/dynactin complex 
leading to reduced transport and protein aggregation (Levy et al., 2006). The 
Legs at odd angles (LOA) mutant mouse carries a missense point mutation in 
the dynein heavy chain, leading to motor neuron loss and inclusion body 
formation (Hafezparast et al., 2003), supporting the idea that disruption to 
axonal transport can lead to neurodegeneration. 
 
Secondly, neurofilaments, which are transported via slow axonal transport, 
accumulate in ALS suggesting disrupted axonal transport may promote this 
aggregate associated pathology (Ackerley et al., 2000; Ackerley et al., 2003). 
 
Evidence from the SOD1 (G93A) mouse model also implicates disruption to the 
axonal transport pathway in the pathogenesis of ALS, as anterograde 
movement of mitochondria is particularly affected in these animals (Bilsland et 
al., 2010; De Vos et al., 2007; Kieran et al., 2005; Williamson and Cleveland, 
1999). Reduced numbers of mitochondria in the distal axon could lead to a 
localised energy deficiency and degeneration (De Vos et al., 2007). However, 
others have demonstrated that axonal degeneration can occur independently of 
axonal transport defects. For example, Marinkovic et al demonstrated that the 
SOD1 (G85R) mouse model of ALS develops axonal degeneration without an 
apparent effect on transport, while over expression of wild type SOD1 in a mice 
leads to chronic transport defects but ultimately no degeneration (Marinković et 
al., 2012). These data support the idea that multiple mechanisms may contribute 
to disease, and it is unlikely that each mechanism is mutually exclusive. 
 
Disruption to axonal transport has been documented in other neurological 
diseases including hereditary spastic paraplagia (HSP) and SMA (Fallini et al., 
2011; Kasher et al., 2009; Xu et al., 2016). Mutations in spastin are the most 
common cause of HSP and have been shown to lead to reduced anterograde 
transport of mitochondria as well as amyloid precursor protein (APP) containing 
cargos (Kasher et al., 2009). In the case of SMA, reduced transport of mRNA as 
well as mitochondria has been reported as potentially pathogenic mechanisms 
(Fallini et al., 2011; Xu et al., 2016). The survival of motor neuron (SMN) protein 
appears to be involved in axonal transport of mRNA via its interactions with 
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other RNA binding proteins, linking two potential mechanisms of 
neurodegeneration: axonal transport defects and RNA dysregulation (Fallini et 
al., 2011; Saal et al., 2014) 
1.4.5 RNA dysregulation 
Mutations in several RNA homeostasis related proteins, such as senataxin, 
FUS, TDP-43 and Matrin 3, are causative for some forms of FALS, suggesting 
RNA dysregulation is involved in disease pathogenesis (Chen et al., 2004; 
Johnson et al., 2014; Kwiatkowski et al., 2009; Sreedharan et al., 2008; Vance 
et al., 2009).  
 
TDP-43 is a nuclear DNA and RNA binding protein involved in a variety of 
cellular processes including transcriptional repression and exon skipping (Ou et 
al., 1995; Wang et al., 2004). Mutations to TDP-43 lead to its aberrant 
cytoplasmic accumulation and inclusion into ubiquitinated aggregates (Arai et 
al., 2006; Kabashi et al., 2008; Neumann et al., 2006). The loss of nuclear TDP-
43 and redistribution to the cytoplasm is seen as an early event in the 
pathogenesis of ALS (Giordana et al., 2010). This mislocalisation has been 
shown to result in dysfunctional splicing in motor neurons (Highley et al., 2014). 
Whether the loss of TDP-43 function, or a gain of toxic function related to the 
cytoplasmic aggregates, is the underlying causes of ALS is unknown. 
 
Crosslinking and immunoprecipitation (iCLIP) has revealed some of the RNA 
binding targets of TDP-43, which comprise a number of ALS related genes, 
including FUS and TDP-43 itself (Sephton et al., 2011; Tollervey et al., 2011). 
TDP-43 also interacts with the other FALS related protein Matrin 3 (Johnson et 
al., 2014; Salton et al., 2011). Thus loss of nuclear TDP-43 may therefore 
impact on other ALS associated genes, supporting a loss of function 
mechanism. 
 
FUS related ALS is characterised by ubiquitinated inclusions of FUS, which are 
negative for TDP-43 (Kwiatkowski et al., 2009; Vance et al., 2009). FUS is 
normally localised to the nucleus and is involved in a range of RNA processing 
activities including transcriptional regulation, splicing and RNA translocation 
(Belly et al., 2005; Fujii et al., 2005; Meissner et al., 2003; Uranishi et al., 2001; 
Wang et al., 2008; Zinszner et al., 1997). ALS associated FUS mutations lead to 
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global alterations to splicing, similar to the effect FUS depletion (Sun et al., 
2015). Thus, FUS loss of function may contribute to ALS pathogenesis. 
 
TDP-43 and FUS may also be involved in RNA stress granule formation 
(Andersson et al., 2008; Colombrita et al., 2009; Dormann et al., 2010). Stress 
granules are cytoplasmic sites of stalled mRNA translation in response to stress, 
leading to the accumulation of mRNA, RNA binding proteins and translational 
initiation components (Buchan and Parker, 2009). Mutant TDP-43 and FUS 
readily accumulate in stress granules (Baron et al., 2013; Walker et al., 2013), 
thus supporting a toxic gain of function of both mutant proteins. 
1.4.6 ER stress 
To maintain cellular homeostasis, cells monitor stress levels through a range of 
sensors and respond via a number of inducible pathways that rectify the 
imbalance. Accumulation of mis or unfolded protein in the ER lumen induces ER 
stress and the unfolded protein response (UPR) detailed in Figure 1.2 (for 
review see (Hetz, 2012)).  The UPR seeks to rebalance protein homeostasis in 
a number of ways. Firstly, further protein translation is inhibited helping to 
reduce the burden on the ER, while an upregulation of molecular chaperones 
helps to aid correct folding of the already translated proteins. Secondly, the main 
cellular degradation pathways of ER associated degradation (ERAD) are 
upregulated to further remove the burden of the unfolded proteins. Finally, 






Figure 1.2. The Unfolded Protein Response (UPR). ER stress causes Inositol-
requiring protein 1α (IRE1α) dimerization. Dimerization activates its intrinsic 
RNAse activity, which allows splicing of the XBP1 mRNA to produce a function 
XBP1 transcription factor. XBP1 increase expression of genes related to protein 
folding and ERAD. Protein kinase RNA-like ER kinase (PERK) dimerization 
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leads to phosphorylation of the eukaryotic initiation factor eIF2α, inhibiting 
general protein synthesis. Inhibition of general translation allows the translation 
of the ATF4 transcription factor. ATF4 increases expression of genes related to 
autophagy and apoptosis. Upon ER stress ATF6 translocates from the ER to the 
Golgi where it is processed by two proteases, Site 1 protease (S1P) and Site 2 
protease (S2P). Proteolytic cleavage produces a cytosolic fragment of ATF6, 
which is a functional transcription factor. ATF6 leads to expression of genes 
related to ERAD but also XBP1, thus promoting the UPR. 
  
 17 
Evidence for ER stress in ALS is firstly supported by the fact that all three 
sensors of UPR (IRE1, PERK and ATF6) are elevated in the CSF and spinal 
cord of SALS patients (Atkin et al., 2008). Similarly, increased levels of UPR 
related chaperone proteins, such as the protein disulphide isomerase (PDI) 
family, are up-regulated in SALS patients and the G93A SOD1 mouse model 
(Atkin et al., 2006; Atkin et al., 2008). UPR activation is evident as early as 
postnatal day 5 in the G93A SOD1 mouse model, indicating an early event in 
pathogenesis (Saxena et al., 2009). Elevated levels of activated caspase-12 
have also been reported in the SOD1 mouse model, suggesting prolonged UPR 
activation and apoptosis is a possible cause of motor neurodegeneration in 
these mice (Atkin et al., 2006; Wootz et al., 2004). 
 
Secondly, mutations in VAPB are causative for ALS (Nishimura et al., 2004). 
VAPB is an integral ER protein and has been implicated in UPR activation 
(Gkogkas et al., 2008; Kanekura et al., 2006). Several investigations have 
reported that the P56S mutation in VAPB, which leads to ALS, induces ER 
stress by hampering efficient UPR activation (Chen et al., 2010; Gkogkas et al., 
2008; Kanekura et al., 2006; Suzuki et al., 2009). This is potentially due to the 
P56S mutant recruiting wild type VAPB into cytoplasmic aggregates, leading to 
its loss of function in UPR activation (Suzuki et al., 2009). VAPB also interacts 
with the outer mitochondrial membrane (OMM) protein PTPIP51 at 
mitochondrial associated membrane (MAM) sites (De Vos et al., 2012; Stoica et 
al., 2014). ER-mitochondrial contacts at MAM are essential to maintain calcium 
homeostasis. The P56S mutant has been shown to enhance the interaction with 
PTPIP51 leading to disrupted calcium homeostasis and elevated calcium levels, 
in turn disrupting anterograde axonal transport of mitochondria (De Vos et al., 
2012; Morotz et al., 2012). Thus, mutations in VAPB provide evidence of links 
between multiple pathogenic mechanisms associated with ALS, namely 
mitochondrial dysfunction, disrupted axonal transport and ER stress. 
 
Finally, TDP-43 also appears to be linked to ER stress. The 
hyperphosphorylated ubiquitinated TDP-43 aggregates are generated from 
cleavage of the full-length protein to leave possibly pathogenic C-terminal 
fragments (Arai et al., 2006; Neumann et al., 2006). In a motor neuron like cell 
line, chemical induction of ER stress led to increased TDP-43 cleavage and C-
terminal fragment production (Suzuki et al., 2011). Also ALS associated 
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mutations in TDP-43 were shown to trigger a number of ER stress responses 
including XBP-1 and ATF6 activation (Walker et al., 2013). 
1.4.7 Protein Aggregation 
Maintaining protein homeostasis is essential for cell survival. The occurrence of 
protein aggregates therefore indicates that protein aggregation is a potential 
pathogenic mechanism in ALS and FTD.  Protein homeostasis or proteostasis 
refers to the equilibrium between protein biosynthesis and clearance. A complex 
regulatory network exists within cells to maintain the equilibrium between 
production and degradation, promoting cellular health and survival. Eukaryotic 
cells have two major pathways of protein degradation, the proteasome and the 
lysosome. The proteasome selectively recognises ubiquitinated protein 
substrates, while autophagy denotes delivery of cytoplasmic components, 
including whole organelles, to the lysosome, see sections 1.5.1 and 1.5.2. 
 
Ubiquitinated and hyperphosphorylated TDP-43 is a prominent feature of the 
aggregates associated with ALS and FTD (Arai et al., 2006; Neumann et al., 
2006). The presence of these TDP-43 aggregates in both SALS and FALS 
provides strong evidence that aberrant aggregation of TDP-43 plays an 
important role in the development of disease (Sreedharan et al., 2008). While 
the loss of nuclear TDP-43 may contribute to disease, the cytoplasmic 
aggregation of this protein may also be toxic (Fang et al., 2014). 
 
Aside from TPD-43, other protein species are found in these ALS associated 
inclusions. Hyaline conglomerate inclusions are comprised of 
hyperphosphorylated neurofilament protein, which can lead to their reduced 
transport and subsequent aggregation (Ackerley et al., 2003; Hirano et al., 1984; 
Manetto et al., 1988), while Bunina bodies consist of cystatin C (Okamoto et al., 
1993). Cystatin C has been shown to upregulate the cellular recycling pathway 
of autophagy as a neuroprotective mechanism (Tizon et al., 2010; Watanabe et 
al., 2014). Aberrant accumulation of cystatin C may therefore impede its normal 
function, leading to a reduced ability of the cell to induce this cellular clearance 
pathway. Similarly to TDP-43, cytoplasmic aggregates of mutated FUS protein 
are found in FUS-related FALS (Kwiatkowski et al., 2009; Vance et al., 2009), 
while accumulations of misfolded SOD1 have been reported in sporadic ALS in 
Lewy Body like inclusions and also familial ALS, particularly FALS cases that 
are caused by SOD1 mutations (Shibata et al., 1994). Using epitope specific 
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antibodies for SOD1, researchers have shown that these accumulations are 
specifically made from misfolded mutant SOD1, which are found prior to onset 
of symptoms in SOD1 mouse models of ALS, suggesting misfolding and the 
accumulations of SOD1 are an early pathogenic event in the development of 
ALS (Rakhit et al., 2007). There also appears to be a propensity of wild type 
SOD1 to misfold and aggregate suggesting a role in SALS (Rakhit et al., 2004; 
Rakhit et al., 2002). 
 
The presence of these protein aggregates therefore suggests defective protein 
degradation and clearance is a factor in their formation. 
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1.5 Protein Degradation 
Degradation in eukaryotic cells is mediated by two systems: the ubiquitin 
proteasome system (UPS) and the autophagy pathway. These will be discussed 
in more detail below. 
1.5.1 The Ubiquitin Proteasome System 
The ubiquitin proteasome system (UPS) involves the specific clearance of 
ubiquitinated proteins by the proteasome, a multimeric ATP-dependent protease 
complex (Voges et al., 1999). Ubiquitin is a small 8.5 kDa heat stable regulatory 
protein responsible for the targeting of protein substrates to the proteasome 
(Ciechanover et al., 1978). The functional 26S proteasome comprises of the 
core 20S protease, capped with two 19S regulatory units (Driscoll and Goldberg, 
1990; Eytan et al., 1989; Hoffman et al., 1992; Voges et al., 1999).  
 
There are three enzymes required for ubiquitin conjugation to a target substrate: 
the E1 ubiquitin-activating enzyme, the E2 ubiquitin conjugating enzyme and the 
E3 ubiquitin ligase. The E1 ubiquitin-activating enzyme activates ubiquitin in an 
ATP dependent manner, forming a thiolester link between the E1 enzyme and 
the ubiquitin molecule (Ciechanover et al., 1982; Ciechanover et al., 1981). The 
ubiquitin molecule is then transferred from the E1 enzyme to the active site of 
the E2 ubiquitin-conjugating enzyme, allowing for the transfer of ubiquitin from 
the E2 enzyme to the target protein by the action of the E3 ubiquitin ligase 
(Ciechanover et al., 1982; Hershko et al., 1983). By binding specifically to the 
substrate target and the E2 ubiquitin-conjugate, the E3 ubiquitin ligase adds 
specificity to the cascade by ensuring that only the correct E2 enzyme is brought 
into contact with the specific substrate (Berndsen and Wolberger, 2014).  
 
The conjugation of ubiquitin to a target protein occurs via the amino side chain 
of an internal lysine of the substrate and the carboxyl group of the C-terminal 
glycine of ubiquitin, forming an isopeptide bond (Goldknopf and Busch, 1977). 
Consequently, further ubiquitin moieties can be ligated to the initial ubiquitin by 
the use of one of the seven internal lysine residues of ubiquitin: lysine 6, lysine 
11, lysine 27, lysine 29, lysine 33, lysine 48 and lysine 63. This allows for poly-
ubiquitination of a substrate and complex ubiquitin chain formation (Chau et al., 
1989; Hershko and Heller, 1985). Depending on the ubiquitin lysine residue 
used, the fate of the protein can vary, ranging from degradation (Chau et al., 
1989; Thrower et al., 2000), to enhanced enzymatic activity (Al-Hakim et al., 
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2008), to even increased protein stability (Nishikawa et al., 2004). However, 
polyubiquitination through lysine 48 is typically the main signal for degradation 
via the proteasome (Chau et al., 1989; Thrower et al., 2000). 
 
There are more than 600 E3 ligases encoded in the human genome (Li et al., 
2008). Eukaryotic E3 ligases are classified into 3 distinct families based on 
conserved domain structure and how the ubiquitin moiety is transferred from the 
E2 conjugating enzyme onto the internal lysine of target protein substrates 
(Berndsen and Wolberger, 2014; Metzger et al., 2012). The really interesting 
new gene (RING) family of E3 ligases transfer ubiquitin from the E2 enzyme 
directly onto the protein substrate (Özkan et al., 2005; Zheng et al., 2002), while 
Homology to E6AP C terminus (HECT) and RING between RING (RBR) E3 
families act in a two-step process, transferring ubiquitin from the E2 conjugate 
onto the E3 ligase and then onto the protein substrate (Huibregtse et al., 1995). 
 
While E3 ligases promote poly-ubiquitin of protein substrates, the removal of 
ubiquitin is mediated by a class of proteins called the de-ubiquitinating enzymes 
(DUBs). There are approximately 79 DUBs encoded in the human genome 
(Nijman et al., 2005). Essentially a class of proteases, the DUBs can be divided 
into five sub-classes based on their catalytic protease domains. The Ubiquitin 
Specific Protease (USP) family is by far the largest group with over 50 known 
USP genes (Nijman et al., 2005). DUBs also display targeted specificity either to 
the type of ubiquitin chain, or to the target protein that has been ubiquitinated. 
1.5.2 Autophagy 
Autophagy, literally meaning “self eating’ involves the delivery of cytosolic 
components and organelles (dubbed mitophagy in case of mitochondria) to the 
lysosome for degradation. 
 
Autophagy is classified into three types depending on how the substrates are 
delivered to the lysosome: chaperone mediated autophagy (CMA), 
microautophagy, and macroautophagy (Figure 1.3). CMA is the selective uptake 
and degradation of intracellular proteins which contain the consensus sequence 
Lys-Phe-Glu-Arg-Gln (KFERQ) (Dice, 1990). Proteins containing this sequence 
are bound by heat shock cognate protein of 70 kDa (Hsc70) and delivered to the 
lysosome via the lysosomal associated membrane protein 2A (LAMP-2A) 
(Cuervo and Dice, 1996). Microautophagy is the simplest form of autophagy as 
 22 
no intermediates or adaptors are required, the lysosomal membrane simply 
invaginates and pinches off, internalising a portion of the cytoplasm plus the 
substrates to be degraded (Marzella et al., 1981; Mortimore et al., 1988). 
Macroautophagy, often seen as classical autophagy, is the bulk clearance of 
cytoplasmic components and requires a large number of essential adaptors and 
intermediates. Although initially identified in yeast, macroautophagy is highly 
conserved amongst eukaryotes (Mizushima et al., 1998). Macroautophagy, 
herein termed autophagy, acts as a quality control mechanism for the cell, 
turning over damaged organelles, such as mitochondria, as well as degrading 
long-lived and misfolded proteins (Knecht et al., 1988; Mortimore et al., 1988; 
Ravikumar et al., 2004; Webb et al., 2003).  
 
The autophagic process can be separated into distinct steps: initiation, vesicle 
formation and elongation, cargo recruitment, maturation and fusion, and 
degradation, which are detailed in Figure 1.4. The proteins involved at different 






Figure 1.3. Micro, Macro and Chaperone Mediated Autophagy. (1) In 
Microautophagy the lysosomal membrane invaginates, engulfing a portion of the 
cytoplasm and any substrates to be degraded. (2) Macroautophagy involves the 
formation of a double membrane structure called the autophagosome. (3) 
Autophagic substrates, including misfolded proteins and organelles, are brought 
into contact with the preautophagosomal structure via the action of a number of 
autophagy receptors, such as p62 and optineurin. (4) The mature 
autophagosome fuses with the lysosome and the contents are degraded. (5) 
Chaperone mediated autophagy involves the recognition of cytosolic proteins 
containing the KFERQ motif by the Hsc70 chaperone (6). (7) Hsc70 mediates 
the delivery of the cytosolic protein to the LAMP-2A receptor on the lysosome. 
The protein substrate unfolds and is translocated across the lysosomal 
membrane to de degraded. (8) Resident acid hydrolyses of the lysosome bring 





Figure 1.4. Macroautophagy. 1) Initiation. Autophagy is induced as the 
inhibitory action of mTOR on the autophagy initiation complex is lost, leading to 
the activation of ULK1. The activated ULK1-FIP200-ATG13 complex initiates 
autophagy, by activating the Vps34 complex, leading to the formation of the 
phagophore. 2) Translocation. The active ULK1 complex and the Vps34 
complex translocate to the site of autophagosome formation. 3) Elongation and 
completion. Recruited by the Vps34 complex, the Atg12-Atg5-16L conjugation 
complex brings about LC3-I lipidation forming LC3-II and promoting elongation 
of the autophagosome. The autophagy substrates, targeted for autophagy by 
poly-ubiquitination and/or bound autophagy receptors, such as p62 and 
optineurin, become nucleated by their interaction with essential autophagy 
proteins found on the newly formed membrane structure such as LC3-II, 
allowing for their efficient encapsulation into the autophagosome. 4) Retrograde 
transport. Cytoplasmic dynein motor protein is recruited to autophagosomes by 
the action of Rab7 and Rab11, allowing for the retrograde transport of 
autophagosomes along microtubules. 5) Fusion. Delivery of autophagosomes 
to the lysosome allows for their fusion, which is mediated by the SNAREs 
VAMP7 and VAMP8 as well as Rab7 and LAMP1 and 2. 6) Degradation. The 
autophagolysosome cargo is degraded by components of the lysosome, such as 
the acid hydrolases. The sites of action of the autophagy inducers, rapamycin 
and Torin1, and the autophagy inhibitor, bafilomycin A1, are also indicated. 
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1.5.2.1 Initiation 
Initiation involves the formation of a double membrane structure called the 
isolation membrane or pre-autophagosomal structure (PAS), and the 
accumulation of a number of essential autophagy proteins to the autophagic 
membrane (Suzuki et al., 2001). A hierarchical scaffold of autophagy related 
proteins is seen in both yeast and mammals, although mammalian initiation 
does not occur at a single phagophore site, as in yeast (Itakura and Mizushima, 
2010). Initiation of autophagy is dependent upon a heterotetrameric protein 
complex, which translocates to the isolation membrane upon the induction of 
autophagy (Jung et al., 2009). The complex is comprised of Unc-51-like kinase 
(ULK1), focal-adhesion kinase family-interacting protein of 200 kDa (FIP200), 
ATG13 and ATG101 (Ganley et al., 2009; Hara et al., 2008; Hosokawa et al., 
2009b; Jung et al., 2009; Mercer et al., 2009). Autophagy initiation is regulated 
in two ways, mTOR dependent and mTOR independent initiation. 
1.5.2.1.1 mTOR dependent autophagy 
Under basal conditions the mammalian target of rapamycin (mTOR) kinase 
keeps autophagy in check by phosphorylating and inactivating ULK1 at serine 
757 (S757) (Kim et al., 2011). Inhibition of mTOR by starvation or with small 
molecule inhibitors, such as rapamycin or Torin1, leads to the 
dephosphorylation of ULK1 at S757, and the subsequent activating 
phosphorylations at serine 317 and 777 by autophosphorylation and AMP 
activated kinase (AMPK), a nutrient sensing kinase (Kim et al., 2011). ATG101 
appears to stabilise both ATG13 and ULK1 and is essential for autophagy 
initiation (Hosokawa et al., 2009b; Mercer et al., 2009). The ULK-FIP200-
ATG13-ATG101 essentially acts as a framework for the recruitment of other 
autophagy related proteins and the eventual formation of the autophagosome 
structure. The induction of autophagy is detailed in figure 1.5. 
 
Upon autophagy initiation and ULK1 activation, ULK1 phosphorylates FIP200 
and ATG13, as well as undergoing autophosphorylation (Ganley et al., 2009; 
Hosokawa et al., 2009b; Jung et al., 2009). The kinase activity of ULK is 
essential for autophagy induction, resulting in conformational changes within the 
C-terminal domain (CTD), allowing for membrane association and interaction 
with subsequent autophagy proteins (Chan et al., 2009). FIP200 appears to 
determine the localisation of ULK1 to the isolation membrane, and thus, is 
essential for initiation (Hara et al., 2008). The loss of ULK1, FIP200 or ATG13 is 
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sufficient to prevent the autophagic response (Chan et al., 2007; Hara et al., 
2008; Hosokawa et al., 2009a; Young et al., 2006), suggesting that the complex 
as a whole is essential for mTOR dependent autophagy initiation (Ganley et al., 
2009; Hosokawa et al., 2009a; Jung et al., 2009).  
1.5.2.1.2 mTOR independent autophagy 
Inositol 1,4,5-triphosphate (IP3) and cyclic AMP (cAMP) levels control the mTOR 
independent induction of autophagy (Williams et al., 2008). Increased levels of 
IP3 bind to IP3 receptors (IP3R) on the ER, releasing Ca2+ ions (Berridge, 1993). 
Increased cytosolic Ca2+ activates of the calpain family of cysteine proteases 
(Williams et al., 2008). Activation of these proteases is dependent upon their 
binding of two Ca2+ ions (Moldoveanu et al., 2002). Activated calpains inhibit 
autophagy by cleaving downstream autophagy proteins beclin1 and ATG5 
(Norman et al., 2010). Calpain activation also leads to cleavage and activation 
of the G-stimulatory protein α (Gsα) (Bamsey et al., 2000), which increases 
cAMP levels (Sato-Kusubata et al., 2000; Williams et al., 2008). Increased 
cAMP levels cause the Epac dependent activation of Rap2B and the 
subsequent activation of phospholipase C-ε (PLCε) (Kopperud et al., 2003; 
Williams et al., 2008). Activated PLCε promotes the formation of IP3 from 
phosphatidylinositol 4,5-bisphosphate (PIP2) completing the cycle and thus 
maintaining autophagy inhibition via calpain activation (Sarkar et al., 2005).  
Reduced IP3 levels decrease the release of ER calcium leading to calpain 
inactivation. Inactive caplains can neither inhibit autophagy nor cleave Gsα. 
Decreased cytosolic Ca2+ also results in decreased mitochondrial activity 
resulting in decreased ATP output. Decreases in ATP production, and the 
associated increase in AMP, leads to activation of AMP-activated protein kinase 
(AMPK) (Cardenas et al., 2010).  AMPK phosphorylates ULK1 directly, leading 
to activation of the ULK1 initiation complex and the activation of autophagy (Kim 
et al., 2011). The mTOR dependent and mTOR independent pathways are 




Figure 1.5. mTOR dependent and mTOR independent autophagy. In mTOR 
dependent autophagy, mTOR binds to the ULK1 initiation complex during 
nutrient rich conditions, phosphorylating and inactivating ULK1 (A). Upon mTOR 
inhibition, mTOR is release from this complex leading to the activation of ULK1. 
ULK1 phosphorylates itself as well as ATG13 and FIP200, leading to activation 
of the complex and the initiation of autophagy (B). mTOR independent 
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autophagy is cyclic. In A) High levels of cyclic AMP (cAMP) lead to activation of 
the Rap GEF Epac. Epac activates Rap2B leading to activation of 
phospholipase C-ε (PLCε). PLCε enhances the formation of Inositol 1,4,5-
triphosphate (IP3) from phosphatidylinositol 4,5-bisphosphate (PIP2). IP3 leads to 
inhibition of autophagy, but also binds the IP3 receptors (IP3R) on the ER, 
bringing about release of Ca2+. Increased cytosolic calcium activates the calpain 
family of cysteine proteases. Calpains inhibit autophagy but also activate the G-
stimulatory protein α (Gsα), which in turn increases the cytosolic levels of cAMP 
thus propagating the inhibition of autophagy. During autophagy induction in B) 
IP3 levels fall, leading to reduced Ca2+ release from the ER resulting in calpain 
inactivation. In addition, low cytosolic Ca2+ leads to reduced Ca2+ uptake by the 
mitochondria reducing the ATP output. Lower levels of ATP result in the 
activation of AMP-activated protein kinase (AMPK), which phosphorylates ULK1 
leading to autophagy initiation. Reduced ATP production also results in reduced 
cAMP levels and so the Epac/Rap2B pathway is no longer induced. 
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1.5.2.2 Vesicle formation and elongation 
As detailed in Figure1.4, after autophagy induction, activated ULK1 
phosphorylates its downstream target, Beclin-1, leading to activation of the class 
III phosphatidylinositol 3-kinase (PI3K) complex (PI3KC3) (Russell et al., 2013). 
The PI3KC3 complex is comprised of the class III PI3K, vacuolar protein sorting 
34 (Vps34), Beclin-1, p150 and mATG14/Barkor (Furuya et al., 2005; Itakura et 
al., 2008; Liang et al., 1999; Sun et al., 2008). The PI3K complex functions to 
synthesise phosphatidylinositol 3-phosphate (PtdIns3P), a signalling lipid that is 
essential for autophagosome formation and the recruitment of further 
components required for autophagosome extension and closure (Axe et al., 
2008; Backer, 2008; Devereaux et al., 2013; Vergne et al., 2009).  
 
Elongation of the double membrane structure is dependent on two protein 
conjugates as detailed in Figure 1.4, the ATG12-ATG5-ATG16L1 conjugate and 
the microtubule-associated protein 1 light chain 3 (LC3) lipid conjugate (Hanada 
et al., 2007). The ubiquitin-like protein (Ubl) ATG12 is covalently bound to ATG5 
by the actions of ATG7 and ATG10 (Mizushima et al., 1998). The ATG12-ATG5 
conjugate interacts with the multimeric protein ATG16L1, which directs this 
complex to the newly forming isolation membrane, possibly via its interaction 
with FIP200 (Fujita et al., 2008; Gammoh et al., 2013; Matsushita et al., 2007; 
Mizushima et al., 2003; Nishimura et al., 2013). ATG12-5-16L1 is then able to 
function as an E3 ubiquitin-ligase-like enzyme for the conjugation of 
phosphatidylethanolamine (PE) to the C-terminal of LC3-I, forming LC3-II 
(Hanada et al., 2007; Noda et al., 2013). LC3-II has been shown to be a 
component of the autophagosome membrane and is therefore often used as a 
marker of autophagosomes during the study of autophagy (Kabeya, 2000; 
Kabeya et al., 2004).  
 
The actual origin of the autophagosomal membrane is unclear (Tooze and 
Yoshimori, 2010). Most evidence suggests that membrane lipids are recruited 
from multiple existing membrane sources such as the ER, Golgi, plasma 
membrane or mitochondria, due to the range of markers present within them 
(Axe et al., 2008; Hailey et al., 2010; Hayashi-Nishino et al., 2009; Ravikumar et 
al., 2010; Yen et al., 2010; Ylä-Anttila et al., 2009). There is also evidence that 
the PI3KC member ATG14/Barkor is able to bind the soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE), syntaxin-17, which is 
localised to ER-mitochondria contact sites, thus suggesting ER-mitochondrial 
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membranes may also play a role in autophagosome biogenesis (Hamasaki et 
al., 2013). In yeast, ATG9, a transmembrane protein required for 
autophagosome formation, forms vesicular and tubular structures during the 
early stages of autophagy induction, aiding in the formation of a PAS (Mari et 
al., 2010). The mammalian homologue of ATG9 (mATG9) is localised to the 
Golgi network, but redistributes to LC3 positive membranes during autophagy 
induction (Young et al., 2006), suggesting mATG9 may also function in 
membrane delivery for autophagosome formation. 
 
The formation of mature autophagosomes is thought to require the fusion of 
multiple ATG16-positive precursor membranes, which is mediated by a number 
of SNAREs including vesicle associated membrane protein 7 (VAMP7), 
syntaxin-7 and syntaxin-8 (Moreau et al., 2011; Moreau and Rubinsztein, 2012).  
1.5.2.3 Defining the cargo 
The targeting of specific cargos for autophagic breakdown is dependent on 
substrate ubiquitination (Kim et al., 2008). Ubiquitinated substrates are 
recognised by autophagy receptor proteins such as p62/SQSTM1 
(Sequestosome) and optineurin (Bjørkøy et al., 2005; Pankiv et al., 2007; Wild 
et al., 2011; Wong and Holzbaur, 2014). P62 binds ubiquitin on the substrate via 
its ubiquitin associated (UBA) domains and LC3 on the pre-autophagosome via 
its LC3-interacting region (LIR) (Lamark et al., 2009). Thus ubiquitinated 
substrates are targeted to autophagosomes, along with p62 itself (Kim et al., 
2008; Komatsu et al., 2007; Pankiv et al., 2007). Loss or reduction of p62 
expression has been shown to lead to increased cell death under stress 
conditions while inhibition of autophagy has been shown to increase the number 
of p62/LC3 positive inclusions within cells (Bjørkøy et al., 2005). Consequently, 
pathological accumulations of p62 are indicative of defective autophagy (Pankiv 
et al., 2007).  
1.5.2.4 Maturation, Transport and Fusion 
Autophagosome formation can occur at multiple positions within the cytosol, and 
thus autophagosomes are transported towards the centrosome to facilitate their 
final fusion with lysosomes (Kimura et al., 2008). The transport of 
autophagosomes to the centrosome is mediated by the molecular motor protein 
cytoplasmic dynein and its binding partner dynactin (Gill et al., 1991; Jahreiss et 
al., 2008; Kimura et al., 2008; Ravikumar et al., 2005). Transport of 
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autophagosomes is particularly important in neuronal cells, where 
autophagosomes can form at the very distal tip of the axon, and so must be 
transported over a considerable distance to allow fusion with the lysosomes, 
which are particularly enriched at the cell body (Lee et al., 2011; Maday et al., 
2012). Several studies indicate that cytoplasmic dynein is required for 
retrograde transport of autophagosomes in neurons (Katsumata et al., 2010; 
Kimura et al., 2008; Ravikumar et al., 2005). Autophagosomes are thought to 
recruit cytoplasmic dynein via their fusion with late endosomes (Cheng et al., 
2015). 
 
The fusion of autophagosomes with other membrane vesicles, such as 
multivesicular bodies (MVBs) and late endosomes, forms amphisomes, 
prelysosomal hybrid organelles (Fader et al., 2008; Filimonenko et al., 2007; 
Razi et al., 2009). This fusion event is thought to be essential for degradation of 
aggregate prone autophagy substrates (Filimonenko et al., 2007). 
Autophagosome and MVB fusion is mediated by the SNARE VAMP3, as well as 
members of endosomal sorting complexes required for transport (ESCRT) 
machinery (Fader et al., 2009; Filimonenko et al., 2007; Rusten et al., 2007).  
The SNAREs, VAMP7 and VAMP8, mediate the final fusion event of the 
autophagosome with the lysosome (Fader et al., 2009; Furuta et al., 2010).  
 
After fusion with the lysosome, active acid hydrolyses such as the cathepsin 
family members, degrade the autophagosome cargo, recycling nutrients and 
metabolites, namely amino acids, back to the cytosol for the maintenance of 
normal cellular function (Tanida et al., 2005). The syntaxin-5 SNARE complex is 
required for correct lysosome function by mediating the activity of lysosomal 
proteases (Renna et al., 2011). The recycling of autophagic cargo feeds back to 
the mTOR complex 1 (mTORC1) reactivating mTOR and re-inhibiting autophagy 
(Yu et al., 2010). 
1.5.2.5 Rab GTPases and autophagy 
GTPases act as molecular switches for a range of processes, switching from an 
inactive GDP bound state to an active GTP-bound state, a process that is 
mediated by the guanine nucleotide exchange factors (GEFs). The Rab family of 
GTPases regulate a wide range of membrane trafficking events, from vesicle 
formation to transport and fusion (Zerial and McBride, 2001). It is therefore not 
surprising that these molecular switches have been found to play important roles 
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throughout the autophagy pathway (Ao et al., 2014). For a review of the Rab 
involvement in autophagy see Ao et al. 2014 (Ao et al., 2014). 
 
The monomeric GTPase Rab1 controls traffic from the ER to the Golgi, but is 
also required for autophagosome formation (Zoppino et al., 2010), while in yeast 
the Rab1 homologue, Ypt1 interacts with ATG9 and regulates trafficking of the 
ATG1 complex (the homologue of the ULK1 complex) to the PAS (Kakuta et al., 
2012; Lipatova et al., 2012; Wang et al., 2013). Interestingly, knock down of 
Rab1a inhibits autophagosome formation and also results in reduced 
recruitment of mATG9, which resides in the Golgi, to LC3 positive structures 
(Winslow et al., 2010; Winslow and Rubinsztein, 2011; Young et al., 2006). 
Rab33B, another Golgi resident Rab, interacts with the ATG16L conjugate, 
again supporting the role of Golgi membrane in the formation of 
autophagosomes (Itoh et al., 2008). 
 
Rab5 is known to activate Vps34 and also to interact with Beclin1 in a Vps34 
dependent manner, suggesting Rab5 is a component of the PI3K complex (Ao 
et al., 2014; Ravikumar et al., 2008). The Rab5 GEF, Alsin, is also implicated in 
ALS, as will be discussed in section 1.6. 
 
Like the Golgi and ATG9 vesicles, ER membranes have been implicated in 
autophagosome formation. Rab32 may aid in the recruitment of ER membranes 
to newly forming autophagosomes (Hirota and Tanaka, 2009). However, Rab32 
is also mitochondrial associated and thus may be involved mitophagy as well as 
bulk autophagy (Alto et al., 2002). 
 
Rab7 is important for the progression of autophagy, interacting indirectly with 
LC3 positive vesicles to mediate their transport and perinuclear accumulation 
(Gutierrez et al., 2004; Jäger et al., 2004; Pankiv et al., 2010). Indeed, Rab7 is 
required for the recruitment of dynactin and dynein to the late endosomes and 
autophagosomes to mediate their retrograde transport (Johansson et al., 2007). 
Rab7 also plays an important role in the final autophagosome-lysosome fusion 
event (Gutierrez et al., 2004; Jäger et al., 2004). The recruitment of Rab7 to the 
autophagosome-lysosome membranes is dependent on the lysosomal 
associated membrane proteins (LAMP) 1 and 2 (Jäger et al., 2004). 
 
 33 
Rab11 localisation to MVBs may be important for their fusion with the 
autophagosomes (Fader et al., 2008), and thus Rab11 may also be involved in 
recruitment of late endosomes and dynein to autophagosomes. 
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1.6 Dysfunctional autophagy in ALS 
The role of autophagy in neuronal health is well established. Neuronal-specific 
knock-out of a number of autophagy genes in mice, such as Atg7, Atg5 and 
RB1CC1 (FIP200), all lead to neurodegeneration, which is accompanied by 
reduced motor function and cytoplasmic inclusion body accumulation in neurons 
(Hara et al., 2006; Komatsu et al., 2006; Liang et al., 2010). Several ALS/FTD 
related genes show direct links to the autophagy pathway, and can be placed at 
distinct positions within the process. These examples will be discussed below. 
The FALS associated mutations and their links to the steps of autophagy are 





Figure 1.6. Autophagy and ALS. The steps of autophagy affected by single gene 
mutations in FALS. Alsin mutations affect Rab5 activation and thus activation of 
the PI3K complex. Mutation in proteins such as p62, Optineurin, UBQLIN2 and 
Tbk1 are thought to prevent sequestration of substrates to the autophagosome 
in cases of ALS. Mutations in VCP and FIG4 may lead to ALS due to a failure in 
maturation of the autophagosome leading to defective autophagy. Mutations in 
dynactin, which causes a subset of FALS, disrupts dynein-mediated transport, 
possibly resulting in damaged transport of autophagosomes. Mutated SOD1 has 
also been implicated in the disruption of cytoplasmic dynein-mediated transport. 
Damage to transport may lead to dysfunctional autophagy by preventing 
maturation of the autophagosomes and their subsequent fusion with the 
lysosome. Mutations that are thought to prevent fusion with the lysosome 
essentially block the final step of autophagy. Ubiquilins regulate autophagosome 
delivery to the lysosome. UBQLIN2 mutations, which cause FALS, possibly lead 
to disease due to impaired fusion with the lysosome. As part of the ESCRT-III 
complex, mutations to CHMP2B may inhibit the final fusion step and therefore 
the completion of autophagy. The C9orf72 associated dipeptide repeat proteins 
may increase pressure on the autophagy pathway. TMEM106B is involved in 
lysosomal biology and SNPs in TMEM106B modulate C9ALS/FTD. 
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1.6.1 Alsin 
The protein product from the ALS2 gene, Alsin, is a GEF for Rab5 (Topp et al., 
2004). As described above, Rab5 interacts with the Vps34 complex to bring 
about activation of the complex and recruitment of the ATG12-ATG5 conjugation 
system (Ravikumar et al., 2008). Pathogenic missense mutation in ALS2 lead to 
the loss of function of Alsin as a Rab5 GEF, thus leading to defective Vps34 
activation and defective autophagosome formation and ultimately the 
development of ALS (Hadano et al., 2001a; Hadano et al., 2010; Otomo et al., 
2011). Loss of Alsin in a SOD1 mouse model of ALS exacerbates disease due 
to reduced lysosomal degradation and increase pathogenic protein 
accumulation (Hadano et al., 2010). 
1.6.2 FIG4 
Mutations to the phosphoinositide 5-phosphatase FIG4 gene cause 
approximately 1-2% of ALS, as well as another neurological disorder, Charcot-
Marie-Tooth (CMT) 4J, a rare autosomal recessive, but severe form of CMT 
characterised by juvenile onset (Chow et al., 2009; Chow et al., 2007). FIG4 
regulates the cellular levels of phosphatidylinositol-3,5-biphosphate (PI(3,5)P2), 
a signalling lipid known to function in autophagy (Ferguson et al., 2009). FIG4-/- 
mice accumulate a number of proteins associated with autophagy, including p62 
and LC3-II, suggesting defective clearance (Ferguson et al., 2009). Mutations in 
FIG4 lead to loss of function and therefore reduced PI(3,5)P2 signalling. This 
may result in defective autophagy by inhibiting vesicle fusion or reducing the 
activity of the lysosome (Ferguson et al., 2009). 
1.6.3 p62 
Mutations in p62 have been found in FALS and SALS (Fecto et al., 2011; Hirano 
et al., 2013; Rubino et al., 2012; Teyssou et al., 2013). As described, p62 is one 
of the main autophagy receptors, delivering ubiquitinated cargo to the 
autophagosome for degradation (Matsumoto et al., 2011; Pankiv et al., 2007). 
Accumulations of p62 are therefore indicative of dysfunctional autophagy, and 
these inclusions are seen in patients with these mutations (Teyssou et al., 
2013). A missense mutation in exon 8 and a substitution in exon 7, which may 
affect splicing, are located in the UBA domain of p62 (Teyssou et al., 2013). 
This may disrupt the ability of p62 to bind its ubiquitinated substrates leading to 
a loss of function of p62 and the accumulation of protein aggregates. 
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1.6.4 Optineurin 
Optineurin functions in a similar way to p62, acting as an autophagy receptor 
and bringing cargoes, such as protein aggregates and mitochondria, into contact 
with the autophagosome by its interaction with LC3-II (Wild et al., 2011; Wong 
and Holzbaur, 2014). Nonsense and missense mutations in OPTN causative for 
ALS have been described, all of which result in increased inclusion body 
accumulation, which contain optineurin (Ito et al., 2011; Korac et al., 2013; 
Maruyama et al., 2010; Weishaupt et al., 2013). The Q398X nonsense mutation 
and the E478G missense mutation result in premature stop codon formation, 
and the likelihood of nonsense mediated decay, suggesting a loss of function of 
optineurin, and reduced autophagic clearance of protein aggregates (Ito et al., 
2011; Maruyama et al., 2010). Due to the involvement of optineurin in mitophagy 
(Wong and Holzbaur, 2014), loss of functional optineurin could also result in the 
accumulation of dysfunctional mitochondria, therefore combining the 
mechanisms of protein aggregation and mitochondrial dysfunction in the 
development of optineurin related ALS. 
1.6.5 VCP 
Valosin containing protein, VCP, is a multi ubiquitin chain binding protein, and is 
involved in delivery of substrates to the proteasome for degradation (Dai and Li, 
2001). R191Q and R155H missense mutations in VCP are causative for a form 
of autosomal dominant ALS (Johnson et al., 2010). Loss of VCP leads to 
accumulations of autophagy substrates due to failure to clear the mature 
autophagosomes, reminiscent of the effect of FIG4 mutations (Ferguson et al., 
2009; Ju et al., 2009; Tresse et al., 2010). In VCP mutant cells or VCP knock 
down cells, LC3 positive autophagosomes fail to fuse with the lysosomes, thus 
resulting in the accumulation of ubiquitin, p62 and LC3 positive structures (Ju et 
al., 2009; Tresse et al., 2010). How the mutations cause this autophagy defect is 
unclear, but other reports have implicated VCP in ubiquitinated substrate sorting 
through endosomal trafficking (Ritz et al., 2011), a process closely linked to the 
autophagy pathway (Razi et al., 2009). The defect in autophagy caused by 
these mutations leads to the redistribution of TDP-43 from the nucleus to the 
cytoplasm of cells, suggesting that TDP-43 may be a substrate of autophagy (Ju 
et al., 2009). Indeed, the induction of autophagy is able to enhance the 
clearance of TDP-43, reducing mislocalisation and aggregation (Barmada et al., 
2014). Mutations to VCP are also associated with inclusion body myopathy, 
Paget’s disease of bone and FTD (IBMPFD), which is characterised by 
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muscular accumulations and inclusions of ubiquitin, TDP-43 as well as p62 and 
LC3 (Johnson et al., 2010; Watts et al., 2004). Similar to p62 mutations, which 
are causative for Paget’s disease of bone (Layfield et al., 2006), the role of VCP 
in IBMPFD may be due to defects in the ubiquitin binding ability of VCP (Watts 
et al., 2004). 
1.6.6 Ubiquilin-2 
Mutations to the ubiquitin-like protein ubiquilin-2 have been shown to cause 
dominantly inherited X-linked ALS and ALS/dementia (Deng et al., 2011). 
Ubiquilin-2 mutants develop protein inclusions, the hallmark of ALS, with 
ubiquilin-2 protein being a component of these inclusions (Deng et al., 2011). 
The C terminus of ubiquilin-2 is able to bind poly-ubiquitin chains and aid in 
delivery of substrates to the proteasome (Ko et al., 2004). However, ubiquilin-2 
has also been implicated in the autophagy pathway, binding both ubiquitinated 
substrates and LC3 in a similar fashion to p62 (N'Diaye et al., 2009a; N'Diaye et 
al., 2009b; Rothenberg et al., 2010). Loss of ubiquilin-2 inhibits autophagy 
induction and autophagosome formation leading to increased susceptibility to 
starvation-induced stress (N'Diaye et al., 2009a; N'Diaye et al., 2009b). It has 
been proposed that the ubiquilin-2 mutants are defective in the delivery of poly-
Ub substrates (Chang and Monteiro, 2015). Ubiquilin-2 also co-localises with 
optineurin on Rab11, p62 and ULK1 positive vesicles (Osaka et al., 2015). ALS 
associated ubiquilin-2 mutations result in loss of ubiquilin-2 from these vesicles 
suggesting a loss of function mechanism (Osaka et al., 2015).  
1.6.7 CHMP2B 
The charged multivesicular body protein 2B (CHMP2B) is involved in the 
endosomal ESCRT-III complex, with mutations known to cause FTD (Skibinski 
et al., 2005), as well as predominantly lower motor neuron ALS (Cox et al., 
2010; Parkinson et al., 2006). The ESCRT-III complex functions to sort 
ubiquitinated integral membrane proteins into intraluminal vesicles and MVBs. 
The formation of these MVBs has been shown to be required for efficient 
autophagic degradation, with loss of ESCRT members or expression of mutant 
CHMP2B leading to the accumulation of autophagic markers such as p62 and 
LC3-II (Filimonenko et al., 2007). Expression of mutant CHMP2B in cells leads 
to accumulations of LC3-II and disrupted lysosomal localisation, supporting a 
role of CHMP2B in autophagy (Cox et al., 2010; Lee et al., 2007). This 
accumulation is potentially due to failure of the final fusion step required for 
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degradation of ubiquitinated substrates (Filimonenko et al., 2007; Urwin et al., 
2010). 
1.6.8 Dynactin 
Dynactin interacts with cytoplasmic dynein to bring about retrograde transport of 
cargos (Fig 1.1) (Waterman-Storer et al., 1997). Missense mutation in the p150 
subunit of dynactin (DCTN1) was initially found in one kindred suffering from a 
form of lower motor neuron disease (Puls et al., 2003). Since this time, multiple 
point mutations have been discovered within DCTN1, leading to a variety of 
phenotypes and neurodegenerative diseases, including Parkinson’s and ALS 
(Münch et al., 2005; Münch et al., 2004; Vilariño-Güell et al., 2009). This 
suggests that dynactin is important for neuronal health and is indeed involved in 
neurodegeneration. The mutations within DCTN1 appear to act as risk or 
susceptibility factors for the development of ALS (Münch et al., 2005). The ALS 
associated mutations of dynactin appear to disrupt dynein-dynactin function 
leading to aggregation of mutant dynactin and other proteins (Levy et al., 2006). 
As autophagosomes are transported in a retrograde manner in neurons by the 
dynein-dynactin complex (Maday et al., 2012), mutation in the p150 subunit of 
dynactin may lead to disease due to failed transport and accumulation of 
autophagosomes. 
1.6.9 TBK1 
A number of loss of function mutations within the TANK-binding kinase 1 (TBK1) 
gene are associated with FALS/FTD by a mechanism of haploinsufficiency 
(Freischmidt et al., 2015). TBK1 regulates autophagy by directly phosphorylating 
optineurin, which increases its interaction with LC3 and the autophagosomes 
(Weidberg and Elazar, 2011). As an autophagy receptor, increasing the 
interaction of optineurin with LC3-II increases the delivery of substrates to the 
autophagosomes (Weidberg and Elazar, 2011). TBK1 also phosphorylates p62 
to efficiently regulate the autophagosomal clearance of mitochondria 
(Matsumoto et al., 2015). As optineurin and p62 are both adaptor proteins of 
TBK1 (Pilli et al., 2012; Wild et al., 2011), loss of function of TBK1 could result in 
reduced autophagosome maturation and defective autophagic clearance, 




Mutation in Sigma-1 receptor (SigR1) has been reported to cause juvenile onset 
ALS and FTD (Al-Saif et al., 2011), which may be a result of loss of function of 
SigR1 (Prause et al., 2013). SigR1 is located at ER mitochondrial contact sites, 
and is involved in regulating calcium signalling and cell survival (Hayashi and 
Su, 2007). However, SigR1 activation has also been linked to autophagy 
induction (Schrock et al., 2013). Interestingly, loss of SigR1 leads to disrupted 
ER and mitochondrial morphology as well as defective autophagic degradation 
(Vollrath et al., 2014). 
1.6.11 Spatacsin 
Deletions within SPG11 lead to frame shift mutations and premature stop codon 
formation, resulting in loss of function of the SPG11 gene product, Spatacsin, 
leading to classical hereditary spastic paraplegia as well as juvenile recessive 
ALS (Orlacchio et al., 2010).  Loss of Spatacsin results in autophagosome 
accumulation, which fail to clear, possibly as a result of defective lysosome 
biogenesis (Chang et al., 2014; Renvoisé et al., 2014). Evidence from patient 
derived neurons and mouse models suggests loss of Spatacsin leads to 
reduced anterograde vesicle transport and therefore defective axonal transport 
(Pérez-Brangulí et al., 2014). As neuronal biology relies heavily on the cells 
ability to efficiently transport cargos to and from the cell body, defective axonal 
transport can be catastrophic for the neuronal health. Both defective autophagy 
and decreased axonal transport could be at play to bring about motor neuron 
degeneration in these patients. 
 
Thus, defective autophagy is a potentially common mechanism of disease in 
ALS and FTD. 
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1.7 C9ORF72 and ALS 
In 2011 Renton et al. and DeJesus-Hernandez et al. discovered the genetic 
mutation that was associated with chromosome 9p21-linked ALS (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). This section will discuss the 
current understanding of C9orf72 related ALS. 
1.7.1 Clinical and pathological features of the C9orf72 repeat 
expansion 
Previous linkage analysis studies had identified a locus on chromosome 9p21 
that appeared to be involved in the development of ALS, FTD and ALS with FTD 
(Boxer et al., 2011; Morita et al., 2006; Vance et al., 2006). In 2011 this locus 
was identified as a large hexanucleotide repeat expansion of GGGGCC within 
the first intron of the C9orf72 gene (DeJesus-Hernandez et al., 2011; Renton et 
al., 2011) (Figure 1.7). 
 
 
Figure 1.7. C9orf72 transcriptional variants. A) Overview of the genomic 
structure of the C9ORF72 locus (top panel) and the C9ORF72 transcripts 
produced by alternative pre-mRNA splicing (bottom panels). Boxes represent 
coding (white) and non-coding (grey) exons and the positions of the start codon 
(ATG) and stop codon (TAA) are indicated. The GGGGCC repeat is indicated 
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with a red diamond. The position of rs10757668 is indicated with a green 
star. Reused with permission from DeJesus-Hernandez et al. 2011 (DeJesus-
Hernandez et al., 2011). 
This defect has been shown to be the most common genetic cause of ALS and 
FTD, with frequencies varying within different populations. For example, the 
repeat expansion accounted for 46% of FALS and 29.3% of FTD cases in a 
Finnish population (Renton et al., 2011), 43% of FALS and 35% of familial FTD 
in a cohort from northern England (Cooper-Knock et al., 2012), but only 3.4% of 
FALS in a Japanese population (Konno et al., 2013b). Giving rise to such 
relatively high proportions of FALS and FTD cases, as well as a proportion of 
sporadic cases, led to the name, C9ALS/FTD (Cooper-Knock et al., 2012; 
Majounie et al., 2012). The pathology and clinical phenotypes typical of ALS are 
observed in C9ALS/FTD, however there are also a number of differences. Aside 
from the higher than expected incidence of FTD amongst C9orf72 related ALS 
patients, there is also an increase in bulbar onset (approximately 20% more 
than non C9orf72 carriers) as well as a shorter disease progression compared 
to non-C9orf72 carriers, both of which suggest a more severe and aggressive 
disease progression (Chiò et al., 2012; Cooper-Knock et al., 2012). 
 
A repeat size of greater than 30 is generally considered pathogenic, but repeats 
of greater than 2000 have been reported in some patients (Buchman et al., 
2013; DeJesus-Hernandez et al., 2011; Renton et al., 2011; van Blitterswijk et 
al., 2013), and relatively small repeats of 20-30 have been correlated with 
increased risk of ALS and FTD (Byrne et al., 2013; Gómez-Tortosa et al., 2013). 
A definite link between repeat length and severity of disease is yet to be 
established with reports of no correlation between repeat length and age of 
onset in ALS (Dols-Icardo et al., 2014; van Blitterswijk et al., 2013). However, 
repeat length in FTD does appear to correlate with age of onset (van Blitterswijk 
et al., 2013). 
 
Anticipation in genetics describes the tendency for a disease to present at an 
earlier age of onset in subsequent generations. While there is little evidence for 
a link between disease severity and repeat length in ALS, there does appear to 
be a level of anticipation, with an earlier age of onset identified in the youngest 
generations (Benussi et al., 2014; Chiò et al., 2012). 
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The pathology of C9orf72 patients is consistent with other forms of ALS, and 
includes the hallmark phosphorylated TDP-43-positive neuronal cytoplasmic 
inclusions (Cooper-Knock et al., 2012). However, C9ALS/FTD cases can be 
distinguished from other ALS and FTD cases by the presence of specific 
ubiquitin and p62 positive, TDP-43 negative, neuronal cytoplasmic inclusions 
and intranuclear inclusions in the cerebellum, hippocampus and the neocortex 
(Al-Sarraj et al., 2011; Arai et al., 2006; Cooper-Knock et al., 2012; Stewart et 
al., 2012). There is also pathology associated with the repeat itself, namely 
nuclear RNA foci and dipeptide repeat proteins. Both these inclusions may 
relate directly to the mechanism of disease as detailed in section 1.7.2. 
1.7.2 Pathogenic Mechanisms in C9orf72 ALS/FTD 
To date there are 3 main disease mechanisms associated with the repeat 
expansion: 1) RNA toxicity of the repeat expansion, 2) protein toxicity from 
aberrantly transcribed dipeptide repeat proteins from the repeat expansion and 
3) haploinsufficiency of C9orf72. All 3 mechanisms have been previously 
described in other repeat expansion disorders associated with 
neurodegeneration (Taneja et al., 1995; Zu et al., 2011). 
1.7.2.1 RNA toxicity 
Nuclear RNA foci transcribed from the repeat expansion were found in the 
original studies detailing the C9orf72 repeat expansion patients (DeJesus-
Hernandez et al., 2011). The repeat expansion is transcribed in a bidirectional 
manner, giving rise to sense and antisense transcripts (Gendron et al., 2013; 
Lagier-Tourenne et al., 2013; Mizielinska et al., 2013). These repeat expansions 
are thought to cause disease due to the sequestration of RNA binding proteins 
to the large RNA expansion, perturbing normal cellular function. A number of 
groups have identified a range of RNA binding proteins (RBPs) that interact with 
the repeat expansion, including heterogeneous nuclear ribonucleoproteins 
(hnRNPs) A1 (hnRNP A1) and H1/F (hnRNP H1/F) and serine/arginine-rich 
splicing factor 2 (SRSF2) (Cooper-Knock et al., 2014; Lee et al., 2013; Mori et 
al., 2013a; Sareen et al., 2013; Xu et al., 2013). All these proteins are involved 
in RNA metabolism and so their increased recruitment to this aberrant 
expansion may lead to their dysfunction, and the development of disease.  
 
RNA-editing deaminase RNA-specific B2 (ADARB2) was also shown to bind 
specifically to the repeat expansion in induced-pluripotent stem cells (iPSC) 
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derived neurons from C9ALS patients. Loss of ADARB2 leads to an increase in 
iPSC neuron susceptibility to glutamate (Donnelly et al., 2013). Therefore, 
recruitment of ADARB2 to these transcribed repeats may lead to its loss of 
function, increased excitotoxicty and the development of ALS (Donnelly et al., 
2013).  
 
The guanine and cytosine rich nature of the repeat expansion lends itself to the 
formation of DNA and RNA secondary structures, including hairpin loops and G-
quadruplex structures, which are tetrameric planar stacks of four G bases 
(Haeusler et al., 2014; Su et al., 2014). These G-quadruplex structures lead to 
abortive transcription, an increase in truncated transcripts as well as recruitment 
of nucleolin (Haeusler et al., 2014). Redistribution of nucleolin from the 
nucleolus to these G-quadruplex repeat expansions-associated structures may 
result in decreased ribosomal RNA maturation, leading to nucleolar stress and 
cell death (Haeusler et al., 2014). 
 
Mouse models of the C9orf72 repeat expansion have been shown to 
recapitulate aspects of C9ALS/FTD. Mice virally transduced with a vector 
harbouring 66 G4C2 repeats exhibited pathology similar to C9ALS/FTD, namely 
the phosphorylated TDP-43 neuronal inclusions as well as RNA foci (Chew et 
al., 2015). While these mice did exhibit cortical neuron loss they did not show 
motor neuron loss or indeed the ubiquitin/p62 positive, TDP-43 negative 
inclusions, which are specific to C9ALS/FTD (Chew et al., 2015). Transgenic 
mice carrying a bacterial artificial chromosome (BAC) containing the human 
C9orf72 gene with 100-1000 G4C2 repeats (O'Rourke et al., 2015) or 
approximately 500 repeats (Peters et al., 2015) showed RNA foci formation and 
nucleolin redistribution. However, expression of these repeats did not lead to 
neurodegeneration or behavioural phenotypes (O'Rourke et al., 2015; Peters et 
al., 2015). 
1.7.2.2 Dipeptide repeat protein toxicity 
Evidence from other repeat expansion disorders has shown that repeat 
expansions can be translated in a non-ATG dependent manner, termed repeat-
associated non-ATG (RAN) translation (Zu et al., 2011). While this leads to 
repeating units of individual amino acids in trinucleotide repeat expansion 
disorders (e.g. polyglutamine proteins in myotonic dystrophy), the 
hexanucleotide repeat expansion in C9orf72 gives rise to dipeptide repeat 
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(DPR) proteins (Mori et al., 2013b). Similar to the CAG expansion in the ataxin8 
gene in spinocereballar ataxia 8 (Zu et al., 2011), this hexanucleotide stretch 
within C9orf72 can be translated in all 3 reading frames, as well as the sense 
and antisense direction (Mori et al., 2013a). This leads to the production of 5 
DPR species: poly-(Glycine-Alanine) (poly-GA), poly-(Glycine-Arginine) (poly-
GR), poly-(Glycine-Proline) (poly-GP), poly-(Proline-Arginine) (poly-PR) and 
poly-(Alanine-Proline) (poly-AP) (Mori et al., 2013a; Mori et al., 2013b). All 5 of 
these DPR species are found to aggregate in p62 positive, TDP-43 negative, 
ubiquitinated cytoplasmic inclusions in patients (May et al., 2014; Mori et al., 
2013a). However, poly-GA proteins appear to be the most prevalent component 
of these inclusions (Mori et al., 2013a; Mori et al., 2013b), while poly-GR and 
poly-PR proteins have the most nuclear localisation out of all the species (Mori 
et al., 2013b). The differences in abundance and distribution could indicate 
different modes of disease for the different DPRs. 
 
Evidence for a possible role of DPR protein toxicity in the development of 
C9ALS/FTD comes from the study of Drosophila models of C9orf72 repeat 
expansion related DPR proteins. Expression of 36 and 100 repeats of poly-GR 
and poly-PR DPR proteins in the Drosophila eye caused degeneration of the 
eye, indicating neuronal toxicity (Mizielinska et al., 2014). This study also 
employed an RNA only model where interruption of the repeat expansion with 
stop codons prevented the formation of DPR proteins. In this case, the 
expansion alone was not sufficient to cause toxicity and did not cause 
neurodegeneration (Mizielinska et al., 2014), suggesting RNA toxicity alone is 
not sufficient to cause disease. DPR protein production has also been reported 
in the BAC mouse models of C9orf72 repeat expansions, but as discussed 
above, there was no evidence of related neurotoxicity (O'Rourke et al., 2015; 
Peters et al., 2015). 
 
Evidence from cell models also indicates poly-GR and poly-PR DPR proteins 
are particularly toxic. Both were capable of inducing nucleolar stress by binding 
irreversibly to the nucleolus leading to dysregulated RNA biogenesis and 
eventually cell death (Kwon et al., 2014). The toxicity of these species may be 
attributed to their effects on RNA processing and ribosome synthesis (Kwon et 
al., 2014). The ability of poly-GR and poly-PR proteins to interact with the 




The cytoplasmic aggregation of these ubiquitinated DPR species suggests their 
ineffective clearance. Their inclusion in p62 positive aggregates in C9ALS/FTD 
patients (May et al., 2014; Mori et al., 2013a) therefore suggests a failure or 
blockage of the autophagy pathway. However, the accumulation of such 
aggregates, labelled with both ubiquitin and p62, also suggests the formation of 
the so called aggresome, a structure of multiple misfolded and aggregating 
proteins that are cleared by a type of specialised autophagy, termed 
aggrephagy (Hyttinen et al., 2014) (see Fig. 1.4). Although potentially 
functioning as a protective mechanism, the formation of protein aggregates has 
been shown to be cytotoxic (Bucciantini et al., 2002). 
  
The DPR species have also been reported to interact with a range of other 
cellular proteins, potentially perturbing their normal cellular function, thus leading 
to disease. Firstly, expression of 149 repeats of poly-GA in cortical neurons has 
identified a number of ubiquitin proteasome related binding partners, including 
p62, ubiquilin-1 and 2, as well as subunits of the proteasome machinery (May et 
al., 2014). GA rich repeats within the Epstein-Barr Virus (EBV) nuclear antigen  
(EBNA) 1 protein have previously been shown to disrupt and inhibit the ubiquitin 
proteasome system (Levitskaya et al., 1997), raising the possibility that the poly-
GA DPR proteins have the same effect. 
 
Secondly, Unc119 was identified as an interacting partner of poly-GA DPR 
proteins. Unc119 has been reported to function in axon development in 
C.elegans, and is conserved in humans (Knobel et al., 2001; Maduro et al., 
2000). Unc119 also appears important for cellular trafficking in neurons, 
regulating transport of G proteins to their correct cellular compartment 
(Constantine et al., 2012; Zhang et al., 2011). Sequestration of Unc119 into 
cytoplasmic aggregates of poly-GA DPR proteins could therefore reduce the 
cellular pool of available Unc119, disrupting normal trafficking in neurons and 
possibly contributing to disease (May et al., 2014). 
1.7.2.3 Haploinsufficiency 
Several groups have reported reduced expression of C9orf72 in patients (Belzil 
et al., 2013; Cooper-Knock et al., 2012; DeJesus-Hernandez et al., 2011; 
Donnelly et al., 2013; Gijselinck et al., 2012; Xi et al., 2013). Reduced C9orf72 
has also been reported at the protein level in a number of disease relevant 
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tissues, such as the cerebellum, hippocampus and frontal cortex consistent with 
the idea that the repeat expansion leads to reduced C9orf72 transcription, and 
therefore less protein (Waite et al., 2014; Xiao et al., 2015). Thus loss of 
function of C9orf72 by haploinsufficiency could contribute to disease. 
 
How the repeat expansion results in reduced C9orf72 expression is unclear. The 
repeat expansion has been shown to lead to hypermethylation of a CpG island 
5’ of the C9orf72 gene (Xi et al., 2014; Xi et al., 2013) and it is well established 
that hypermethylation of CpG islands functions as a gene silencing mechanism 
(Al-Mahdawi et al., 2008; Greger et al., 1989; Herman et al., 1995; Jones and 
Baylin, 2002; Sephton et al., 2011; Sutcliffe et al., 1992). If the repeat expansion 
somehow promotes CpG methylation, then this could lead to the observed 
decrease in expression of C9orf72. Higher levels of methylation were reported 
to correlate with a shorter disease progression, suggesting increased 
methylation leads to a more severe phenotype (Xi et al., 2013). The precedent 
for this effect of non-coding repeat expansions on CpG island hypermethylation 
in other disorders such as Friedreich ataxia and fragile X mental retardation 
syndrome, strengthens the argument for the role in C9ALS/FTD (Al-Mahdawi et 
al., 2008; Sutcliffe et al., 1992). 
 
Morpholino knockdown of C9orf72 in a zebrafish model led to decreased axonal 
length and reduced swimming ability associated with motor defects (Ciura et al., 
2013). These defects were effectively rescued upon overexpression of human 
C9orf72 mRNA (Ciura et al., 2013). On the other hand neural specific ablation of 
C9orf72 in conditional C9orf72 knockout mice does not cause motor neuron 
degeneration or reduced survival but does result in reduced body weight 
(Koppers et al., 2015). This suggests that haploinsufficiency alone, is also not 
the sole cause of disease in C9ALS/FTD. However, these mice were not tested 
for the characteristic p62 positive pathology that is associated with C9ALS/FTD. 
It may be that loss of C9orf72 is able to replicate the disease associated 
pathology, suggesting that haploinsufficiency of C9orf72 does contribute 
towards disease pathogenesis. 
1.7.3 C9orf72 protein 
Three alternatively spliced C9orf72 mRNA transcripts give rise to two C9orf72 
protein isoforms (Figure 1.7). Transcripts 1 and 3 encode a protein of 481 amino 
acids (C9orf72 Long, C9orf72L), while transcript 2 encodes a shorter protein of 
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222 amino acids lacking the last 6 exons, which encode 259 C-terminal amino 
acids (C9orf72 Short, C9orf72S) (DeJesus-Hernandez et al., 2011; Renton et 
al., 2011). Expression of these two isoforms has been reported in a range of 
tissues from liver to testis, but also across a range of brain regions including 
cerebellum, frontal cortex and hippocampus (DeJesus-Hernandez et al., 2011). 
C9orf72 appears to be particularly enriched in the cerebellum (Waite et al., 
2014). The expression of C9orf72 has also been shown to be enriched in mouse 
neuronal cells, suggesting the functional C9orf72 protein is important to these 
cellular populations (Suzuki et al., 2013). 
 
The C9orf72 protein is highly conserved across species, with up to 98% identity 
between mice and humans and 73% identity between zebrafish and humans, 
suggesting an important cellular role. While Drosophila melanogaster lack a 
C9orf72 homologue, the Caenorhabditis elegans homologue shares 26% 
identity with the human form (Therrien et al., 2013). 
 
Although there are no obvious domains, C9orf72 does share secondary 
structural homology with the Differentially Expressed in Normal and Neoplasia 
(DENN) family of proteins (Levine et al., 2013; Zhang et al., 2012). DENN 
domain containing proteins are guanine nucleotide exchange factors (GEFs) for 
the Rab family of GTPases, exchanging guanine diphosphate (GDP) for guanine 
triphosphate (GTP), and thus regulating Rab activation (Marat et al., 2011). The 
functional DENN domain is made up of 3 distinct modules termed the upstream 
DENN (uDENN) or Longin domain, the central DENN domain and the 
downstream (dDENN) domain (Levivier et al., 2001). The position of these 
potential domains in relation to the C9orf72 protein isoforms is detailed in Figure 
1.8. The structural homology with DENN proteins suggests that C9orf72 might 
function as a regulator of the Rab GTPases, which are involved in a variety of 
cellular membrane trafficking and transport events (Stenmark, 2009; Stenmark 
and Olkkonen, 2001; Zerial and McBride, 2001), as detailed in section 1.5.2.5. 
In agreement with this, C9orf72 has been shown to co-localise with a number of 






Figure 1.8 The predicted DENN-like domains of C9orf72. Coloured boxes 
indicate the different DENN modules with predicted secondary structure similar 
to that of known DENN proteins. The uDENN (or Longin) module (blue box) 
spans from amino acids 23 to 151. The central DENN domain (green box) spans 
from amino acids 212 to 322, while the dDENN module (orange box) spans from 
amino acid 323 to 481. The location of these DENN modules in relation to the 
full-length C9orf72L protein and C9orf72S are shown. C9orf72S is mainly 
comprised of the uDENN domain with a short section of the DENN domain. 
Black lines indicate linker regions with no predicted homology. Numbers indicate 
corresponding amino acids of C9orf72. 
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Isoform specific antibodies have been developed to investigate the difference in 
subcellular localisation of C9orf72S and C9orf72L (Xiao et al., 2015). C9orf72L 
was shown to have a diffuse cytoplasmic distribution, while C9orf72S displayed 
a more specific localisation to the nuclear membrane, which was observed to be 
more cytoplasmic in C9ALS patient motor neurons (Xiao et al., 2015). The 
antibody was also used to demonstrate the interaction of C9orf72S with 
members of the nuclear pore complex, including Importin β1 and Ran-GTPase, 
suggesting a possible role in nuclear import and export (Xiao et al., 2015). RNA 
foci formed from the repeat expansion, were also shown to disrupt 
nucleocytoplasmic transport by interacting with the Ran-GTPase activating 
protein (RanGAP) (Zhang et al., 2015), suggesting a common or shared 
mechanism of disease.  
 
Further clues as to the function of the C9orf72 protein come from a GWAS that 
identifies single nucleotide polymorphisms (SNPs) in transmembrane protein 
106 B (TMEM106B) as a modifier of disease risk (Van Deerlin et al., 2010). The 
major risk SNP (rs 1990622 T/C) is particularly associated with FTLD in patients 
with the GGGGCC C9orf72 repeat expansion (Gallagher et al., 2014; Van 
Blitterswijk et al., 2014; Vass et al., 2011). The TMEM106B protein has been 
shown to localise to the endo-lysosome compartment and is involved in various 
aspects of lysosomal biology, including size and trafficking (Brady et al., 2013; 
Schwenk et al., 2014; Stagi et al., 2014). The major risk allele for FTD in 
C9orf72 expansion patients is associated with a later age of onset of ALS as 
well as later age of death, while the minor allele appears to be protective for the 
development of FTD in C9orf72 expansion carriers (Van Blitterswijk et al., 
2014). As variants of this endo-lysosomal associated protein are able to modify 
risk of FTLD-TDP in C9orf72 expansion carriers, it suggests lysosomal biology, 
and thus autophagy, may be involved in the pathogenesis of C9ALS/FTD. 
However, currently the exact function of the C9orf72 protein remains elusive. 
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1.8 Hypothesis and aims 
As loss of function caused by haploinsufficiency of C9orf72 is a possible cause 
of C9ALS/FTD, it is important to understand the cellular function of C9orf72. 
Substantial evidence points towards a role of defective autophagy in many 
cases of ALS. While the presence of TDP-43 positive inclusions is considered a 
hallmark of ALS, unlike other ALS cases C9orf72 patients also display specific 
p62-positive, TDP-43 negative, inclusions in the cerebellum and hippocampus. 
Accumulations of p62 are indicative of defective autophagy and as such 
defective autophagy may be involved in C9ALS/FTD. 
 
C9orf72 codes for two protein isoforms of unknown function that are structurally 
related to the DENN family of Rab GEFs. Rabs are involved in a range of 
membrane trafficking events, including many aspects of autophagy. A previous 
study into the network organisation of the autophagy pathway identified C9orf72 
as a possible interacting partner of FIP200 (Behrends et al., 2010). Thus, due to 
the potential role in Rab biology, the p62 positive accumulations in patients and 
the link with FIP200, this lead to the hypothesis that C9orf72 is involved in the 
autophagy pathway. 
 
The aim of this thesis was to understand the function of the C9orf72, in 
particular, to test whether C9orf72 was involved in the autophagy pathway and 
whether loss of C9orf72 would disrupt this pathway. The aim was to initially 
identify a range of C9orf72 interacting proteins to provide clues as to the 
function of this uncharacterised protein, before investigating what effect 
modulating C9orf72 protein levels would have on cellular biology. 
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2 Materials	  and	  Methods	  
Unless otherwise stated all chemicals were purchased from Sigma. All solutions 
were prepared using distilled H2O and sterilised by autoclaving or filtration 
through a 0.2 µm filter. 
2.1 Materials 
2.1.1 Stock Solutions 
Acrylamide-bis-acrylamide (30%) 
Ammonium Persulphate (APS; 10%) 
Ampicillin (100 mg/ml) 
Bafilomycin A1 (100 µM) 
Β-mercaptoethanol 
Bovine serum albumin (BSA) 
Bradford reagent (5x stock) 
Cycloheximide (10 mg/ml) 
Dimethyl sulphoxide (DMSO; 100%) 
Ethanol (100%) 
Ethidium Bromide (10 mg/ml) 
Ethylenediaminetetraacetic acid (EDTA; 0.5 M) 
Ethylene glycol-bis (β-aminoethylether) N,N,N’,N’-tetraacetic acid (EGTA; 0.25 
M) 
Foetal bovine serum (100%)  
Formaldehyde (37% (w/v)) 
Glacial acetic acid (100%) 
Glycerol (100% (v/v)) 
Hydrochloric acid (HCl) 
Isopropyl β-D-1-thiogalactopyranoside (IPTG; 1 M) 
Kanamycin (100 mg/ml) 
K-Piperazine-N,N’-bis (2-ethanesulphonic acid) buffered with potassium 
hydroxide to pH 6.8 (K-PIPES; 400 mM) 
Magnesium chloride (MgCl2; 1 M) 
Methanol (100%) 
MG132 (N-(Benzyloxycarbonyl)leucinylleucinylleucinyl; 10 mM) 
NP40 (Nonidet P-40 or octylphenoxypolyethoxyethanol or IGEPAL CA-630; 
100%) 
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Phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 0.7 mM KH2PO4, 4 
mM Na2HPO4) 
Potassium chloride 
Rapamycin (1 mM) 
Sodium dodecyl sulphate (SDS; 10% (w/v)) 
Sodium chloride (NaCl; 5 M) 
Sodium pyruvate (100 mM) 
TEMED (N,N,N’,N’-tetramethylethylenediamine; 100%) 
Torin1 (1 mM) 
Trypsin-EDTA 
Tris-buffered saline (TBS; 20 mM Tris (tris(hydroxymethyl)aminomethane); 137 
mM NaCl buffered with HCl to pH 7.6 
Tris-HCl (1.5 M Tris buffered with HCl to pH 8.8) 
Tris-HCl (0.5 M Tris buffered with HCl to pH 6.8) 
Triton X-100 (100%) 
Tween-20 (100%) 
2.1.2 Microbiology reagents 
2.1.2.1 Plasmids and vectors 
Vectors used for in-house cloning and other expression plasmids are detailed in 
Table 2.1 and 2.2.  
 
Table 2.1 Vectors 










Promega – modified in house 
BD Biosciences 




Table 2.2 Expression plasmids 




EGFP pEGFP-C2 Clontech 
EGFP-LC3 pEGFP-C1 Prof Chris Miller (Basic 
and Clinical 
Neuroscience, Kings 
Collage London, UK) 
EGFP-USP8 EGFP-C1 Prof Sylvie Urbe (Institute 
of Translational Medicine, 
University of Liverpool, 
UK) (Row et al., 2006) 
FIP200-6xHis 1-638 pCI-neo In house: See 2.2.1.6 
FIP200-6xHis 639-1373 pCI-neo In house: See 2.2.1.6 
FIP200-6xHis 1374-1591 pCI-neo In house: See 2.2.1.6 
FLAG-C9orf72L 3xFLAG-CMV In house: Dr. Mathew 
Walsh and Dr. Adrian 
Higginbottom 
FLAG-C9orf72S 3xFLAG-CMV In house: Dr. Mathew 
Walsh and Dr. Adrian 
Higginbottom 
FLAG-FIP200 3xFLAG-CMV10 Addgene #24300 (Hara et 
al., 2008) 
GST pGEX6p1 GE Healthcare Life 
Sciences 
GST-C9orf72L pGEX6p1 In house: See 2.2.1.6 
GST-C9orf72S pGEX6p1 In house: See 2.2.1.6 
HA-ULK pRK5 Addgene #31963 (Jung et 
al., 2009) 
mCherry-EGFP-LC3 pmCherry-C1-pEGFP Dr. Xuejun Jiang 
(Memorial Sloan-Kettering 
Cancer Centre, NYC, 
USA) (Ganley et al., 
2009) 
mCherry-FIP200 pmCherry-C1-EGFP Prof Terje Johansen 
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(Institute for Medical 
Biology, University of 
Tromsø, Norway) (Pankiv 
et al., 2007) 
mVenus pCI-neo In house: Dr Kurt De Vos 
from prSETB-mVenus 
Myc-ATG13 pRK5 Addgene #3165 (Jung et 
al., 2009) 
Myc-C9orf72L pRK5 In house: Dr. Mathew 
Walsh and Dr. Adrian 
Higginbottom 
Myc-C9orf72L pCI-neo-Myc In house: See 2.2.1.6 
Myc-C9orf72L K14R pCI-neo-Myc In house: See 2.2.1.6 
Myc-C9orf72S pRK5 In house: Dr. Mathew 
Walsh and Dr. Adrian 
Higginbottom 
Myc-Rab1a pCMV-intron myc Addgene #46776 (Dupre 
et al., 2006) 
Myc-Rab1a Q70L pCMV-intron myc In-house from Myc-











2.1.2.2 Escherichia coli growth media 
Luria Bertani agar (LB agar; 32 g/l) 
LB-ampicillin agar (LB agar supplemented with 100 µg/ml ampicillin) 
LB-kanamycin agar (LB agar supplemented with 100 µg/ml kanamycin) 
LB broth (20 g/l) 
LB-ampicillin broth (LB broth supplemented with 100 µg/ml ampicillin) 
LB-kanamycin broth (LB broth supplemented with 100 µg/ml kanamycin) 
2.1.2.3 Reagents for preparation and purification of plasmid DNA 
Plasmids were isolated from bacterial culture using a Nucleospin® plasmid 
purification kit. The reagents used were provided with the kit: 
Resuspension buffer A1 supplemented with RNase A 
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Lysis buffer A2 
Neutralisation buffer A3 
Wash buffer AW 
Wash buffer A4 supplemented with ethanol (80% (v/v) final ethanol 
concentration) 
Elution buffer AE 
2.1.2.4 Reagents for cloning of FIP200 fragments, C9orf72S, 
C9orf72L and C9orf72L K14R 
2.1.2.4.1 Primers for PCR generation of FIP200 fragments, C9orf72S, 
C9orf72L and C9orf72L K14R 
FIP200 fragments were generated with Xho1 restriction sites at the 5’ end and 
6xHis repeats followed by Not1 restriction site at the 3’ end using the following 
primers, in preparation for cloning into the pCI-neo expression vector. 
 
Xho1-FIP200 Fw:  
5’-CTCGAGGCCACCATGAAGTTATATGTATTTCTGGTTA-3’ 
 
Xho1-FIP200 639 Fw:  
5’-CTGGAGGCCACCATGCAAAAGGCATCTGTGAGTCAG-3’ 
 
Xho1-FIP200 1374 Fw:  
5’-CTCGAGGCCACCATGGATCGAGCTCGTTTGCTTGAG-3’ 
 
















The lysine residue at position 14 in C9orf72 was mutated using missense bp 
mutation in the PCR primer. Primers contained a 5’ Xho1 restriction site and a 3’ 
Not1 restriction site in preparation for cloning into the pCI-neo-Myc expression 
vector. The primer sequences are detailed below: 
 








C9orf72S and C9orf72L sequences were amplified by PCR with Xho1 and Not1 
restriction sites 5’ and 3’ in preparation for cloning into the pGEX6p1 GST 










2.1.2.4.2 PCR amplification 
PCR was conducted using the Phusion High-Fidelity DNA polymerase kit (New 
England BioLabs). The manufacturer supplied the following reagents: 
 
5x Phusion HF Buffer 
10 mM dNTP’s 
Phusion High Fidelity DNA polymerase 
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2.1.2.4.3 Reagents for cloning into pCRTM-Blunt II-TOPO vector 
The Zero Blunt® TOPO® PCR cloning kit (Invitrogen) was used for blunt ended 
cloning. The following reagents were supplied with the kit: 
 
10 ng/µl pCRTM-Blunt II TOPO plasmid DNA in: 
50% glycerol 
50 mM Tris-HCl pH 7.4 
1 mM EDTA 
2 mM DTT 
0.1% Triton X-100 
100 µg/ml BSA 
30 µM bromophenol blue 
 
Salt solution: 
1.2 M NaCl 
0.06 M MgCl2 
 
Nuclease Free water 
2.1.2.4.4 Reagents for Transformation of XL10-Gold ultracompetent 
cells 
The following reagents were supplied by the manufacturer (Stratagene: An 
Agilent Technologies Division): 
 
XL10-Gold® ultracompetent cells 
XL10-Gold® β-mercaptoethanol mix 
2.1.2.4.5 Reagents for restriction digest of DNA 
Plasmid DNA was digested using the FastDigestTM enzyme system (Thermo 
Fisher Scientific). 
Nuclease free water 
10x FastDigest® Green Buffer 
FastDigest® enzymes (Xho1 and Not1) 
Plasmid DNA 
2.1.2.4.6 Reagents for agarose gel electrophoresis 
Tris-Acetate EDTA (TAE) buffer: 
40 mM Tris 
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0.11% (v/v) glacial acetic acid 
1 mM EDTA 
buffered to pH 8.0 with NaOH 
 
Agarose 
2.1.2.4.7 Reagents for gel extraction of restriction digested DNA 
The GenEluteTM Gel Extraction Kit (Sigma) was used for gel extraction and 
purification of restriction digested plasmid DNA after agarose gel 
electrophoresis.  
 
The reagents supplied by the manufacturer were: 
Column Preparation Solution 
Gel Solubilisation Solution 
Wash Solution Concentrate (to be diluted with 48 ml 100% ethanol) 
GenElute Binding Column G 
Collection Tubes, 2 ml 
 
Other reagents required were: 
100% ethanol for dilution of wash solution concentrate 
100% isopropanol 
 
2.1.2.4.8 Reagents for de-phosphorylation of linearized DNA vectors 
10x Antarctic Phosphatase Reaction Buffer 
Antarctic Phosphatase 
Linearized vector DNA 
2.1.2.4.9 Reagents for ligation of DNA vectors and inserts 
1:3 molar ratio of linearized vector to insert 
Nuclease free water 
2x Quick Ligation Buffer 
Quick T4 DNA Ligase 
2.1.2.4.10 Reagents for the transformation of Rosetta pLysS 
competent cells 
Rosetta pLysS cells (Novagen) 
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LB-chloramphenicol-ampicillin agar (LB agar supplemented with 34 µg/ml 
chloramphenicol and 100 µg/ml ampicillin) 
Terrific Broth (TB; 1.2% (w/v) Tryptone, 2.4% (w/v) Yeast Extract, 17 M 
Monopotassium phosphate (KH2PO4) and 72 M Dipotassium phosphate 
(K2HPO4) and 0.4% glycerol) 
TB-Chloramphenicol-Ampicillin (TB supplemented with 34 µg/ml 
chloramphenicol and 100 µg/ml ampicillin) 
2.1.2.4.11 Reagents for bacterial production of GST-tagged 
proteins 
Rosetta pLysS competent cells with pGEX6p1 plasmid of interest 
TB-Ampicillin (TB supplemented with 100 µg/ml ampicillin) 
0.5 mM IPTG (working concentration; 1 M stock) 
2.1.3 Mammalian cell culture and transfection 
2.1.3.1 HeLa and Human embryonic kidney (HEK) 293 cell culture 
reagents 
HeLa and HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) with 4.5 g/l glucose supplemented with 10% (v/v) FBS and 1 mM 
sodium pyruvate. Cells were washed with phosphate buffered saline and 
detected with Trypsin-EDTA solution. 
2.1.3.2 Lipofectamine 2000 transfection reagents 
OptiMEM reduced serum media 
Lipofectamine 2000 transfection reagent 
2.1.3.3 Lipofectamine RNAiMax siRNA transfection reagent 
OptiMEM reduced serum media 
Lipofectamine RNAiMax transfection reagent 
Non targeting control siRNA 
C9orf72 siRNA #2: gugcuauagauguaaaguu 
C9orf72 siRNA #D: gaucagggucagaguauua 
FIP200 siRNA #1 caaguuagagguugaacuu 
FIP200 siRNA #2 gaucuuaugugaucgucca 
Rab1a siRNA #1 gaacaaucaccuccaguua 
Rab1a siRNA #2 cagaucaggaguccuucaa 
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2.1.4 General biochemical reagents 
2.1.4.1 Cell lysis buffer 
Radioimmunoprecipitation assay (RIPA) buffer: 
50 mM Tris HCl pH 6.8 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0.1% (w/v) SDS 
0.5% (w/v) deoxycholic acid 
1% (v/v) Triton X-100 
Complete protease inhibitor cocktail 
 
5x Laemmli buffer 
250 mM Tris-HCl pH 6.8 
10% (w/v) SDS 
0.5% (w/v) Bromophenol blue 
50% (v/v) glycerol 
25% (v/v) β-mercaptoethanol 
2.1.4.2 Bradford reagents 
Distilled H2O 
5x BioRad Protein Assay Dye reagent concentrate (Bradford reagent) 
2.1.4.3 Immunoprecipitation 
BRB80 lysis buffer: 
80 mM K-PIPES pH 6.8 
150 mM NaCl 
1 mM EDTA 
1% (v/v) NP40 
Protease inhibitor cocktail 
 
50% protein G bead slurry 
2.1.4.4 In vitro binding assays 
Bacterial lysis and binding: 
RB100 lysis buffer: 
25 mM HEPES (pH 7.5) 
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100 mM KOAc 
10 mM MgCl2 
1 mM DTT 
0.05% (v/v) Triton X-100 
10% (v/v) glycerol 
 
GST protein binding: 
50% glutathione-agarose (GSH) bead slurry 
RB100 buffer 
 
in vitro protein translation 




GSH elution buffer 
50 mM Tris-HCl (pH 7.5) 
100 mM NaCl  
40 mM reduced glutathione 
2.1.4.5 SDS-PAGE and Immunoblotting 
2.1.4.5.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Resolving gel: 
375 mM Tris-HCl pH 8.8 
10, 12 or 15% (v/v) acrylamide 
0.1% (w/v) SDS 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
 
Stacking gel: 
117 mM Tris-HCl pH 6.8 
5.6% (v/v) acrylamide 
0.1% (w/v) SDS 
0.05% (w/v) APS 




25 mM Tris 
192 mM glycine 
0.1% (w/v) SDS 




25 mM Tris 
192 mM glycine 
20% (v/v) methanol 
 
Ponceau S: 
5% (v/v) glacial acetic acid 
0.1% (w/v) Ponceau S 
2.1.4.5.3 Probing of nitrocellulose membranes with antibodies 
TBS-Tween 
0.1% (v/v) Tween-20 in TBS 
 
Blocking buffer 
0.1% (v/v) Tween-20 in TBS 
5% (w/v) dried milk powder 
 
Enhanced Chemiluminescence (ECL) reagent kit (ThermoFisher Scientific): 
Solution A (luminol solution) 
Solution B (peroxide solution) 
Reagents mixed 1:1 
Autoradiography film (GE Healthcare) 
 
The primary and secondary antibodies and their dilutions are detailed in Table 
2.3 and 2.4 
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Table 2.3 Primary antibodies 
Antibody Supplier Species Dilution 
α-tubulin (DM1A) Sigma Mouse WB: 1:10,000 
FLAG tag (M2) Sigma Mouse WB: 1:2000, IF: 1:1000 
GFP (JL8) Clontech Mouse WB: 1:5000 
Myc tag (9B11) Cell Signalling Mouse WB: 1:2000, IF: 1:2000 
p62 (610833) BD Biosciences Mouse IF: 1:1000 
ATG13 (#6940) Cell Signalling Rabbit WB 1:1000 
C9orf72 (HPA023873) Sigma - Atlas Rabbit WB: 1:250, IF: 1:100 
C9orf72 (22637-1-AP) ProteinTech Rabbit WB: 1:250, IF 1:100 
C9orf72 (sc-138763) Santa Cruz Rabbit WB: 1:500, IF: 1:100 
FIP200 
(SAB4200135) 
Sigma Rabbit WB:  1:500 
GAPDH (14C10) Signalling Rabbit WB 1:1000 
HA Sigma Rabbit WB: 1:2000, IF: 1:1000 
LC3 (NB100-2220) Novus Biological Rabbit WB: 1:1000 
Myc tag (#9106) Abcam Rabbit WB: 1:2000, IF: 1:1000 
Phopho-ULK1 S757 
(#6888) 
Cell Signalling Rabbit WB: 1:1000 
ULK1 Cell Signalling Rabbit WB: 1:1000 
 
 
Table 2.4 Secondary antibodies 
Antibody Supplier Species Dilution 
Anti-mouse IgG conjugated to 
horseradish peroxidase 
Abcam Goat WB: 1:5000 
Anti-rabbit IgG conjugated to 
horseradish peroxidase 
Dako Goat WB: 1:5000 
Anti-mouse IgG coupled to 
Alexa Fluor 488 
Invitrogen Goat IF: 1:500 
Anti-mouse IgG coupled to 
Alexa Fluor 568 
Invitrogen Donkey IF: 1:500 
Anti-rabbit IgG coupled to 
Alexa Fluor 488 
Invitrogen Goat IF: 1:500 
Ant-rabbit IgG coupled to Alexa 
Fluor 568 
Invitrogen Goat IF: 1:500 
 
 65 
2.1.4.6 RNA extraction and reverse-transcription quantitative PCR 
(RT-qPCR) 
2.1.4.6.1 RNA extraction 




RNase free water 
2.1.4.6.2 cDNA preparation and RT-qPCR 
cDNA preparation: 
NEB DNase 
10x DNase buffer 




25 mM dNTP mix 
5x reverse transcriptase buffer 
100 mM DTT 
Superscript III Reverse Transcriptase 
 
qPCR: 
2x SYBR Green 
Primer sequences:  
C9orf72 (S and L), FW: gttgatagattaacacatataatccgg 
C9orf72 (S and L) REV: cagtaagcattggaataatactctga  
Rab1a FW: tgtccagcatgaatcccgaa  
Rab1a REV: ggcaagactttccaacccct  
GAPDH FW: gggtggggctcatttgcaggg 








50 mM NH4Cl in PBS 
 
Permeabilisation solution: 
0.2% (v/v) Triton X-100 in PBS 
 
Blocking solution: 
0.2% (v/v) cold water fish gelatin in PBS 
 
Mounting medium: 
Dako fluorescent mounting medium 
2.1.5.2 Proximity Ligation Assay (PLA) 
Blocking solution 
Antibody diluent 
PLA probe MINUS (5x stock) 
PLA probe PLUS (5 x stock) 
Wash buffer A 
Wash buffer B 
Detection reagent Orange (excitation 554 nm: emission 579 nm) 
2.1.6 Drug treatments 
2.1.6.1 Autophagy induction 
Rapamcyin induction: 
500 nM rapamycin in DMEM cell culture medium 
 
Torin1 induction: 
250 nM Torin1 in DMEM cell culture medium 
2.1.6.2 Autophagy inhibition 
Bafliomycin treatment: 
100 nM Bafilomycin A1 in DMEM cell culture medium 
2.1.6.3 Proteasome inhibition 
MG132 treatment: 
10 µM MG132 in DMEM cell culture medium 
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2.1.6.4 Inhibition of protein translation 
Cycloheximide treatment: 
30 µg/ml cycloheximide in DMEM cell culture medium 
2.2 Methods 
2.2.1 General molecular biology methods 
2.2.1.1 Growth and storage of E.coli for plasmid DNA preparation 
E.coli transformed with plasmids of interest were stored at -80 oC in sterile 25% 
(v/v) glycerol in LB broth containing the correct antibiotic for the plasmid. 
 
When culturing bacteria for plasmid purification, E.coli containing the desired 
plasmid were spread onto LB agar plates containing the appropriate antibiotic. 
E.coli were grown for 16 h at 37 oC. Single colonies were picked and grown in a 
1 ml starter culture of LB broth containing the correct antibiotic at 37 oC with 
shaking for 6 h. 100 µl of starter culture was added to 5 ml of LB broth with 
correct antibiotic and incubated at 37 oC for 16 h while shaking at 220 rpm. 
2.2.1.2 Plasmid DNA purification 
Plasmid DNA was purified using a Nucleospin Plasmid purification kit. E.coli 
from a 5 ml overnight bacterial culture were pelleted at 4,000 rpm. The bacterial 
pellet was then resuspended in 250 µl of Resuspension buffer A1. Cells were 
lysed at room temperature for 5 min using 250 µl of Lysis buffer A2. The lysis 
buffer was then neutralised by adding 300 µl of Neutralisation buffer A3. Lysates 
were washed over the silica membrane of the spin column by centrifugation. 
Plasmid DNA binds to the silica membrane. The membranes were washed with 
500 µl Wash buffer AW and then 600 µl Wash buffer A4. Purified plasmid DNA 
was eluted from the silica membrane in 50 µl Elution buffer AE. 
2.2.1.3 Quantification of plasmid DNA 
Spectrophotometric quantitation of plasmid DNA was performed using a 
NanoDrop 1000 (Thermo Scientific) spectrophotometer. The absorbance of 
DNA samples at 260 nm and 280 nm was recorded. An optical density (OD) of 1 
at 260 nm corresponds to a DNA concentration of 50 µg/ml. Protein 
contaminants absorb at 280 and so the ratio of OD readings at 260 nm and 280 
nm indicates purity of the sample (OD260/280). Pure DNA has an OD260/280 value of 
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1.8. 1 µl of elution buffer was used as a blank reading before 1 µl of 
experimental samples were analysed.  
2.2.1.4 Restriction enzyme digest of DNA 
Plasmid DNA was digested with the appropriate FastDigest restriction enzyme 
and corresponding FastDigest buffer according to the manufacturers instructions 
(ThermoFisher Scientific). 1 µl of FastDigest enzyme is sufficient to cut 1 µg of 
DNA in 5 - 15 min at 37 oC. Although no star activity is reported at with such 
short incubation times the volume of enzyme never exceeded 10% v/v of the 
final volume. Reactions were set up in the order as follows: 
 
15.5 µl H2O 
2 µl 10x FastDigest® Green Buffer 
2 µl DNA (up to 1 µg) 
0.5 µl FastDigest® Enzyme 
2.2.1.5 Agarose gel electrophoresis of DNA 
Agarose was dissolved in boiling TAE buffer at a final concentration of 0.5-1.5% 
(w/v) with 1 µl ethidium bromide added per 100 ml and cast on a horizontal gel 
bed with suitable comb. After setting gels were placed in an electrophoresis gel 
tank, submerged in TAE buffer and run at 100 V. Nucleic acid markers were 
used to determine DNA band size (Hyperladder, Bioline). 
2.2.1.6 Cloning of FIP200 fragments, C9orf72 and C9orf72 K14R  
2.2.1.6.1 PCR generation of FIP200 fragments, C9orf72S, C9orf72L 
and C9orf72L K14R 
FIP200 fragments were generated using Phusion High Fidelity DNA polymerase 
(New England BioLabs), 3xFLAG-CMV10-hFIP200 as template and the primers 
indicated in 2.1.2.4.1. C9orf72L, C9orf72L K14R for cloning into pCI-neo-Myc 
were generated using Phusion High Fidelity DNA polymerase (New England 
BioLabs), pRK5-Myc-C9orf72L as template and the primers indicated in 
2.1.2.4.1. C9orf72S and C9orf72L for cloning into pGEX6p1 vectors were 
generated using Phusion High Fidelity DNA polymerase (New England 
BioLabs), pRK5-Myc-C9orf72L as template and the primers indicated in 
2.1.2.4.1. 
 
The individual reaction mix was as follows: 
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12.4 µl nuclease free H2O 
4 µl 5 x High Fidelity Phusion Buffer 
0.4 µl 10 mM dNTP’s 
1 µl template DNA (5 ng/µl stock) 
1 µl 10 µM Fw Primer 
1 µl 10 µM Rev Primer 
0.2 µl Phusion High Fidelity DNA polymerase 
The PCR reaction cycle are detailed in table 2.5 
 
Table 2.5 PCR cycling parameters of Phusion High Fidelity PCR 
Step Number of 
Cycles 
Temperature (oC) Time 












Extension 1 72 Final extension 10 min 
Cooling 1 4 Hold 
 
2.2.1.6.2 Sub cloning into pCRTM-Blunt II TOPO vector 
Phusion High Fidelity DNA polymerase produces blunt ended products. The 
blunt ended FIP200 fragments, C9orf72L, C9orf72L K14R and C9orf72S were 
cloned into the pCRTM-Blunt II-TOPO vector using the Zero Blunt TOPO PCR 
Cloning Kit (ThermoFisher Scientific) according to the manufacturers 
instructions. The pCRTM-Blunt II-TOPO vector is supplied linearized with viral 
topoisomerase covalently bound to the 3’ end of the DNA. The topoisomerase 
cleaves the DNA backbone at 5’-CCCTT forming a phosphor-tyrosyl bond 
between the DNA backbone and the enzyme (Shuman, 1994). This bond is then 
attacked by the 5’OH group of the blunt PCR product, releasing the 
topoisomerase form the DNA backbone. 
 
Ligation of the FIP200 fragments, C9orf72L, C9orf72L K14R and C9orf72S into 
the pCRTM-Blunt II-TOPO was conducted as follows: 
 
4 µl fresh blunt PCR product 
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0.5 µl sterile H2O 
1 µl salt solution 
0.5 µl pCRTM-Blunt II-TOPO vector 
 
Reactions were mixed and incubated at room temperature for 10 min before 
transformation into E.coli. 
2.2.1.6.3 Transformation of XL10-Gold® ultracompetent cells 
1 µl of β-mercaptoethanol (supplied with XL10-Gold® ultracompetent cells) was 
added to 25 µl thawed XL10-Gold® ultracompetent and the cells mixed by 
swirling before incubation on ice for 10 min. 4 µl of the pCRTM-Blunt II-TOPO 
vector with new insert was added to the cells and incubated on ice for 30 min. 
Cells were then heat shocked at 42 oC for 30 s before placing back on ice for 2 
min. Following heat shock, 500 µl pre-warmed LB broth (without antibiotic) was 
added to the cells. Cells were incubated at 37 oC for 1 h while shaking at 220 
rpm. After incubation cells were pulsed down at 500 x g and resuspended in 50 
µl LB broth before plating onto LB-kanamycin agar plates for growth and 
selection. The pCRTM-Blunt II-TOPO vector confers kanamycin resistance. 
Plates were incubated at 37 oC for 16 h. 
2.2.1.6.4 Screening of bacterial colonies 
After overnight incubation at 37 oC, bacterial colonies were picked using sterile 
inoculation loops. Plasmid DNA was prepped from these colonies following the 
protocol detailed in section 2.2.1.2. To screen for the correct insert, pCRTM-Blunt 
II-TOPO plasmid DNA was subjected to restriction digest with Xho1 and Not1 
restriction enzymes as detailed in section 2.2.1.4 and analysed by agarose gel 
electrophoresis detailed in 2.2.1.5. 
2.2.1.6.5 Restriction digest and agarose gel extraction of inserts and 
vector 
After screening of positive pCRTM-Blunt II-TOPO clones, inserts were excised by 
double restriction digest with Xho1 and Not1 FastDigest restriction enzymes 
(Thermo Fisher Scientific). To allow ligation of these inserts into the appropriate 
expression vectors, pCI-neo, pCI-Neo-Myc and pGEX6p1 vectors were 
subjected to restriction digest with the same restriction enzymes. Thus 
complementary sticky ends were produced to allow ligation. The restriction 
digests were set up as follows: 
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FIP200 fragment, C9orf72L K14R, C9orf72S and C9orf72L pCRTM-Blunt II-
TOPO digest: 
2 µg pCRTM-Blunt II-TOPO vector with insert 
4 µl FastDigest® Green Buffer 
up to 38 µl with H2O 
1 µl Xho1 FD enzyme 
1 µl Not1 FD enzyme 
 
pCI-neo, pCI-neo-Myc and pGEX6p1 digest: 
3 µg vector 
4 µl FastDigest® Green Buffer 
up to 38 µl with H2O 
1 µl Xho1 FD enzyme 
1 µl Not1 FD enzyme 
 
Restriction digests were incubated at 37 oC for 1h to allow complete digestion. 
Restriction digests were run on 1% agarose gels as detailed in section 2.2.1.5 to 
allow separation of insert and linearized vectors. Bands were visualized on 
transilluminator and excised using a scalpel blade. 
 
Inserts and linearized plasmids were purified using a GenEluteTM Gel Extraction 
Kit according to the manufacturers protocol. Excised bands were weighed and 
300 µl Gel Solubilization Buffer added per 100 mg of gel (or 3 gel volumes) and 
incubated at 60 oC for 10 min or until the gel was completely dissolved. The 
GenElute Binding Column G was prepared by adding 500 µl Column 
Preparation Solution to maximise DNA binding to the membrane. The column 
and collection tube was centrifuged at 17,000 x g for 1 min and the flow-through 
discarded. After solubilisation of the gel, 1 gel volume of 100% isopropanol was 
added to Solubilization Buffer and mixed. DNA was bound to the column by 
loading this solution to the GenElute Binding Column G and centrifuging at 
17,000 x g for 1 min. The flow through discarded and 700 µl Wash Solution 
loaded and centrifuged at 17,000 x g for 1 min. The flow through was discarded 
and the column centrifuged again at 17,000 x g for 1 min to remove excess 
ethanol from the Wash Solution. To elute the DNA, 30 µl Elution Solution (pre-
heated to 65 oC) was added to the centre of the GenElute Binding Column G 
membrane and incubated for 1 min, before centrifuging at 17,000 x g for 1 min. 
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The purified inserts and linearized vectors were quantified as detailed in section 
2.2.1.3. 
2.2.1.6.6 De-phosphorylation of linearized vectors 
To prevent re-ligation of the linearized vectors, vectors were dephosphorylated 
with Antarctic Phosphatase (New England BioLabs) to remove the 5’ phosphate. 
The de-phosphorylation reaction was set up as follows: 
 
27 µl eluted gel purified linearized vector 
2.8 µl 10x Antarctic Phosphatase Reaction Buffer 
0.2 µl Antarctic Phosphatase 
 
The de-phosphorylation reaction was incubated at 37 oC for 20 min and then 75 
oC for 10 min to inactivate the enzyme. 
2.2.1.6.7 Ligation of purified inserts and linearized vectors 
Ligation of purified inserts into linearized de-phosphorylated vectors was 
performed using Quick T4 DNA Ligase (New England BioLabs). For efficient 
ligation a 1:3 molar ratio of vector to insert was used. The ligation reaction was 
set up as follows: 
 
50 ng of linearized vector with 3-fold molar excess of insert 
up to 10 µl with H2O 
10 µl 2x Quick Ligation Buffer 
1 µl Quick T4 DNA Ligase 
 
Ligation reactions were mixed and incubated at room temperature for 5 min, 
before chilling on ice. The following ligations were performed: 
 
Xho1-FIP200-6xHis 1-638-Not1 was ligated into pCI-neo 
Xho1-FIP200-6xHis 639-1373-Not1 was ligated into pCI-neo 
Xho1-FIP200-6xHis 1374-1591-Not1 was ligated into pCI-neo 
Xho1-C9orf72L K14R-Not1 was ligated into pCI-neo-Myc 
Xho1-C9orf72L-Not1 was ligated into pCI-neo-Myc 
Xho1-C9orf72L-Not1 was ligated into pGEX6p1 
Xho1-C9orf72S-Not1 was ligated into pGEX6p1 
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pCI-neo based vectors were transformed into XL10-Gold® ultracompetent cells 
as detailed in 2.2.1.6.3. pGEX6p1 based vectors were transformed into Rosetta 
pLysS cells for bacterial expression, as detailed in 2.2.1.6.7 below. 
2.2.1.6.8 Transformation of Rosetta pLysS cells with 
Rosetta pLysS cells are derivatives of BL-21 E.coli cells. 80 µl of Rosetta pLysS 
cells were thawed on ice and 500 ng of pGEX6p1 control, pGEX6p1-C9orf72S 
or pGEX6p1-C9orf7L vector added. Cells were incubated on ice for 10 min 
before heat shock at 42 oC for 30 s and then placed back on ice for 2 min. 
Following heat shock, 500 µl pre-warmed LB broth (without antibiotic) was 
added to the cells. Cells were incubated at 37 oC for 1 h while shaking at 220 
rpm. After incubation cells were pulsed down at 500 x g and resuspended in 50 
µl LB broth before plating onto LB-ampacillin/chloramphenicol agar plates for 
growth and selection. The pLysS cells carry a chloramphenicol resistant plasmid 
encoding a T7 lysozyme, while the pGEX6p1 vector confers ampicillin 
resistance. Plates were incubated at 37 oC for 16 h. 
2.2.1.6.9 Bacterial production of GST-tagged proteins 
After overnight incubation, multiple colonies were picked from the plates with a 
single sterile inoculation loop and cultured in 50 ml TB-chloramphenicol-
ampicillin overnight at 37 oC while shaking at 220 rpm. After overnight 
incubation, 10 ml of this culture was used to inoculate 750 ml TB with ampicillin 
in baffled 1 l Erlenmeyer flasks to aid oxygenation while shaking, and mixed 
thoroughly. Chloramphenicol was absent from this TB as it can inhibit protein 
translation during the induction. The optical density of this solution was then 
measured using a WPA Spectrawave S1200 Visible Spectrophotometer 
(Biochrom Ltd) at 600 nm. Flasks were incubated at 37 oC while shaking at 220 
rpm and the OD recorded every 30 min. When bacteria were in the exponential 
phase, i.e. doubling every 30 min, and an OD of 0.7 at 600 nm was reached, the 
Rosetta pLysS cells were induced to express the protein of interest from the 
pGEX6p1 vector by the addition of 0.5 mM IPTG for 3 h. After induction for 3 h 
at 37 oC while shaking at 220 rpm the culture was centrifuged at 4,000 rpm in an 
Avanti J-26 XP centrifuge (Beckman Coulter) using a JA-10 rotor, to pellet the 
bacteria. These induced bacterial pellets were then used in the in vitro binding 
assays as detailed in 2.2.3.3. 
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2.2.2 Mammalian cell culture and transfection 
2.2.2.1 HeLa and HEK293 cell culture 
HeLa and HEK293 cell cultures were maintained in a monolayer in DMEM at 37 
oC in a 5% CO2 atmosphere. Cells were passaged when then reached 
approximately 90% confluency. Growth media was removed and cells washed in 
PBS to remove excess serum. Cells were detached from the culture surface 
using Trypsin-EDTA solution at a sufficient volume to cover the surface of the 
culture vessel (e.g. 1 ml of Trypsin-EDTA to a 25 cm2 culture flask). Cells were 
then incubated at 37 oC for 2 min. Trypsin-EDTA was quenched with the 
addition of DMEM cell culture medium (e.g. 4ml to 25 cm2 culture flask). Cells 
were pipetted up and down to triturate them and the suspension split to new 
flasks and vessels for further culture or experimentation. 
2.2.2.2 Induced Neural Progenitor Cell (iNPC) production and 
neuronal differentiation 
iNPC production, and neuronal progenitor differentiation was performed 
by Dr. Laura Ferraiuolo and Miss Monika Myszczynska. Induced neural 
progenitor cells (iNPCs) were derived from human skin fibroblasts as 
previously described (Meyer et al., 2014). Briefly, 10,000 fibroblasts were 
transduced with lentiviral vectors for OCT3, Sox2, KLF4, and C-MYC for 
12h. 48h after transduction, the cells were washed with PBS and 
fibroblast medium was replaced with NPC medium (DMEM/F-12 with 
Glutamax supplemented with 1 %N2, 1% B27, 20 ng/ml FGF-b, 20 ng/ml 
EGF and 5 µg/ml Heparin. As the cells started changing shape and form 
neurospheres they were expanded as neural rosettes. When the iNPC 
culture was confluent (~3 weeks) EGF and Heparin were withdrawn and 
the FGF-b concentration increased to 40 ng/ml. The iNPCs can be 
maintained for ~30 passages. iNPCs are not expanded by clone and 
therefore do not display clonal variability. 
For differentiation, 30,000 iNPCs were plated in a 6-well plate coated with 
fibronectin (Millipore) and expanded to 70-80% confluence after which 
iNPC medium was replaced with neuron differentiation medium 
(DMEM/F-12 with Glutamax supplemented with 1% N2, and 2% B27). On 
day one of differentiation the cells were treated with 2.5 µM DAPT 
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(Tocris) to determine differentiation towards neuronal lineage. On day 
three the neuron differentiation medium was supplemented with 1 mM 
retinoic acid (Sigma), 0.5 mM Smoothened Agonist (SAG) (Millipore) and 
2.5 mM Forskolin (Sigma) for 7 days. This protocol leads to typical yields 
of 70% ß-III tubulin (Tuj1) positive cells.  
iNeuron experiments were repeated at least 3 times for each sample 
starting from iNPCs at different passages, typically between passage 10 
and 20 to ensure that the results observed are not determined by batch 
effects or passage number. 
2.2.2.3 Transient transfection of HeLa and HEK293 cells with 
plasmid DNA 
HeLa and HEK293 cells were transiently transfected using Lipofectamine 2000 
transfection reagent according to the manufacturers instructions. Cells were 
plated to 12 mm diameter cover slips in 24 well plates, 12 well plates, 6 well 
plates or 10 cm diameter plates the day before transfection to ensure 
approximately 70% confluency on the day of transfection. The volumes of each 
reagent are detailed in table 2.6.  
 
Table 2.6 DNA transfection with Lipofectamine 2000 
Plate Lipofectamine 










24 well plate 1 µl 25 µl 0.5 µg 25 µl 
12 well plate 2 µl 50 µl 1 µg 50 µl 
6 well plate 4 µl 100 µl 2 µg 100 µl 
10 mm plate 20 µl 250 µl 10 µg 250 µl 
 
The correct volume of Lipofectamine 2000 transfection reagent was diluted in 
OptiMEM to give Mix A. Mix B contained the correct amount of plasmid DNA 
diluted in OptiMEM. Mix A was incubated for 5 min at room temperature and 
then combined with Mix B. The transfection solution was then incubated at room 
temperature for 15-20 min before being added drop-wise to the cells. Media was 
replaced on the cells after 6 h. Cells were incubated at 37 oC in a 5% CO2 
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atmosphere for 24 h post transfection before cells were used for 
experimentation. 
2.2.2.4 siRNA transfection of HeLa and HEK293 cells 
HeLa cells were transfected with siRNA using the Lipofectamine RNAiMax 
transfection reagent according to the manufacturers instructions. Cells were 
seeded on 13 mm diameter cover slips the day before transfection. Cells were 
seeded such that they would reach 70-80% confluency 4 days post transfection. 
siRNA was reconstituted in 100 µl RNase free water to give 10 µM stocks of 
each siRNA. For RNAiMax siRNA transfection this stock solution was then 
diluted 1:10 in RNase free water. The volumes of each reagent are detailed in 
Table 2.7. 
 
Table 2.7 siRNA transfection with Lipofectamine RNAiMax 
Plate RNAiMax vol 
per well (µl) 
RNAiMax 
OptiMEM vol 
per well (µl) 
Diluted 
siRNA vol 
per well (µl) 
siRNA 
OptiMEM vol 
per well (µl) 
24 well plate 0.6 µl 25 µl 0.6 µl 25 µl 
  
Lipofectamine RNAiMax was diluted in OptiMEM to give Mix A and the correct 
volume of siRNA diluted separately in OptiMEM to give Mix B. Mix A was 
incubated for 5 min at room temperature before being combined with Mix B. The 
combined transfection solution was incubated at room temperature for 15-20 
min before being added drop wise to the cells. The media on the cells was 
replaced after 6 h. Cells were incubated at 37 oC in a 5% CO2 atmosphere for 4 
days. Cells were either fixed for immunofluorescence on day 4 or transiently 
transfected with DNA constructs using Lipofectamine 2000 reagent on day 3 
and then fixed for immunofluorescence on day 4. 
 
HEK293 cells were transfected with siRNA using Lipofectamine 2000 
transfection reagent according to the manufacturers protocol. Cells were seeded 
to 12 well or 6 well plates the day before transfection. Cells were seeded such 
that they should reach 70-80% confluency 4 days post transfection. siRNA was 
used from the 10 µM stock and not diluted further for use with Lipofectamine 
2000 transfection. The volumes of each reagent are detailed in Table 2.8. The 
same protocol used for RNAiMax siRNA transfection was used for 
Lipofectamine 2000 siRNA transfection. 
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Table 2.8 siRNA transfection with Lipofectamine 2000 
Plate Lipofectamine 










per well (µl) 
12 well plate 2 µl 50 µl 1 µl 50 µl 
6 well plate 4 µl 100 µl 2 µl 100 µl 
 
2.2.3 General Biochemical methods 
2.2.3.1 Cell lysis 
Cells were harvested in Trypsin-EDTA solution and resuspended in fresh DMEM 
cell culture medium to quench the trypsin. Cells were pelleted at 400 x g for 4 
min and pellets washed in PBS. Cell pellets were lysed on ice for 30 min in ice-
cold RIPA buffer. Lysates were clarified at 17,000 x g for 20 min at 4 oC. 
2.2.3.2 Bradford Assay 
The colorimetric Bradford assay was used to determine the protein 
concentration of cell lysates (Bradford, 1976). The assay is based on the 
principle that the Bradford reagent is able to bind protein, which results in a 
colour change of the reagent. This change in absorbance can be easily 
measured to quantify the amount of protein present in a sample. Bradford 
reagent was diluted 1:5 to give a working solution. Using a 96 well plate, the top 
row was reserved for Bradford reagent alone for background reads. The second 
row was reserved for the standard curve. 200 µg of BSA was added to 200 µl of 
Bradford reagent and added to the first well of the second row. A serial dilution 
of 1:2 was then conducted across this row to allow the construction of a 
standard curve. To measure protein concentration of the samples, 2 µl of 
sample was added to 200 µl of Bradford reagent, and a 1:2 serial dilution of 
each sample was conducted. The plate was read in a Pherastar plate reader 
(BMG LABTECH) at an absorption wavelength 595 nm. The Bradford-only 
average was subtracted from all readings and a standard curve constructed by 
plotting OD against protein concentration. Using the gradient of the standard 
curve the concentration of each sample was calculated using the equation: 
concentration = (OD x gradient x dilution factor). 
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2.2.3.3 Immunoprecipitation 
Cells were harvested in Trypsin-EDTA solution and resuspended in fresh DMEM 
cell culture medium to quench the trypsin. Cells were pelleted at 400 x g for 4 
min and pellets washed in PBS. Cells were lysed at 4 oC for 1 h with rolling in 
BRB80 buffer. Lysates were clarified at 17,000 x g for 20 min at 4 oC and the 
protein concentration measured via the Bradford assay (section 2.2.3.2). 50 µg 
of protein was kept as an Input sample. For the immunoprecipitation, 1 mg or 
protein was incubated with 1 µg of primary antibody for 16 h at 4 oC while rolling. 
20 µl of 50% protein G sepharose bead slurry was added to each sample for 2 h 
at 4 oC while rolling to capture the antibody. Samples were centrifuged for 3 min 
at 3,000 x g at 4 oC to pellet the beads. Slow speeds were used to prevent the 
beads from crushing and collapsing. Immune pellets were washed 5 x in ice cold 
BRB80 immunoprecipitation lysis buffer. After the final wash, the remaining 
BRB80 buffer was removed and the proteins eluted from the protein G beads in 
2 x laemmli buffer ready for analysis by SDS-PAGE and immunoblot. FLAG-
tagged proteins were eluted by competition rather than 2 x laemmli by 
incubating the immune pellets in excess of the FLAG-peptide at 4 oC for 1 h 
while rolling. Beads were spun down at 3,000 x g and the eluate removed and 
prepared for SDS-PAGE and immunoblot. In all cases half the 
immunoprecipitation sample was analysed by SDS-PAGE and immunoblot, 
excluding endogenous immunoprecipitations. In these experiments the whole 
immune pellet was analysed. 
2.2.3.4 In vitro binding assays 
[35S]-methionine labelled FLAG-FIP200 1-638, 639-1373, 1374-1591, HA-ULK, 
Myc-ATG13 or Myc-Rab1a proteins were produced from their corresponding 
vectors using the Sp6 or T7 TnT Quick Coupled Transcription/Translation kit 
(Promega) as detailed in Table 2.9. In vitro translated protein was produced 
according to the manufacturers instructions. Individual reactions were mixed as 
follows: 
 
0.5 µg plasmid DNA in 1.5 µl H2O 
0.5 µl [35S]-methionine 
8 µl corresponding Reticulocyte lysate 
 




Table 2.9 Plasmids and TnT quick-coupled transcription/translation kits 
Construct Vector Promoter/TnT Kit 
6xHis-FIP200 1-638 pCI-neo T7 
6xHis-FIP200 639-1373 pCI-neo T7 
6xHis-FIP200 1374-1591 pCI-neo T7 
Myc-Rab1a pCMV-intron T7 
Myc-ATG13 pRK5 Sp6 
HA-ULK1 pRK5 Sp6 
 
GST, GST-C9orf72S and GST-C9orf72L were expressed from the pGEX6p1 
vector in Rosetta PLysS cells as detailed in section 2.2.1.6.9. 0.1 g GST cell 
pellet and 0.25 g GST-C9orf72 cell pellets were lysed by sonication in 1 ml of 
buffer RB100 and GST tagged proteins bound to 30 µl of glutathione-agarose 
(GSH) bead slurry. Binding reactions were carried out in 400 µl buffer RB100 
containing the 30 µl GSH beads and bound proteins along with 8 µl of 
radiolabelled protein. In the case of myc-Rab1a 1 mM GDP or 1 mM GMP-PNP 
(Guanosine 5’-[β,γ-imido]triphosphate trisodium salt hydrate) was added to the 
binding assays as indicated. Proteins were eluted from GSH beads using 
glutathione elution buffer and analysed by SDS-PAGE. 1 µl reticulocyte lysate 
was loaded as input. The gel was stained with Coomassie to show GST-tagged 
proteins and radioactivity detected using a BioRad phosphorimager and 
phosphorplate. 
2.2.3.5 SDS-PAGE and Immunoblot 
2.2.3.5.1 SDS-PAGE 
Protein samples were boiled in laemmli sample buffer at 95 oC for 5 min. 
Depending on protein size, proteins were separated on 10, 12 and 15% 
polyacrylamide gels by electrophoresis at 100 V for 2 h (or until the dye front 
reached the bottom of the gel) using the Mini-PROTEAN Tetra Cell gel 
electrophoresis system (Bio-Rad) in 1 x running buffer. Depending on the 
number of samples 10 or 15 well combs were used. A Precision Plus Protein™ 
All Blue Prestained Protein Ladder (Bio-Rad) comprising of prestained proteins 
of 250, 150, 100, 75, 50, 37, 25, 20, 15 and 10 kDa was used to determine 
molecular weights of proteins of interest. 
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2.2.3.5.2 Coomassie staining of polyacrylamide gels 
After separation of radiolabelled in vitro binding assay samples via SDS-PAGE, 
gels were stained with Coomassie G-250 to allow visualisation of purified 
proteins prior to exposure to a phophoplate. Gels were stained in Coomassie for 
30 min at room temperature while shaking. After staining, gels were placed in 
destain for 30 min at room temperature while shaking. Destain was replaced 
every 30 min until background staining of the gel was removed and only the 
protein bands remained. Gels were washed thoroughly in H2O before mounting 
and drying onto Whatmann paper. Destained, mounted and dried gels were 
exposed to a phosphoplate in a phophoplate cassette for 3 to 7 days.  
2.2.3.5.3 Transfer of proteins to nitrocellulose membranes 
After SDS-PAGE, proteins were transferred to Protran nitrocellulose membranes 
with a pore size of 0.45 µm. The transfer was set up as follows: 
Cathode – Sponge / 2 x cellulose blot paper (Whatman) / SDS-PAGE gel / 
nitrocellulose membrane / 2 x cellulose blot paper / sponge – Anode 
The sandwich was assembled submerged in transfer buffer, fixed into cassettes 
and placed in a Mini-Transblot cell (Bio-Rad). The transfer was run at 100 V for 
1 h or 30 V for 16 h. After transfer membranes were stained in Ponceau S 
solution for 1 min to determine transfer efficiency of proteins and allow 
membranes to be cut accurately as necessary. Membranes were rinsed for 1 
min in ultrapure H2O to remove excess Ponceau S solution. 
2.2.3.5.4 Antibody probing of nitrocellulose membranes 
Membranes were blocked in 5% milk TBST for 1 h at room temperature while 
shaking. Membranes were then incubated with primary antibodies at the 
appropriate concentration (Table 2.3) in blocking buffer for 1 h at room 
temperature or for 16 h at 4 oC. After incubation with primary antibodies, 
membranes were washed 3 x for 10 min TBST while shaking. Blots were then 
probed with an appropriate dilution of secondary antibody (Table 2.4) coupled to 
horseradish peroxidasee in TBST for 1 h at room temperature. After final 
washing of membranes for 3 x 10 min in TBST, bound secondary antibody was 
detected using enhanced chemiluminescence (ECL) detection reagents 
(ThermoFisher Scientific). Chemiluminescence was visualised on 
autoradiography film (GE Healthcare) or the Syngene G:Box Chemi system 
(Syngene). Oxidation of the luminol substrate in the presence of hydrogen 
peroxide by horseradish peroxidase-coupled secondary antibodies increases 
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the energy state of luminol, which emits energy as light as it returns to its ground 
state. ECL substrates enhance the light output of this reaction. ELC solutions 
were mixed in a 1:1 ratio (luminol solution A: peroxide solution B) and incubated 
on the nitrocellulose membrane for 5 min at room temperature while shaking. 
Membranes were placed in a clear plastic wallet before being placed in an X-ray 
cassette or the Syngene G:Box. When exposing to film, autoradiograph films 
were placed on top of the membrane in a dark room for 5 s to 1 h. Films were 
developed using developer and fixer. 
2.2.3.5.5 Densitometry of bands 
Bands detected on immunoblots were quantified using ImageJ (Abràmoff M. D, 
2004). A region of interest was drawn around the bands of interest and a 
histogram constructed using the plot lanes tool. Background signal was 
subtracted from the histogram and the area under the histogram used to 
represent the level of the protein. In all cases the level of the protein of interest 
was normalised to that of a loading control. 
2.2.3.6 Modulation of autophagy 
Autophagy was induced in HeLa and HEK293 cells by incubation with 500 nM 
rapamycin for 6 h or 250 nM Torin1 for 3 h in DMEM cell culture medium at 37 
oC in a 5% CO2 atmosphere. Autophagy was inhibited by the addition of 100 nM 
Bafilomycin A1 to the cell culture medium for 6 h at 37 oC in a 5% CO2 
atmosphere. To measure specifically autophagy initiation, autophagy was 
induced with rapamycin or Torin1 in the presence of Bafilomycin A1. Cells were 
then lysed as above and the levels of LC3 analysed by SDS-PAGE and 
immunoblot. Where Torin1 was added along with Bafliomycin A1, 250 nM Torin1 
was added after the first 3 h of 100 nM Bafilomycin A1 treatment. 
2.2.3.7 Inhibition of protein translation 
Protein translation was inhibited in HEK293 cells by the addition of 33 µg/ml of 
cycloheximide to the DMEM cell culture medium. Samples were harvested after 
different time points and the levels of the protein of interested analysed by SDS-
PAGE and immunoblot. 
 
To determine which system was responsible for degradation of C9orf72, 
HEK293 cells transfected with Myc-tagged C9orf72S and L were either 
untreated, treated with 100 nM Bafilomycin A1, to inhibit autophagy, or 10 µM 
MG132, to inhibit the proteasome, in the presence of 33 µg/ml cycloheximide for 
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the indicated times. Levels of C9orf72 were analysed by SDS-PAGE and 
immunoblot to determine levels of C9orf72 protein. 
2.2.3.8 RNA extraction and RT-qPCR 
2.2.3.8.1 RNA extraction 
RNA was extracted from HeLa, HEK293 and iNeuron cells using Trizol reagent 
(Invitrogen) according to the manufacturers instructions. 1 ml of Trizol was 
added per 10 cm2 of cell monolayer and incubated at room temperature for 5 
min. Cell lysate was transferred to 1.5 ml eppendorf and 200 µl chloroform 
added. Samples were shaken vigorously by hand for 15 s and then incubated at 
room temperature for 3 min. Samples were centrifuged at 12,000 x g for 15 min 
at 4 oC to separate the sample into three distinct phases. RNA remained 
exclusively in the upper aqueous phase. RNA was precipitated from the upper 
aqueous phase by mixing with 500 µl of isopropanol per 1 ml of Trizol used 
initially. Samples were incubated at room temperature for 10 min and then 
centrifuged at 12,000 for 10 min at 4 oC to pellet the RNA. The supernatant was 
removed and the RNA pellet washed once with 1 ml 75% ethanol per 1 ml of 
Trizol reagent used initially. Samples were mixed by vortex and centrifuged at 
7,500 x g for 5 min at 4 oC. The supernatant was removed and the RNA pellet 
was allowed to air dry for 3 min. RNA was dissolved in 20 µl RNase free water 
and incubated at 55 oC for 10 min. 
2.2.3.8.2 RT-qPCR 
RNA from whole cell extraction was reverse transcribed into cDNA using 
Superscript III reverse transcriptase (Invitrogen) as follows:  
 
2 µg RNA was transcribed in a final volume of 10 µl 
2 µl 25 mM dNTP mix (NEB) 
2 µl 5 x reverse transcriptase buffer (Invitrogen) 
2 µl 0.1 M DTT 
1 µl of Superscript III 
1 µl of Oligo(dT) (Thermo Scientific).  
RT-qPCR was performed using the Stratagene Mx3000P and MxPro 
v4.10 software. Samples were amplified in triplicate in 10 µl volumes 
using SYBR-Green master mix and 250 nM of each optimized forward 
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and reverse primer. Cycling conditions for RT-qPCR were as follows: 
95˚C for 10 min to denature followed by 35 cycles of 95˚C for 30 s, 60˚C 
for 1 min. Levels of mRNA were quantified relative to GAPDH mRNA 
levels according to the ΔΔCt method. 
2.2.4 Microscopy 
2.2.4.1 Immunofluorescence 
Immunostaining was performed as described previously (De Vos et al., 2005). 
HeLa or HEK293 cells on glass coverslips were fixed with 3.7 % formaldehyde 
in phosphate buffered saline (PBS) for 20 min at room temperature. After 
washing with PBS, residual formaldehyde was quenched by incubation with 50 
mM NH4Cl in PBS for 10 min at room temperature, followed by a second round 
of washing with PBS. Subsequently, the cells were permeabilized by incubation 
with 0.2% Triton-X100 in PBS for 3 min. Triton-X100 was removed by washing 
with PBS. After fixing, the cells were incubated with PBS containing 0.2% fish 
gelatine (PBS/F) for 30 min at room temperature and then with the primary 
antibody in PBS/F for 1 h. After washing with PBS/F, the cells were incubated 
with secondary antibody in PBS/F for 45 min at room temperature. After a final 
wash, the samples were mounted in fluorescence mounting medium (Dako). 
Images were recorded using MicroManager 1.4 software (Edelstein et al., 2014) 
on a Zeiss Axioplan 2 microscope fitted with a Hamamatsu C4880-80 multi-
format CCD camera and a 63x, Plan Apochromate 1.4NA objective. 
2.2.4.2 Proximity Ligation Assay 
In-situ proximity ligation assays were performed using rabbit anti-HA (Sigma, 
1:1000) and mouse anti-Myc (9B11, Cell Signaling, 1:2000) antibodies with the 
Duolink In-Situ Kit following the manufacturer’s protocol (Olink Bioscience). 
HeLa cells seeded on glass cover slips and treated with control (Ctrl) or C9orf72 
siRNA for 72 h were transfected with HA-ULK1, Myc-Rab1a or HA-ULK1+Myc-
Rab1a along with mVenus to indicate co-transfection. 24 h post transfection, 
cells were fixed, quenched and permeabilized as described in 2.2.4.1. Samples 
were blocked according to the manufacturer’s instructions using the blocking 
solution provided. Samples were then probed with anti-HA and anti-myc 
antibodies for 1 h at room temperature. After washing in Wash Buffer A, cells 
were incubated with mouse-minus and rabbit-plus PLA probes according to the 
manufactures instructions for 1 h at 37oC in antibody diluent. After further 
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washes in Wash Buffer A, the PLA probes were ligated for 30 min at 37oC 
before the amplification step was performed for 100 min at 37oC using the 
Duolink Orange detection reagents. After final washes in Wash Buffer B the 
samples were mounted in fluorescence mounting medium (Dako). 
2.2.4.3 Image Analysis 
All image analysis was performed using ImageJ (Abràmoff M. D, 2004). 
mCherry-FIP200, EGFP-LC3 and mCherry-EGFP-LC3 puncta, and PLA 
proximity signals were counted in single cells using the Particle Analysis facility 
of ImageJ. Where possible the cells for analysis were selected based on 
fluorescence in the other channel, else the samples were blinded to the 
operator. Images were filtered using a Hat filter (7x7 kernel) (De Vos and 
Sheetz, 2007) to extract puncta and proximity signals and thresholded such that 
the visible puncta within the cell were highlighted, but no background was 
included. The result of thresholding was further checked against the original 
image to ensure no background signal was identified as puncta or signals. In 
case of mCherry-EGFP-LC3, puncta in the red and green channels were 
counted separately. Red only puncta were determined by subtracting the green 
puncta from the red puncta. 
2.2.5 Statistical analysis 
Calculations and statistical analysis were performed using Excel (Microsoft 
Corporation, Redmond, WA), and Prism 6 software (GraphPad Software Inc., 
San Diego, CA). 
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3 Identification	  of	  C9orf72	  binding	  partners	  
3.1 Introduction 
A hexanucleotide repeat expansion of GGGGCC in C9orf72 is the most 
common genetic defect associated with ALS and FTD. C9orf72 encodes two 
uncharacterised proteins that are highly conserved in vertebrates. As detailed in 
section 1.7.2, there are multiple mechanisms by which the expansion may 
cause disease, including C9orf72 haploinsufficiency (Belzil et al., 2013; Cooper-
Knock et al., 2012; DeJesus-Hernandez et al., 2011; Xi et al., 2013). Protein-
protein interaction networks have been suggested as a possible method to 
predict protein function (Schwikowski et al., 2000; Vazquez et al., 2003). Thus 
by identifying binding partners of C9orf72, the aim was to characterize the 
cellular function of this protein. 
 
The specific p62 positive, TDP-43 negative, pathology associated with 
C9ALS/FTD suggested that C9ALS/FTD patients might be deficient in 
autophagy (Al-Sarraj et al., 2011; Cooper-Knock et al., 2012; Stewart et al., 
2012). A screening study investigating the autophagy network had previously 
identified C9orf72 as a potential interacting partner of FIP200 (Behrends et al., 
2010). Interestingly, neural specific conditional knockout of FIP200 in mice leads 
to neurodegeneration, and cerebellar accumulations of p62, similar to 
C9ALS/FTD (Liang et al., 2010), suggesting loss of FIP200 and 
haploinsufficiency of C9orf72 may share a common pathology. Thus, in a 
hypothesis driven approach, the first set of protein interaction studies were 
focused around FIP200 and the autophagy pathway. To investigate the 
interaction of C9orf72 and members of the autophagy pathway co-
immunoprecipitation experiments were conducted along with in vitro binding 
assays.  
 
Secondly, two unbiased approaches were conducted to identify interacting 
partners: a mass spec screen, conducted by Dr. Mathew Walsh, Dr. Guillaume 
Hautbergue and Professor Pamela Shaw, and a yeast two hybrid (Y2H) screen. 
Positive hits received from these screens were then confirmed in the laboratory 
by co-immunoprecipitation experiments.  
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Firstly, a characterization of the C9orf72 protein was conducted using the 
commercially available antibodies in an attempt to detect endogenous C9orf72 
via immunoblot and immunofluorescence.  
3.2 Results 
3.2.1 Characterization of C9orf72 antibodies and siRNA 
Several commercial antibodies against C9orf72 are available, but their 
specificity for endogenous C9orf72 protein has been questioned (DeJesus-
Hernandez et al., 2011). Recently, one group has developed isoform specific 
antibodies for C9orf72, which appear to detect endogenous C9orf72S and 
C9orf72L (Xiao et al., 2015). Unfortunately, these antibodies were unavailable 
during preparation of this thesis. Three commercial rabbit polyclonal anti-
C9orf72 antibodies were tested: anti-C9orf72 from Santa Cruz Biotechnology 
(sc-138763), anti-C9orf72 from Atlas Antibodies (HPA023873) and anti-C9orf72 
from ProteinTech (22637-1-AP). Santa Cruz anti-C9orf72 sc-138763 and 
ProteinTech anti-C9orf72 22637-1-AP were raised against peptides 
corresponding to unspecified internal regions of the C9orf72 protein, Atlas anti-
C9orf72 HPA023873 was raised against amino acids 110 to 200 of C9orf72 
protein. While Atlas anti-C9orf72 HPA023873 should recognise both isoforms of 
C9orf72, whether the other antibodies would have this ability was unknown. To 
determine the specificity of these antibodies, they were initially used in western 
blot analysis of HEK293 cell lysates. As a positive control HEK293 cells were 
transfected with either Myc-tagged C9orf72S or Myc-tagged C9orf72L. Both 
these constructs were produced in-house. HEK293 cells were transfected with 
empty vector, Myc-C9orf72S or Myc-C9orf72L. 24 h post transfection lysates 
were subjected to SDS-PAGE and immunoblot. Blots were probed with anti-Myc 
9B11 antibody to show the positions of Myc-C9orf72S and Myc-C9orf72L (Fig. 
3.1D) or one of the three commercial C9orf72 antibodies as indicated (Figs 
3.1A-C). As shown in Figure 3.1 all three commercial antibodies were able to 
detect transfected Myc-tagged C9orf72S and L. However, at short exposures no 
commercially available antibodies produce a banding pattern that could 
correspond to endogenous C9orf72. The Santa Cruz anti-C9orf72 sc-138763 
antibody detected a range of other bands with the longer exposure, but only in 
samples that had been transfected with Myc-C9orf72, suggesting these were 
some sort of aggregates or degradation products (Fig. 3.1A). There were faint 
bands in the empty vector transfected control lane at around 25 kDa and 50 
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kDa, possibly corresponding to endogenous C9orf72S and L (Fig 3.1A). A 
longer exposure with the anti-C9orf72 antibody from ProteinTech (22637-1-AP), 
revealed only a band that ran at a higher molecular weight than Myc-C9orf72L 
suggesting this antibody was unable to detected endogenous C9orf72 (Fig. 
3.1B). A longer exposure with the Atlas anti-C9orf72 HPA023873 antibody 
revealed a slightly lighter band at approximately 50 kDA in all samples below 
that of Myc-C9orf72L, which could correspond to endogenous C9orf72L, but no 
band corresponding to endogenous C9orf72S was detected (Fig. 3.1C). It 
appeared that in all cases the strength of the Myc-C9orf72 signal was masking 







Figure 3.1 Commercial anti-C9orf72 antibodies detect transfected epitope 
tagged C9orf72 on immunoblot. HEK293 cells transfected with empty vector 
(Ctrl), Myc-tagged C9orf72S or Myc-tagged C9orf72L were lysed 24 h post 
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transfection and subjected to SDS-PAGE and immunoblot. Myc-tagged proteins 
were detected with anti-Myc antibodies (D). Blots were probed with three 
commercial anti-C9orf72 antibodies: anti-C9orf72 from Santa Cruz 
Biotechnology (sc-138763) (A), anti-C9orf72 from ProteinTech (22637-1-AP) (B) 
and anti-C9orf72 from Atlas Antibodies (HPA023873) (C). 
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To confirm whether the bands detected by the endogenous antibodies at longer 
exposures related to endogenous C9orf72, the antibodies were tested on cell 
samples that had been treated with targeted siRNA to ablate C9orf72 
expression. HEK293 cells were treated with control (Ctrl) siRNA or C9orf72 
targeted siRNA. After 4 days of treatment cells were harvested, lysed and 
samples analysed by SDS-PAGE and immunoblot. Samples were probed with 
anti-C9orf72 sc-138763, anti-C9orf72 22637-1-AP and anti-C9orf72 
HPA023873. GAPDH was used as a loading control. The banding pattern 
detected by the Santa Cruz sc-138763 antibody was unaffected by C9orf72 
siRNA suggesting that the bands at 25 kDa and 50 kDa (indicated by * in Fig. 
3.2A) were non-specific and not endogenous C9orf72 (Fig. 3.2A). Similarly, the 
bands detected by the ProteinTech 22637-1-AP antibody at approximately 150 
kDa and 60 kDa (indicated by * in Fig. 3.2B) were unaffected by C9orf72 siRNA, 
suggesting these were not related to endogenous C9orf72. However, the 
banding pattern detected by the Atlas HPA023873 antibody was altered after 
C9orf72 knock down (Fig. 3.2C). Three bands around 50 kDa (one at 50 kDa, 
one above and one below) were all reduced by C9orf72 siRNA (indicated by <), 
suggesting that these bands may relate to the endogenous C9orf72L signal (Fig. 
3.2C). There was also a band at 75 kDa that was reduced, although how this 
related to the C9orf72L and S isoforms is unclear (Fig. 3.2C). There was no 
band corresponding to C9orf72S and also there was at least one high molecular 
weight band that was unaffected by siRNA knock down at approximately 150 
kDa (*) (Fig. 3.2C). To detect this banding pattern, these commercial antibodies 
were used a relatively high concentrations of 1:250. This suggested that this 
antibody also had low specificity to endogenous C9orf72. The level of C9orf72 
knock down was confirmed by quantitative PCR, which showed approximately 
50% knockdown of C9orf72 mRNA after targeted siRNA (Fig. 3.2D). This led to 
the conclusion that it was unfeasible to conduct further experiments using these 
antibodies, even the Atlas HPA023873 antibody, as it was not possible to 
reliably detect the endogenous C9orf72 isoforms. 
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Figure 3.2 Anti-C9orf72 HPA023873 is able to detect endogenous C9orf72. 
HEK293 cells were transfected with non-targeting (Ctrl) siRNA or a pool of 
C9orf72 targeted siRNA. 4 days post transfection cells were lysed and samples 
analysed by SDS-PAGE and immunoblot. Immunoblots were probed for 
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endogenous C9orf72 with anti-C9orf72 from Santa Cruz Biotechnology (sc-
138763) (A), anti-C9orf72 from ProteinTech (22637-1-AP) (B), and anti-C9orf72 
from Atlas Antibodies (HPA023873) (C - < indicate possible C9orf72 bands, * 
indicate non-specific bands). (D) Level of C9orf72 mRNA was quantified by real 
time quantitative PCR (RT-qPCR). Graph represents mean relative level of 




These antibodies were next tested on immunofluorescence experiments, to 
investigate the localisation of C9orf72. HeLa cells were fixed and stained with 
each of the commercial antibodies. As a positive control HeLa cells were 
transfected with Myc-C9orf72S or Myc-C9orf72L. Again, all three antibodies 
were able to detect transiently transfected C9orf72 as shown by the co-
localisation of the Myc antibody signal and the corresponding C9orf72 antibody 
signal (Fig. 3.3A-C). Neither Myc-C9orf72S nor Myc-C9orf72L showed any 
specific sub cellular localisation, with all three anti-C9orf72 antibodies, as well 
as the Myc antibody, showing a diffuse distribution throughout the cytoplasm 
and nucleus. Both Myc-C9orf72S and Myc-C9orf72L showed a distinct absence 
from the nucleolar type structures of the nucleus (Fig. 3.3A-C). All three 
commercial antibodies showed a diffuse speckled pattern of staining throughout 
the cytoplasm, but with the Atlas HPA023873 and Santa Cruz sc-138763 
antibodies also showing a much more nuclear localised signal that did not 
correspond to the Myc-C9orf72 signal (Fig. 3.3A and B). In comparison, the 
ProteinTech 22637-1-AP antibody showed a diffuse cytoplasmic speckled stain 
that was not enriched in the nucleus (Fig. 3.3C). To determine whether the 
signal seen with these antibodies via immunofluorescence was specific, the 
same staining was conducted on HEK293 cells that had been treated with 
C9orf72 siRNA to ablate expression (Fig. 3.4A). Cells that were treated with 
siRNA in Figure 3.2 were fixed and stained with the commercial C9orf72 
antibodies. None of the commercial antibodies showed any difference in staining 
after C9orf72 siRNA (Fig. 3.4A). It was concluded that the commercial 
antibodies that were available at this time were unable to detect endogenous 
C9orf72 protein. For this reason, the investigations into C9orf72 binding partners 




Figure 3.3 Commercial anti-C9orf72 antibodies detect transfected epitope 
tagged C9orf72 in immunofluorescence. HeLa cells were transfected with empty 
vector control (ev), Myc-C9orf72S or Myc-C9orf72L. Cells were fixed and co-
stained with mouse anti-Myc (Alexa568) and either (A) rabbit anti-C9orf72 
HPA023873 (Alexa488), (B) rabbit anti-C9orf72 sc-138763 or (C) rabbit-anti-
C9orf72 22637-1-AP (Alexa488) (Alexa 488).  
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Figure 3.4 Commercial antibodies do not detect endogenous C9orf72 in 
immunofluorescence. (A) HEK293 cells were treated with non-targeting (Ctrl) 
siRNA or a pool of C9orf72 targeted siRNA for 4 days. Cells were then fixed and 
stained with rabbit anti-C9orf72 HPA023873 (Alexa 488), rabbit anti-C9orf72 sc-
138763 (Alexa488), or rabbit-anti-C9orf72 22637-1-AP (Alexa488). (B) 
knockdown of C9orf72 was confirmed by RT-qPCR. 
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3.2.2 C9orf72 interacts with FIP200 
Neuronal cytoplasmic inclusions are a hallmark of ALS (Wood et al., 2003). 
While C9ALS/FTD patients show TDP-43 positive accumulations that are typical 
of ALS, they also show characteristic p62 positive, TDP-43 negative pathology 
(Al-Sarraj et al., 2011; Cooper-Knock et al., 2012). P62 accumulations are 
indicative of dysfunctional autophagy (Pankiv et al., 2007), suggesting that 
C9orf72 patients may have a defective autophagy pathway and that the C9orf72 
protein may function in this pathway. The p62 specific accumulations associated 
with C9ALS/FTD are primarily found within the hippocampus and the cerebellum 
(Al-Sarraj et al., 2011; Cooper-Knock et al., 2012). These cerebellar 
accumulations of p62 are also seen within a neural specific conditional FIP200 
knock-out mouse model (Liang et al., 2010), suggesting that loss of FIP200 and 
haploinsufficiency of C9orf72 share a common pathology. Interestingly, a 
previous screen for proteins involved in the autophagy network highlighted 
C9orf72 as a potential binding partner of the essential autophagy protein FIP200 
(Behrends et al., 2010). To further investigate this, the interaction of C9orf72 
and FIP200 was investigated by co-immunoprecipitation and in vitro binding 
assays. 
 
HEK293 cells were co-transfected with FLAG-tagged FIP200 and either empty 
vector, Myc-tagged C9orf72S or Myc-tagged C9orf72L. Cells were lysed 24 h 
post transfection. Myc-C9orf72 was immunoprecipitated from lysates using 9106 
anti-Myc antibodies, and the immune pellets analysed by SDS-PAGE and 
immunoblot. FLAG-FIP200 was found to co-immunoprecipitate with both 
C9orf72S and C9orf7L (Fig. 3.5A). 
 
As section 3.2.1 showed, the specificity of the commercial C9orf72 antibodies 
was questionable. It may be that there is little C9orf72 protein within HEK293 
cells making the detection of endogenous protein difficult. Therefore, while it 
would be advantageous to show the interaction of FIP200 and C9orf72 at the 
endogenous level, there was no reliable way of immunoprecipitating 
endogenous C9orf72. As a compromise, the interaction of endogenous FIP200 
and transfected C9orf72 was investigated. The specificity of the FIP200 
antibody was first confirmed by western blot of FIP200 knockout mouse 
embryonic fibroblasts (MEFs). The antibody detected two bands in the wild-type 
control MEF, one under 150 kDa and one at approximately 250 kDa. The band 
at 250 kDa was absent in the FIP200 -/- MEFs showing this to be endogenous 
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FIP200 and that the antibody was able to detect the endogenous protein (Fig. 
3.5B). Next, HEK293 cells were transiently transfected with empty vector, Myc-
C9orf72S or Myc-C9orf72L. 24 h post transfection cells were lysed and Myc-
C9orf72 immunoprecipitated using 9B11 anti-Myc antibodies. Immune pellets 
were analysed by SDS-PAGE and immunoblot, and endogenous FIP200 
detected. Endogenous FIP200 was found to co-immunoprecipitate with both 
isoforms of C9orf72 (Fig. 3.5C). A double band corresponding to endogenous 
FIP200 was co-immunoprecipitated with C9orf72S and to a greater extent with 
C9orf72L (Fig. 3.5C). Higher molecular weights suggest a degree of post-




Figure 3.5 C9orf72 interacts with FIP200. (A) Whole cell lysates of HEK293 cells 
co-transfected with FLAG-FIP200 and either empty vector control, Myc-
C9orf72S or Myc-C9orf72L were subjected to immunoprecipitation with rabbit 
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anti-Myc 9106 antibodies. Immune pellets were probed for Myc-C9orf72 (bottom 
panel) with 9B11 anti-Myc antibodies and FLAG-FIP200 (top panel) using M2 
anti-FLAG antibodies on immunoblot. (B) Whole cell lysates of FIP200+/+ and 
FIP200 -/- MEFs were analysed by SDS-PAGE and immunobot. Blots were 
probed with anti-FIP200 antibodies to check specificity and GAPDH as a loading 
control. (C) Whole cell lysates of HEK293 cells transfected with empty vector 
control, Myc-C9orf72S or Myc-C9orf72 were subjected to immunoblot with 9B11 
anti-Myc antibodies. Immune pellets were probed for Myc-C9orf72 (using rabbit 
anti-Myc 9106 antibodies) and endogenous FIP200 on immunoblot. In all cases 
20 µg (2%) of the immunoprecipitation was loaded as Input. 
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To investigate whether C9orf72 was directly interacting with FIP200, in vitro 
binding assays were performed. Recombinant GST-tagged C9orf72 protein 
produced in bacteria was incubated with in vitro translated S35-labelled 
fragments of FIP200, corresponding to the N-terminus (NT-FIP200), Middle 
domain (MD-FIP200) and C-terminus (CT-FIP200) (Fig. 3.6A) (Abbi et al., 
2002). GST control and GST-tagged C9orf72 proteins were pulled down using 
glutathione beads and proteins eluted using excess glutathione. Samples were 
analysed by SDS-PAGE and radiolabelled protein detected using a 
phosphoimager. The N-terminus of FIP200 was found to directly interact with 
both C9orf72S and C9orf72L, but not with the GST control (Fig. 3.6B). The 
middle domain of FIP200 did not interact with GST, C9orf72S or C9orf72L (Fig. 
3.6C), while the C-terminus of FIP200 interacted with both C9orf72S and 
C9orf72L, but also with the GST control (Fig. 3.6D). When taken together these 
results suggest that the N-terminal region of C9orf72 directly binds the N-
terminal of FIP200. Thus these data identify C9orf72 as a direct binding partner 
of FIP200, an interaction that occurs between the N-terminus of FIP200 and a 




Figure 3.6 C9orf72 directly interacts with the N terminus of FIP200. (A) 
Schematic of the FIP200 fragments that were generated by PCR, showing how 
the N-terminus, the middle domain and the C-terminus of FIP200 fragments 
relate to full length FIP200. 35S-radiolabelled recombinant FIP200 fragments 
correlating to the N-terminus (B), the middle domain (C) and the C-terminus (D) 
were incubated with GST, GST-C9orf72S or GST-C9orf7L immobilized on 
glutathione-coated beads. 35S-radiolabelled recombinant FIP200 fragments 
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were visualised on a phosphoplate (top panel: B, C and D). Coomassie-stained 
GST, GST-C9orf72S and GST-C9orf72L from the pull down are shown (bottom 
panel; B, C and D). The identity of the Coomassie protein bands were confirmed 




3.2.3 C9orf72 interacts with ULK1 
The autophagy initiation complex is comprised of FIP200, ULK1, ATG13 and 
ATG101 (Ganley et al., 2009; Hara et al., 2008; Hosokawa et al., 2009b; Jung et 
al., 2009; Mercer et al., 2009). FIP200 directly interacts with ULK1 to mediate its 
correct localisation during autophagy induction (Ganley et al., 2009). The direct 
interaction of C9orf72 with FIP200 presented in section 3.2.2, therefore raised 
the possibility that C9orf72 was also capable of binding ULK1. Thus, the 
interaction between C9orf72 and ULK1 was investigated by co-
immunoprecipitation and in vitro binding assays. 
 
HEK293 cells were co-transfected with HA-tagged ULK1 and either empty 
vector, Myc-C9orf72S or Myc-C9orf72L. C9orf72 was immunoprecipitated from 
cell lysates with 9B11 anti-Myc antibodies and immune pellets were subjected to 
SDS-PAGE and immunoblot. HA-ULK1 was found to efficiently co-
immunoprecipitate with both C9orf72S and C9orf72L (Fig. 3.7A). 
 
As with FIP200, the interaction of C9orf72 with endogenous ULK1 was 
investigated. The specificity of the ULK1 antibody was firstly confirmed by 
western blot. The antibody detected a single band at the predicted molecular 
weight that was reduced after targeted ULK1 siRNA knock down (Fig. 3.7B). 
HEK293 cells were then transfected with empty vector, Myc-C9orf72S or Myc-
C9orf72L were lysed and Myc-C9orf72 immunoprecipitated with anti-Myc 
antibodies. Immune pellets were subjected to SDS-PAGE and immunoblot and 
endogenous ULK1 detected. Endogenous ULK1 was found to co-
immunoprecipitate with both isoforms of C9orf72, but to a greater extent with 
C9orf72L (Fig. 3.7C). Again, a higher molecular weight band corresponding to 
endogenous ULK1 was observed when ULK1 was co-immunoprecipitated with 
C9orf72L, suggesting C9orf72 was preferentially binding a post-translationally 





Figure 3.7 C9orf72 interacts with ULK1. (A) Whole cell lysates of HEK293 cells 
co-transfected with HA-ULK1 and either empty vector control, Myc-C9orf72S or 
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Myc-C9orf72L were subjected to immunoprecipitation with 9B11 mouse anti-
Myc antibodies. Immune pellets were probed for Myc-C9orf72 (using rabbit 9106 
anti-Myc antibodies) and HA-ULK1 (using rabbit anti-HA antibodies) on 
immunoblot. (B) Whole cell lysates of HEK293 cells treated with non-targeting 
control (Ctrl) siRNA, two individual ULK1 targeted siRNAs or a pool of both 
ULK1 targeted siRNAs were subjected to SDS-PAGE and immuoblot to test the 
specificity of the endogenous ULK1 antibody. (C) Whole cell lysates of HEK293 
cells transfected with empty vector control, Myc-C9orf72S or Myc-C9orf72L 
were subjected to immunoprecipitation with 9B11 mouse anti-Myc antibodies. 
Immune pellets were probed for Myc-C9orf72 (using rabbit anti-Myc 9106 
antibodies) and endogenous ULK1 on immunoblot. In all cases 20 µg (2%) of 
the immunoprecipitation was loaded as Input. 
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The direct interaction of C9orf72 and ULK1 was investigated using in vitro 
binding assays. Recombinant GST-tagged C9orf72 was incubated with in vitro 
translated S35-labelled ULK1. GST proteins were pulled down using glutathione 
beads and eluted using excess glutathione. Samples were analysed by SDS-
PAGE and radiolabelled proteins detected via a phosphoimager. ULK1 was 
found to directly interact with C9orf72S and C9orf72L but not with the GST 
control (Fig. 3.8). 
 
These data show that the N-terminus of C9orf72 directly interacts with ULK1, 





Figure 3.8 C9orf72 directly interacts with ULK1. 35S-radiolabelled recombinant 
HA-ULK1 protein was incubated with GST, GST-C9orf72S or GST-C9orf7L 
immobilized on glutathione-coated beads. 35S-radiolabelled recombinant HA-
ULK1 protein was visualised on a phosphoplate (top panel). Coomassie-stained 
GST, GST-C9orf72S and GST-C9orf72L from the pull down are shown (bottom 
panel). The identity of the Coomassie protein bands were confirmed by mass 
spectrometry (* = CH60 E. coli, 60kD Chaperonin, # = DnaK Chaperonin E.coli). 
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3.2.4 C9orf72 interacts with ATG13 
Finally, the interaction with ATG13 was investigated. ATG13 functions as a 
scaffold of the autophagy initiation complex, mediating the interaction between 
ULK1 and FIP200, ATG101 and ULK1 and also enhancing the kinase activity of 
ULK1 on FIP200 (Ganley et al., 2009; Jung et al., 2009; Mercer et al., 2009). 
HEK293 cells were co-transfected with Myc-tagged ATG13 and either empty 
vector, FLAG-tagged C9orf72S or FLAG-tagged C9orf72L. C9orf72 was 
immunoprecipitated from cell lysates with anti-FLAG antibodies. FLAG-tagged 
proteins were eluted from the protein G beads using excess FLAG peptide. 
Immune pellets were subjected to SDS-PAGE and immunoblot. Myc-ATG13 
was found to efficiently co-immunoprecipitate with both C9orf72S and C9orf72L 
(Fig. 3.9A).  
 
The interaction of endogenous ATG13 with Myc-C9orf72 was investigated by 
co-immunoprecipitation. The specificity of the ATG13 antibody was confirmed by 
western blot. The antibody detected a single band at the predicted molecular 
weight of ATG13. This band was reduced when cells were transfected with 
targeted ATG13 siRNA (Fig. 3.9B). Next, HEK293 cells were transfected with 
Myc-C9orf72. After lysis, Myc-C9orf72 was immunoprecipitated with anti-Myc 
antibodies. The immune pellets were subjected to SDS-PAGE and immunoblot 
and blots probed for endogenous ATG13. ATG13 was found to co-
immunoprecipitate with both isoforms of C9orf72 (Fig. 3.9C), thus identifying 
C9orf72 as a novel binding partner of ATG13. Unlike the endogenous FIP200 
and ULK1 interactions with C9orf72, which suggested higher molecular weight 
species co-immunoprecipitation with C9orf72L, a lower molecular weight 
species of endogenous ATG13 (indicated with * in Fig. 3.9C) was found to co-
immunoprecipitate with C9orf72S and C9orf72L (Fig. 3.9C). This endogenous 
ATG13 species could relate to a proteolytic processed form of ATG13, although 
no such processing has been reported, or a degradation product of the full-
length protein. Alternatively, ATG13 has been shown to undergo alternative 
splicing (Alers et al., 2011), and so this lower molecular weight species of 




Figure 3.9 C9orf72 interacts with ATG13. (A) Whole cell lysates of HEK293 cells 
co-transfected with Myc-ATG13 and either empty vector control, FLAG-
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C9orf72S or FLAG-C9orf72L were subjected to immunoprecipitation with M2 
mouse anti-FLAG antibodies. Immune pellets were probed for FLAG-C9orf72 
(using M2 anti-FLAG antibodies) and Myc-ATG13 (using 9B11 anti-Myc 
antibodies) on immunoblot. (B) Whole cell lysates of HEK293 cells treated with 
non-targeting control (Ctrl) siRNA, two individual ATG13 targeted siRNAs or a 
pool of both ATG13 targeted siRNAs were subjected to SDS-PAGE and 
immuoblot to test the specificity of the endogenous ATG13 antibody. (C) Whole 
cell lysates of HEK293 cells transfected with empty vector control, Myc-
C9orf72S or Myc-C9orf72L were subjected to immunoblot with anti-Myc 
antibodies. Immune pellets were probed for Myc-C9orf72 and endogenous 
ATG13 on immunoblot. In all cases 20 µg (2%) of the immunoprecipitation was 
loaded as Input. 
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To test if C9orf72 was also directly interacting with ATG13 in vitro binding 
assays were performed using recombinant GST-tagged C9orf72 incubated with 
in vitro translated S35-labeleld ATG13. GST negative control and GST-C9orf72 
were pulled down using glutathione beads. Samples were analysed by SDS-
PAGE and radiolabelled ATG13 detected using a phosphoimager. ATG13 was 
found to interact with C9orf72S and C9orf72L in this assay, suggesting a direct 
interaction (Fig. 3.10). Thus C9orf72 directly interacts with three members of the 
autophagy initiation complex: FIP200, ULK1 and ATG13. 
 
Along with the data from sections 3.2.2, 3.2.3 C9orf72 has been identified as a 
novel binding partner of the ULK1 autophagy initiation complex, strongly 
supporting the idea that C9orf72 is involved in the autophagy pathway, perhaps 





Figure 3.10 C9orf72 directly interacts with ATG13. 35S-radiolabelled 
recombinant Myc-ATG13 protein was incubated with GST, GST-C9orf72S or 
GST-C9orf7L immobilized on glutathione-coated beads. 35S-radiolabelled 
recombinant Myc-ATG13 protein was visualised on phosphoplate (top panel). 
Coomassie-stained GST, GST-C9orf72S and GST-C9orf72L from the pull down 
are shown (bottom panel). The identity of the Coomassie protein bands were 




3.2.5 Unbiased mass spec identification of C9orf72 binding 
partners 
In an indirect approach to identify C9orf72 binding proteins, Dr. Mathew Walsh 
from the Sheffield Institute for Translational Neuroscience conducted a mass-
spec analysis of proteins that were co-immunoprecipitated with C9orf72L. Using 
a stable FLAG-tagged C9orf72L inducible HEK293 cell line, and a HEK FlpIN 
control line, FLAG-C9orf72L was immunoprecipitated from cell lysates using an 
anti-FLAG antibody. Immunpellets were either subjected to SDS-PAGE and 
immunoblot to show enrichment of C9orf72L (Fig. 3.11A), or separated via SDS-
PAGE and the gel stained in colloidal coomassie, in preparation for mass spec 
analysis (Fig. 3.11B). After coomassie staining of the gel, bands were excised 
and subjected to ms/ms mass-spec analysis to identify C9orf72L interacting 
proteins (Fig. 3.11B). The identities of the bands labeled in Figure 3.11B are 
detailed in table 5.1. From the list of proteins that were identified specifically 
from the FlpIN FLAG-C9orf72L cell line, FIP200 was identified as a potential 




Figure 3.11 Mass spectrometry analysis of C9orf72L binding partners (A) Pull 
down of C9orf72L from a Flp-In inducible cell line to investigate binding partners 
by mass spec. FLAG-C9orf72L Flp-In cells were lysed and subjected to 
immunoprecipitation with anti-FLAG antibodies. Samples were analysed by 
SDS-PAGE and immunoblots probed with anti-FLAG antibodies. IP sample 
shows the enrichment of FLAG-C9orf72L from the input. (B) Flp-In Ctrl and 
FLAG-C9orf72 Flp-In cells were lysed and subjected to immunoprecipitation with 
anti-FLAG antibodies. Immune pellets were subjected to SDS-PAGE and the gel 
stained with colloidal coomassie. Bands were excised and analysed by ms/ms 
mass spec. The excised bands are labelled A-I in the FLAG-C9orf72 Flp-In cells 
and W-Z in the Ctrl Flp-In cells. Mass spectrometry was conducted by Dr 
Mathew Walsh and Dr Guillaume Hautbergue. 
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Table 3.1: Identities of the bands from C9orf72L pulldown  
Green indicates Flp-In C9orf72L specific – Orange indicates Ctrl specific – Red 
indicates protein was isolated from Flp-In C9orf72L and Ctrl lines  
Region'of'gel Identifier Score Protein'Name Common'Symbol
A FLNA_HUMAN 298 Filamin1A FLNA
A WDR41_HUMAN7 276 WD7repeat1containing7protein741 WDR41
A MAP1B_HUMAN7 139 Microtubule1associated7protein71B MAP1B
A PRKDC_HUMAN 106 DNA1dependent7protein7kinase7catalytic7subunit PRKDC
A GCN1L_HUMAN7 99 Translational7activator7GCN1 GCN1L
A PYR1_HUMAN 61 CAD7protein CAD
A TITIN_HUMAN7 54 Titin TTN
A CAND1_HUMAN7 49 Cullin1associated7NEDD81dissociated7protein71 CAND1
A ZC3HE_HUMAN 41 Zinc7finger7CCCH7domain1containing7protein714 ZC3H14
A DAPLE_HUMAN 41 Protein7Daple CCDC88C
A S12A1_HUMAN7 38 Solute7carrier7family7127member71 SLC12A1
B SMCR8_HUMAN 2080 SmithAMagenis'syndrome'chromosomal'region'candidate'gene'8'protein SMCR8
B CLH1_HUMAN 246 Clathrin7heavy7chain71 CLTC
B SYIC_HUMAN7 85 Isoleucine11tRNA7ligase,7cytoplasmic IARS
B WDR41_HUMAN77 67 WD7repeat1containing7protein741 WDR41
B PUR2_HUMAN77 55 Trifunctional7purine7biosynthetic7protein7adenosine13 GART
B RBCC1_HUMAN 47 RB1Ainducible'coiledAcoil'protein'1 RB1CC1'/'FIP200
B AKAP9_HUMAN 44 A1kinase7anchor7protein79 AKAP9
B DYH9_HUMAN 40 Dynein7heavy7chain79,7axonemal DNAH9
B HDGR2_HUMAN7 39 Hepatoma1derived7growth7factor1related7protein72 HDGFRP2
C HS90B_HUMAN 259 Heat7shock7protein7HSP7901beta HSP90AB1
C HS90A_HUMAN 185 Heat7shock7protein7HSP7901alpha HSP90AA1
C NUCL_HUMAN77 143 Nucleolin NCL
C SMCR8_HUMAN' 127 SmithAMagenis'syndrome'chromosomal'region'candidate'gene'8'protein SMCR8
C EF2_HUMAN 69 Elongation7factor72 EEF2
C TITIN_HUMAN77 66 Titin TTN
C ENPL_HUMAN7 42 Endoplasmin HSP90B1
C KDM4B_HUMAN77 37 Lysine1specific7demethylase74B KDM4B
D HSP71_HUMAN 924 Heat7shock7707kDa7protein71A/1B HSPA1A
D HSP7C_HUMAN77 643 Heat7shock7cognate7717kDa7protein HSPA8
D CI072_HUMAN7 147 Uncharacterized7protein7C9orf72 C9orf72
D SMCR8_HUMAN'' 102 SmithAMagenis'syndrome'chromosomal'region'candidate'gene'8'protein SMCR8
D GRP75_HUMAN7 82 Stress1707protein,7mitochondrial HSPA9
D HNRPK_HUMAN7 49 Heterogeneous7nuclear7ribonucleoprotein7K HNRNPK
D TCPG_HUMAN7 46 T1complex7protein717subunit7gamma CCT3
D K2022_HUMAN 45 Uncharacterized7protein7KIAA2022 KIAA2022
D DAPK1_HUMAN77 44 Death1associated7protein7kinase71 DAPK1
D PRKDC_HUMAN7 42 DNA1dependent7protein7kinase7catalytic7subunit PRKDC
D UNC80_HUMAN7 41 Protein7unc1807homolog UNC80
D KDM4A_HUMAN7 40 Lysine1specific7demethylase74A KDM4A
E CI072_HUMAN 1079 Uncharacterized7protein7C9orf72 C9orf72
E STK38_HUMAN77 578 Serine/threonine1protein7kinase738 STK38
E COR1C_HUMAN 166 Coronin11C CORO1C
E SMCR8_HUMAN' 117 SmithAMagenis'syndrome'chromosomal'region'candidate'gene'8'protein SMCR8
E KPYM_HUMAN 90 Pyruvate7kinase7isozymes7M1/M2 PKM
E ATPA_HUMAN7 89 ATP7synthase7subunit7alpha,7mitochondrial ATP5A1
E ABCC8_HUMAN7 75 ATP1binding7cassette7sub1family7C7member78 ABCC8
E TCPQ_HUMAN7 66 T1complex7protein717subunit7theta CCT8
E HNRPK_HUMAN77 60 Heterogeneous7nuclear7ribonucleoprotein7K HNRNPK
E SERA_HUMAN 60 D131phosphoglycerate7dehydrogenase PHGDH
E VIME_HUMAN7 56 Vimentin VIM
E VIP2_HUMAN77 45 Inositol7hexakisphosphate7and7diphosphoinositol1pentakisphosphate7kinase72 PPIP5K2
E PIM3_HUMAN 42 Serine/threonine1protein7kinase7pim13 PIM3
E EPIPL_HUMAN7 42 Epiplakin EPPK1
E CENPF_HUMAN 40 Centromere7protein7F CENPF
E CD53_HUMAN77 39 Leukocyte7surface7antigen7CD53 CD53
E UBR4_HUMAN 38 E37ubiquitin1protein7ligase7UBR4 UBR4
E ADCYA_HUMAN7 38 Adenylate7cyclase7type710 ADCY10
F WDR41_HUMAN 959 WD7repeat1containing7protein741 WDR41
F MEP50_HUMAN77 417 Methylosome7protein750 WDR77
F EF1A1_HUMAN 398 Elongation7factor711alpha71 EEF1A1
F CI072_HUMAN77 253 Uncharacterized7protein7C9orf72 C9orf72
F IF4A1_HUMAN7 253 Eukaryotic7initiation7factor74A1I EIF4A1
F ILF2_HUMAN 103 Interleukin7enhancer1binding7factor72 ILF2
F PSD11_HUMAN7 55 26S7proteasome7non1ATPase7regulatory7subunit711 PSMD11
F PA2G4_HUMAN7 40 Proliferation1associated7protein72G4 PA2G4
F RSSA_HUMAN77 40 40S7ribosomal7protein7SA RPSA
F ZN551_HUMAN7 39 Zinc7finger7protein7551 ZNF551
F NMD3A_HUMAN77 38 Glutamate7[NMDA]7receptor7subunit73A GRIN3A
F UB2E2_HUMAN 37 Ubiquitin1conjugating7enzyme7E27E2 UBE2E2
G RLA0_HUMAN7 238 60S7acidic7ribosomal7protein7P0 RPLP0
G GBB1_HUMAN7 85 Guanine7nucleotide1binding7protein7G(I)/G(S)/G(T)7subunit7beta11 GNB1
G PRPS1_HUMAN 63 Ribose1phosphate7pyrophosphokinase71 PRPS1
G ICLN_HUMAN 50 Methylosome7subunit7pICln CLNS1A
G PLCB2_HUMAN7 42 11phosphatidylinositol74,51bisphosphate7phosphodiesterase7beta12 PLCB2
H RS3_HUMAN7 234 40S7ribosomal7protein7S3 RPS3
H ADT2_HUMAN7 232 ADP/ATP7translocase72 SLC25A5
H RS4X_HUMAN 194 40S7ribosomal7protein7S4,7X7isoform RPS4X
H 1433E_HUMAN7 164 1413137protein7epsilon YWHAE
H RL7_HUMAN7 145 60S7ribosomal7protein7L7 RPL7
H RL7A_HUMAN7 87 60S7ribosomal7protein7L7a RPL7A
H RL8_HUMAN7 75 60S7ribosomal7protein7L8 RPL8
H TAGAP_HUMAN 42 T1cell7activation7Rho7GTPase1activating7protein TAGAP
H SN_HUMAN7 41 Sialoadhesin SIGLEC1
H RYR1_HUMAN7 41 Ryanodine7receptor71 RYR1
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Table 3.1 continued  
I RL13A_HUMAN, 61 60S,ribosomal,protein,L13a RPL13A
I MIA3_HUMAN, 50 Melanoma,inhibitory,activity,protein,3 MIA3
I UACA_HUMAN 43 Uveal,autoantigen,with,coiledHcoil,domains,and,ankyrin,repeats UACA
I NOTC3_HUMAN, 41 Neurogenic,locus,notch,homolog,protein,3 NOTCH3
I FRAS1_HUMAN, 39 Extracellular,matrix,protein,FRAS1 FRAS1
I RL15_HUMAN 37 60S,ribosomal,protein,L15 RPL15
W HSP71_HUMAN 128 Heat,shock,70,kDa,protein,1A/1B HSPA1A
W PRKDC_HUMAN 72 DNAHdependent,protein,kinase,catalytic,subunit PRKDC
W AKAP9_HUMAN, 64 AHkinase,anchor,protein,9 AKAP9
W HSP7C_HUMAN, 62 Heat,shock,cognate,71,kDa,protein HSPA8
W PCLO_HUMAN, 58 Protein,piccolo PCLO
W TDRD1_HUMAN 52 Tudor,domainHcontaining,protein,1 TDRD1
W ATM_HUMAN, 47 SerineHprotein,kinase,ATM ATM
W SRBS2_HUMAN 44 Sorbin,and,SH3,domainHcontaining,protein,2 SORBS2
W ATOH8_HUMAN, 43 Protein,atonal,homolog,8 ATOH8
W DYHC2_HUMAN 42 Cytoplasmic,dynein,2,heavy,chain,1 DYNC2H1
W MBP_HUMAN, 42 Myelin,basic,protein MBP
W CJ079_HUMAN, 41 WD,repeatHcontaining,protein,96 WDR96
W SPG17_HUMAN, 39 SpermHassociated,antigen,17 SPAG17
W ABHD8_HUMAN, 38 Abhydrolase,domainHcontaining,protein,8 ABHD8
X STK38_HUMAN, 332 Serine/threonineHprotein,kinase,38 STK38
X AKAP9_HUMAN, 40 AHkinase,anchor,protein,9 AKAP9
X ATS6_HUMAN, 37 A,disintegrin,and,metalloproteinase,with,thrombospondin,motifs,6 ADAMTS6
Y MEP50_HUMAN,, 253 Methylosome,protein,50 WDR77
Y ASH1L_HUMAN, 46 HistoneHlysine,NHmethyltransferase,ASH1L ASH1L
Y TLL1_HUMAN, 43 TolloidHlike,protein,1 TLL1
Y ATG2B_HUMAN, 43 AutophagyHrelated,protein,2,homolog,B ATG2B
Z KI13B_HUMAN, 43 KinesinHlike,protein,KIF13B KIF13B
Z TITIN_HUMAN, 42 Titin TTN
Z CDK13_HUMAN, 41 CyclinHdependent,kinase,13 CDK13
Z TPX2_HUMAN, 40 Targeting,protein,for,Xklp2 TPX2
Z PPWD1_HUMAN, 39 Peptidylprolyl,isomerase,domain,and,WD,repeatHcontaining,protein,1 PPWD1
Z LRRK2_HUMAN, 38 LeucineHrich,repeat,serine/threonineHprotein,kinase,2 LRRK2
Z ADA28_HUMAN, 37 Disintegrin,and,metalloproteinase,domainHcontaining,protein,28 ADAM28
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The top hit and interacting partner identified from this mass spec screen was the 
Smith-Magenis syndrome chromosome region candidate 8 protein (SMCR8). 
Little is known about the function of the SMCR8 protein. In a link to C9orf72, the 
autophagy network screen conducted by Behrends et al, identified SMCR8 as a 
potential FIP200 interacting protein, similar to C9orf72 (Behrends et al., 2010). 
Interestingly SMCR8 was also identified as a novel DENN domain containing 
protein in the same study that identified C9orf72 as a potential DENN protein 
(Zhang et al., 2012). Therefore, this link to FIP200 and the DENN homology 
suggests that SMCR8 may function in the autophagy pathway. To confirm the 
interaction, HEK293 cells were co-transfected with Myc-C9orf72S or Myc-
C9orf72L and either empty vector or Myc-DDK-tagged SMCR8. After lysis, 
SMCR8-Myc-DDK was immunoprecipitated from samples with anti-FLAG 
antibodies and immune pellets were subjected to SDS-PAGE and immunoblot. 
Both isoforms of C9orf72 were found to co-immunoprecipitate with SMCR8 (Fig. 
3.12A and B). The binding of SMCR8 and C9orf72L appeared to be particularly 





Figure 3.12 C9orf72 interacts with SMCR8. Whole cell lysates of HEK293 cells 
co-transfected with Myc-C9orf72S (A) or Myc-C9orf72L (B) and either empty 
vector control or SMCR8-Myc-DDK were subjected to immunoprecipitation with 
mouse M2 anti-FLAG antibodies. Immune pellets were probed for SMCR8-Myc-
DDK and Myc-C9orf72 on immunoblot using rabbit 9106 anti-Myc antibodies. 20 
µg (2%) of the immunoprecipitation was loaded as Input. 
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3.2.6 Unbiased Y2H screen 
As a second method of identifying novel C9orf72 binding partners, a Y2H screen 
was conducted. Essentially a complementation assay, Y2H screens involve a 
bait protein fused with the DNA binding domain of a transcription factor and prey 
proteins fused to the activation domain of the transcription factor. Only if the bait 
and prey interact is a functional transcription formed. The functional transcription 
factor binds upstream of a reporter gene, therefore allowing for selection. 
C9orf72S and C9orf72L were cloned into the pGBKT7 vector for high levels of 
expression in yeast. The screen, performed by Protein Interaction Screening of 
the Genomics and Proteomics Core Facilities, German Cancer Research 
Centre, Heidelberg, Germany, used these C9orf72S and C9orf72L constructs as 
bait proteins to screen a human brain cDNA library comprising of cDNA 
fragments as well as full length ORFs to identify prey proteins, which could 
correspond to potential binding partners. In a second round of screening 
C9orf72L was used as bait in a full length ORF library. Y2H screens can identify 
false positives, where physical interactions are observed that cannot be 
replicated in an independent system (Brückner et al., 2009). To account for this 
error rate, only preys that were pulled out more than once were considered as 
positive “hits”. As there are often a number of false positives with this type of 
method it has been possible to identify commonly promiscuous preys, i.e. preys 
that are often found as positive hits in screens and are therefore more likely than 
not false positives. These highly promiscuous or “sticky” hits were rejected 
based on this principle (Brückner et al., 2009). From this screen a number of 
novel potential C9orf72 binding proteins were identified. These are highlighted 
from the full list in table 3.2. These interactions were then confirmed or rejected 
by co-immunoprecipitation experiments. The interaction with USP8 will be 
discussed in more detail in chapter 5. Of the other hits, the Coilin interaction is 
being investigated by Miss Yolanda Gibson within the lab, Decorin was not 
investigated further at this time due to its role in the extracellular matrix 
formation, and mitochondrial ribosomal protein L48 and Claudin 10 were 
rejected based on the fact that the peptide regions of these preys were located 
in the 5’ UTRs.  
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Table 3.2 Clones identified from the Y2H screen 













































































































C9orf72_L	   COX6C	   2	   0	   2	   0	   0	   4	   cytochrome	  c	  oxidase	  subunit	  VIc	  
C9orf72_L	   SYN3	   37	   0	   37	   0	   0	   1	   synapsin	  III	  
C9orf72_L	   COIL	   5	   0	   5	   0	   0	   1	   coilin	  
C9orf72_L	   HRK	   1	   0	   0	   0	   0	   1	   Activator	  of	  apoptosis	  harakiri	  (Neuronal	  death	  protein	  DP5)	  
C9orf72_L	   LOC100506746	   1	   0	   1	   0	   0	   1	  
LOC100506746	  uncharacterized	  LOC100506746	  [	  Homo	  sapiens	  
(human)	  ]	  
C9orf72_L	   na-­‐Hs.633061	   1	   0	   0	   0	   0	   1	   NCBI	  UniGene	  cluster:	  Hs.633061	  
C9orf72_L	   RALA	   1	   1	   0	   0	   252	   1	   v-­‐ral	  simian	  leukemia	  viral	  oncogene	  homolog	  A	  (ras	  related)	  
C9orf72_L	   SNTA1	   1	   0	   1	   0	   0	   4	  
syntrophin,	  alpha	  1	  (dystrophin-­‐associated	  protein	  A1,	  59kDa,	  acidic	  
component)	  
	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
C9orf72_S	   MRPL48	   3	   3	   0	   0	   93	   3	   mitochondrial	  ribosomal	  protein	  L48	  
C9orf72_S	   CLDN10	   2	   2	   0	   0	   32	   4	   claudin	  10	  
C9orf72_S	   DCN	   2	   0	   2	   0	   0	   4	   decorin	  
C9orf72_S	   USP8	   2	   0	   2	   0	   0	   6	   ubiquitin	  specific	  peptidase	  8	  
C9orf72_S	   OAT	   2	   0	   2	   0	   0	   7	   ornithine	  aminotransferase	  (gyrate	  atrophy)	  
C9orf72_S	   ADPRM	   1	   0	   1	   0	   0	   1	  
ADPRM	  ADP-­‐ribose/CDP-­‐alcohol	  diphosphatase,	  manganese-­‐
dependent	  
C9orf72_S	   ATP5I	   1	   1	   0	   0	   9	   1	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F0	  complex,	  subunit	  E	  
C9orf72_S	   BEX1	   1	   1	   0	   0	   213	   1	   brain	  expressed,	  X-­‐linked	  1	  
C9orf72_S	   CACTIN	   1	   0	   1	   0	   0	   1	  
CACTIN	  cactin,	  spliceosome	  C	  complex	  subunit	  [	  Homo	  sapiens	  
(human)	  ]	  
C9orf72_S	   ERI1	   1	   0	   1	   0	   0	   1	   ERI1	  exoribonuclease	  1	  [	  Homo	  sapiens	  (human)	  ]	  
C9orf72_S	   EXOSC10	   1	   0	   1	   0	   0	   1	   exosome	  component	  10	  
C9orf72_S	   IGIP	   1	   1	   0	   0	   639	   1	  
IGIP	  IgA-­‐inducing	  protein	  homolog	  (Bos	  taurus)	  [	  Homo	  sapiens	  
(human)	  ]	  
C9orf72_S	   JAKMIP2	   1	   0	   1	   0	   0	   1	   janus	  kinase	  and	  microtubule	  interacting	  protein	  2	  
C9orf72_S	   LOC100130938	   1	   0	   1	   0	   0	   1	   hypothetical	  protein	  LOC100130938	  
C9orf72_S	   LOC645513	   1	   0	   1	   0	   0	   1	   hypothetical	  LOC645513	  
C9orf72_S	   PITRM1	   1	   0	   1	   0	   0	   1	   pitrilysin	  metallopeptidase	  1	  
C9orf72_S	   PPP2R2B	   1	   0	   1	   0	   0	   1	  
protein	  phosphatase	  2	  (formerly	  2A),	  regulatory	  subunit	  B,	  beta	  
isoform	  
C9orf72_S	   RAD54B	   1	   0	   1	   0	   0	   1	   RAD54	  homolog	  B	  (S.	  cerevisiae)	  
C9orf72_S	   TJP2	   1	   0	   1	   0	   0	   1	   tight	  junction	  protein	  2	  (zona	  occludens	  2)	  
C9orf72_S	   UBA3	   1	   0	   1	   0	   0	   1	   ubiquitin-­‐like	  modifier	  activating	  enzyme	  3	  
C9orf72_S	   USP48	   1	   0	   1	   0	   0	   1	   ubiquitin	  specific	  peptidase	  48	  
C9orf72_S	   ANXA7	   1	   0	   1	   0	   0	   2	   annexin	  A7	  
C9orf72_S	   DARS	   1	   0	   1	   0	   0	   2	   aspartyl-­‐tRNA	  synthetase	  
C9orf72_S	   HERC2P9	   1	   0	   1	   0	   0	   2	   HERC2P9	  hect	  domain	  and	  RLD	  2	  pseudogene	  9	  [	  Homo	  sapiens	  ]	  
C9orf72_S	   HSPD1	   1	   0	   1	   0	   0	   2	   heat	  shock	  60kDa	  protein	  1	  (chaperonin)	  
C9orf72_S	   KCNMB4	   1	   0	   1	   0	   0	   2	  
potassium	  large	  conductance	  calcium-­‐activated	  channel,	  subfamily	  M,	  
beta	  member	  4	  
C9orf72_S	   WAC	   1	   0	   1	   0	   0	   2	   WW	  domain	  containing	  adaptor	  with	  coiled-­‐coil	  
C9orf72_S	   ZDHHC6	   1	   0	   1	   0	   0	   2	   zinc	  finger,	  DHHC-­‐type	  containing	  6	  
C9orf72_S	   ZDHHC9	   1	   0	   1	   0	   0	   2	   zinc	  finger,	  DHHC-­‐type	  containing	  9	  
C9orf72_S	   ZNF585A	   1	   0	   1	   0	   0	   2	   zinc	  finger	  protein	  585A	  
C9orf72_S	   CXXC5	   1	   0	   1	   0	   0	   3	   CXXC	  finger	  5	  
C9orf72_S	   NDUFA10	   1	   0	   1	   0	   0	   3	   NADH	  dehydrogenase	  (ubiquinone)	  1	  alpha	  subcomplex,	  10,	  42kDa	  
C9orf72_S	   RPE	   1	   1	   0	   0	   5	   3	   ribulose-­‐5-­‐phosphate-­‐3-­‐epimerase	  
C9orf72_S	   SENP6	   1	   0	   1	   0	   0	   3	   SUMO1/sentrin	  specific	  peptidase	  6	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Green indicates preys that were isolated more than once 
Yellow indicates preys that were only isolated once  
C9orf72_S	   ANXA2	   1	   0	   1	   0	   0	   4	   annexin	  A2	  
C9orf72_S	   ITM2A	   1	   0	   1	   0	   0	   4	   integral	  membrane	  protein	  2A	  
C9orf72_S	   LDHA	   1	   0	   1	   0	   0	   4	   lactate	  dehydrogenase	  A	  
C9orf72_S	   RAB1A	   1	   0	   1	   0	   0	   4	   RAB1A,	  member	  RAS	  oncogene	  family	  
C9orf72_S	   STMN2	   1	   1	   0	   0	   104	   4	   stathmin-­‐like	  2	  
C9orf72_S	   TCP1	   1	   0	   1	   0	   0	   4	   t-­‐complex	  1	  
C9orf72_S	   ALDOA	   1	   1	   0	   0	   131	   5	   aldolase	  A,	  fructose-­‐bisphosphate	  
C9orf72_S	   COL5A2	   1	   0	   1	   0	   0	   6	   collagen,	  type	  V,	  alpha	  2	  
C9orf72_S	   FEZ1	   1	   0	   1	   0	   0	   6	   fasciculation	  and	  elongation	  protein	  zeta	  1	  (zygin	  I)	  
C9orf72_S	   RAD1	   1	   0	   1	   0	   0	   6	   RAD1	  homolog	  (S.	  pombe)	  
C9orf72_S	   DSTN	   1	   0	   1	   0	   0	   7	   destrin	  (actin	  depolymerizing	  factor)	  
C9orf72_S	   NR1D2	   1	   0	   1	   0	   0	   7	   nuclear	  receptor	  subfamily	  1,	  group	  D,	  member	  2	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3.2.7 C9orf72 interacts with Cox6C 
Cytochrome c oxidase subunit VIc (Cox6C) was identified as a C9orf72L 
interacting protein from the Y2H screen. Cytochrome c oxidase is the final 
complex of the electron transport chain, complex IV, and is comprised of 13 
different subunits (Yoshikawa et al., 1998). Of the 13 subunits, subunits 1-3 are 
encoded on mitochondrial DNA, while the other 10 are nuclear encoded 
(Lazarou et al., 2009) Cox6C has been shown to assemble into an intermediate 
complex that may be necessary for the formation of mature, functional and 
complete holo-Complex IV (Lazarou et al., 2009). Cox6C is a 75 amino acid 
mitochondrial transmembrane protein, with a peptide segment within the 
mitochondrial matrix and a 4-turn α helix on the cytosolic side (Tsukihara et al., 
1996). The exact function of Cox6C is not fully understood but it is thought to 
provide structural integrity to complex IV as a whole (Musatov and Robinson, 
2002). Cox6C was isolated as a C9orf72L prey twice in this screen, with the 
same Cox6C fragment identified in each case. The known domains of Cox6C 
and the peptide sequence interacting with C9orf72L are detailed in Figure 3.13.  
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                                  -------------------------- 
-M--A--P--E--V--L--P--K--P--R--M--R--G--L--L--A--R--R--L--R- 
 
------------------------------------------------------------                 
-N--H--M--A--V--A--F--V--L--S--L--G--V--A--A--L--Y--K--F--R- 
 









Helical Transmembrane domain 
Mitochondrial intermembrane domain 
------ = Cox6C prey region interacting with C9orf72L 
  
Figure 3.13 The Cox6C clones identified from the Y2H screen map across the 
transmembrane domain of Cox6C. Two Cox6C clones identified as prey of the 
C9orf72L bait protein map across the transmembrane domain of Cox6C. The 
Matrix domain is indicated in yellow, the transmembrane domain in cyan and the 
mitochondrial intermembrane domain in grey. The dotted red dashes indicate 
the peptide sequence of the clone identified in the Y2H screen. 
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The interaction of C9orf72 with Cox6C was investigated by co-
immunoprecipitation. HEK293 cells were co-transfected with Myc-C9orf72S or 
Myc-C9orf72L and either empty vector or Myc-DDK-tagged Cox6C. Cox6C-Myc-
DDK was immunoprecipitated using anti-FLAG antibodies and immune pellets 
analyse by SDS-PAGE and immunoblot. Cox6C-Myc-DDK was enriched in the 
immunoprecipitated samples. In these assays, C9orf72L was found to efficiently 
co-immunoprecipitate with Cox6C (Fig. 3.14B). However, C9orf72S did not (Fig. 
3.14A). The fact that C9orf72L interacted with Cox6C, while C9orf72S did not, 
suggested that the interaction required a region within the C terminus of 
C9orf72L, i.e. between amino acids 222-481; the region lacking in C9orf72S 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). Thus, these data identify 
Cox6C as a novel interacting partner of C9orf72L. This interaction of C9orf72 
and Cox6C, and the possible role of C9orf72 in mitochondrial biology, is being 






Figure 3.14 C9orf72L interacts with Cox6C. Whole cell lysates of HEK293 cells 
co-transfected with Myc-C9orf72S (A) or Myc-C9orf72L (B) and either empty 
vector control or Cox6C-Myc-DDK were subjected to immunoprecipitation with 
M2 mouse anti-FLAG antibodies. Immune pellets were probed for Cox6C-Myc-
DDK with rabbit 9106 anti-Myc antibodies and Myc-C9orf72 with rabbit sc-
138763 anti-C9orf72 antibodies on immunoblot. 20 µg (2%) of the 
immunoprecipitation was loaded as Input. 
  
 126 
3.2.8 C9orf72 does not interact with OAT 
A second mitochondrial protein identified from the Y2H screen was Ornithine 
aminotransferase (OAT). OAT is a nuclear encoded 45 kDa mitochondrial matrix 
enzyme responsible for arginine catabolism as well as proline biosynthesis (Aral 
and Kamoun, 1997; Shah et al., 1997). Mutations to OAT, leading to OAT 
deficiency, are a known cause of familial inherited gyrate atrophy of the choroid 
and retina (Brody et al., 1992). OAT was identified twice from this screen as a 
C9orf72S prey, with the same peptide region identified in each case. The 
peptide region of OAT identified from this screen is detailed in Figure 3.15. 
 
The interaction of OAT with C9orf72 was investigated by co-
immunoprecipitation. HEK293 cells were co-transfected with Myc-C9orf72S or 
Myc-C9orf72L and either empty vector or OAT-Myc-DDK. OAT-Myc-DDK was 
immunoprecipitated with anti-FLAG antibodies and immune pellets analysed by 
SDS-PAGE and immunoblot. OAT-Myc-DDK was enriched in the 
immunoprecipitated samples. In these assays, neither C9orf72S nor C9orf72L 
was found to co-immunoprecipitate with OAT (Fig. 3.16A and B), suggesting this 



































---- = OAT prey region interacting with C9orf72S 
 
Figure 3.15 Mapping of the OAT clones identified from the Y2H screen to the 
OAT amino acid sequence. Two OAT clones were identified as prey of 
C9orf72S bait protein in the Y2H screen. The dotted red line indicates the 




Figure 3.16 C9orf72 does not interact with OAT. Whole cell lysates of HEK293 
cells co-transfected with Myc-C9orf72S (A) or Myc-C9orf72L (B) and either 
empty vector control or OAT-Myc-DDK were subjected to immunoprecipitation 
with M2 mouse anti-FLAG antibodies. Immune pellets were probed for OAT-
Myc-DDK using rabbit anti-Myc 9106 antibodies and Myc-C9orf72 using rabbit 
sc-138763 anti-C9orf72 antibodies on immunoblot. * indicates Myc-C9orf72L 
bands in the input. To detect Myc-C9orf72L alone first, blots were probed with 
rabbit sc-138763 anti-C9orf72 antibodies. The same blot was then re-probed 
with 9106 rabbit anti-Myc antibodies to show both Myc-C9orf72 and OAT-Myc-
DDK. 20 µg (2%) of the immunoprecipitation was loaded as Input. 
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3.2.9 C9orf72 interacts with Synapsin III 
Synapsin III was identified as a potential C9orf72L binding partner from the Y2H 
screen. The family of synapsin proteins are important phosphoproteins 
associated with synaptic vesicles (Rosahl et al., 1993). The actual function of 
the synapsins is currently unknown but knockout mouse models have revealed 
they are required for synaptic vesicle regulation and formation (Rosahl et al., 
1995; Ryan et al., 1996). The function of synapsin III is relatively unknown, but it 
shares homology with synapsins I and II (Hosaka and Südhof, 1998a). As with 
synapsin I and II, synapsin III has been shown to bind ATP, suggesting a 
possible enzymatic role (Hosaka and Südhof, 1998a, b). However, unlike 
synapsin I, where the presence of Ca2+ ions increases ATP binding, Ca2+ inhibits 
ATP binding by synapsin III (Hosaka and Südhof, 1998a). Synapsin III was 
identified as a C9orf72L prey 37 times from this screen, with the same peptide 
region identified each time. The peptide region interacting with C9orf72L in this 
screen is detailed in Figure 3.17, along with the domain structure shared by the 
synapsin family of proteins (Hosaka and Südhof, 1998a) (Fig. 3.17). 
 
The interaction of Synapsin III (SynIII) with C9orf72 was investigated by co-
immunoprecipitation. HEK293 cells were co-transfected with Myc-C9orf72S or 
Myc-C9orf72L and either empty vector or SynIII-Myc-DDK. SynIII-Myc-DDK was 
immunoprecipitated with anti-FLAG antibodies and immune pellets analysed by 
SDS-PAGE and immunoblot. SynIII-Myc-DDK was enriched in the 
immunoprecipitated samples. In these assays both isoforms of C9orf72 were 
found to co-immunoprecipitiate with Synapsin III (Fig. 3.18A and B). However, 
the interaction with C9orf72S appeared much weaker than that of C9orf72L. The 
interaction of C9orf72 with the synapsin family, and the role of C9orf72 in 
synaptic vesicle formation, is being further investigated by Miss Rebecca Cohen 















































A domain B domain C domain  ----- = SynIII prey region interacting with C9orf72 
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Figure 3.17 The Synapsin III clones identified from the Y2H screen map across 
the conserved C domain of Synapsin III. 37 Synapsin III clones were identified 
as prey of C9orf72L bait protein in the Y2H screen. The conserved A (cyan), B 
(green) and C (yellow) domains of the synapsin family members are indicated. 







Figure 3.18 C9orf72 interacts with Synapsin III. Whole cell lysates of HEK293 
cells co-transfected with Myc-C9orf72S (A) or Myc-C9orf72L (B) and either 
empty vector control or Myc-DDK-SynIII were subjected to immunoprecipitation 
with M2 mouse anti-FLAG antibodies. Immune pellets were probed for SynIII-
Myc-DDK and Myc-C9orf72 on immunoblot using rabbit anti-Myc 9106 




The purpose of this chapter was to identify novel C9orf72 interacting partners 
with the aim of shedding light on the possible biological function of C9orf72. In a 
hypothesis driven approach, the interaction of C9orf72 with the autophagy 
initiation complex was investigated. Furthermore, in an unbiased approach, a 
mass spec screen was conducted on C9orf72L immunoprecipitates to identify 
C9orf72L interacting proteins and a Y2H screen was also performed using 
C9orf72S and C9orf72L as bait proteins. 
 
A previous screen of the autophagy regulation network identified C9orf72 as a 
possible interacting partner of FIP200 (Behrends et al., 2010). The pathology 
associated with C9ALS/FTD, also suggested a possible autophagy deficit in 
these patients (Al-Sarraj et al., 2011; Cooper-Knock et al., 2012). In this Chapter 
C9orf72 was found to directly interact with FIP200, ULK1 and ATG13 (Figs 3.5 – 
3.10), all of which are important members of the autophagy initiation complex 
(Ganley et al., 2009; Hosokawa et al., 2009a; Jung et al., 2009), thus suggesting 
that C9orf72 may play a role at the initiation stage of autophagy. Endogenous 
FIP200, ULK1 and ATG13 were all found to co-immunoprecipitate with Myc-
C9orf72S and Myc-C9orf72L (Figs 3.5, 3.7 and 3.9). In the case of FIP200 and 
ULK1, a higher molecular weight species was found to be the most prominent 
band co-immunoprecipitating with C9orf72L (Fig. 3.5C and 3.7C). ULK1 
phosphorylates a number of targets after autophagy induction, including itself, 
FIP200 and ATG13 (Ganley et al., 2009; Hosokawa et al., 2009a; Jung et al., 
2009). Thus, the higher molecular weight bands of FIP200 and ULK1 that were 
found to interact with C9orf72L could be phosphorylated forms of these proteins, 
raising the possibility that C9orf72L interacts with FIP200 and ULK1 
predominantly after autophagy induction. Phosphatase treatment of the 
immunoprecipitates from these endogenous experiments would confirm whether 
these bands were indeed phosphorylated forms of either protein. The lower 
molecular weight species of endogenous ATG13 that was found to co-
immunoprecipitate with C9orf72 (Fig. 3.9C) could be related to the 7 
alternatively spliced isoforms of ATG13 (Alers et al., 2011). Full length ATG13 
(isoform A) and isoform B, which is alternatively spliced to skip exon 8, are the 
predominant splice variants found in cells based on their relative mRNA levels 
(Alers et al., 2011). Thus, the lower molecular weight variant found to co-
immunoprecipitate with C9orf72 in Fig 3.9C could be related to ATG13 isoform 
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B. Interestingly, isoform B is one of only two isoforms that is capable of 
interacting with FIP200 (Alers et al., 2011). The lack of reliable commercial 
C9orf72 antibodies prevented the investigation of endogenous C9orf72 with its 
binding partners. While this is an obvious limitation of these studies, the fact that 
the interaction was confirmed firstly via overexpression immunoprecipitation 
assays, then via co-immunoprecipitation of endogenous binding partners and 
finally via in-vitro binding assays, gave confidence to the results. Xiao et al 
recently developed isoform specific antibodies towards C9orf72S and C9orf72L 
(Xiao et al., 2015). The use of such antibodies in future may allow the detection 
and investigation of endogenous C9orf72 and its binding partners.  
 
All interaction studies detailed in this Chapter were conducted on HEK293 cells. 
Due to its role in ALS/FTD, studies of the interaction partners in a more neuronal 
cell line would be of benefit, making the findings potentially more relevant for the 
understanding of the disease. To further investigate the binding partners of 
C9orf72, as well as the subcellular localisation of C9orf72 within intact cells, the 
proximity ligation assay could be employed (Soderberg et al., 2006), as could 
fluorescent resonance energy transfer (FRET) microscopy (Broussard et al., 
2013). Again, conducting such studies on more neuronal cell types would 
beneficial to the understanding of this protein. 
 
Bioinformatics analysis has revealed C9orf72 to be structurally related to the 
DENN family of proteins and may function in Rab activity (Levine et al., 2013; 
Zhang et al., 2012). This is supported by another study showing that C9orf72 
co-localises with a number of Rab proteins (Farg et al., 2014). SMCR8 was 
identified as the top hit from the mass spec screen of C9orf7L interacting 
proteins, which was then confirmed by co-immunoprecipitation (Fig. 3.11 and 
3.12). SMCR8 was also identified as a novel DENN domain protein in the same 
screen as C9orf72 (Zhang et al., 2012). The DENN domain proteins are known 
GEFs for the Rab GTPases (Levine et al., 2013; Yoshimura et al., 2010; Zhang 
et al., 2012). The involvement of Rab proteins in the autophagy pathway has 
been discussed in section 1.5.2.5. Interestingly, SMCR8 was also identified in 
the same autophagy screen as C9orf72 as a possible FIP200 interacting protein 
(Behrends et al., 2010). Thus, as potential DENN Rab GEFs, C9orf72 and 
SMCR8 could be important for regulation of the autophagy initiation complex 
and the induction of autophagy. 
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The identification of Cox6C and OAT as potential C9orf72 interacting proteins, 
suggested the C9orf72 protein might in part have some link to the mitochondrial 
network. While C9orf72 did not show any interaction with OAT (Fig. 3.16A and 
B), Cox6C was shown to co-immunoprecipitate with C9orf72L (Fig. 3.14B). As a 
mitochondrial transmembrane protein, only the short 4-turn helix structure of 
Cox6C is exposed to the cytoplasm, with another peptide segment within the 
mitochondrial matrix (Tsukihara et al., 1996). The peptide sequence of Cox6C 
found to interact with C9orf72L in the Y2H screen mapped across this 
transmembrane domain and the mitochondrial matrix domain (Fig. 3.13). The 
immunofluorescence data presented in Figure 3.3 suggested C9orf72 was 
relatively diffuse throughout the cell. However, this does not rule out the 
possibility that C9orf72 could be associated with the mitochondria. Assuming 
C9orf72 is only present within the cytoplasm would mean C9orf72 could only 
interact with Cox6C en route to the mitochondria, or with the short 4-turn helix 
structure exposed to the cytoplasm, as suggested by the Y2H data (Fig. 3.13). 
On the other hand, if it is assumed C9orf72 could be present within mitochondria 
then C9orf72 could interact with the mitochondrial matrix portion of Cox6C, 
which was also suggested by the clones identified in the Y2H screen (Fig. 3.13). 
The interaction of C9orf72 with Cox6C suggests C9orf72 may play a role in 
mitochondrial biology, whether it be delivery of nuclear encoded mitochondrial 
proteins, as in the case of Cox6C, or even regulation of the mitochondrial 
network, including mitochondrial morphology and clearance.  
 
The interaction of C9orf72 with synapsin III (Fig. 3.18) suggests C9orf72 plays 
an important role in neuronal biology, as the synapsin family are important for 
synaptic vesicle regulation in neurons (Rosahl et al., 1993; Rosahl et al., 1995; 
Ryan et al., 1996). Synapsins I, II and III share a common domain structure, 
comprising of A, B, C, D and E domains (Hosaka and Südhof, 1998a, b). The C 
domain of synapsins is thought to be involved in ATP binding, and possibly 
phosphotransfer to other protein targets (Esser et al., 1998; Hosaka and Südhof, 
1998b). The protein region of synapsin III interacting with C9orf72 in the Y2H 
screen was mapped to the B and C domains (Fig. 3.17) As a simplistic model, 
synapsin III could therefore be involved in phosphotransfer to C9orf72, or 
C9orf72 could be involved in directing synapsin III to its correct protein target 
and aiding in correct phosphotransfer. Ca2+ levels are known to inhibit the 
binding of ATP by synapsin III (Hosaka and Südhof, 1998a). As Ca2+ levels are 
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important in synaptic transmission this could impact on the binding of C9orf72 
with synapsin III during neurotransmission. 
 
The involvement of autophagy in C9ALS/FTD is supported by the pathology that 
is specifically associated with these patients, namely the accumulation of p62 
(Al-Sarraj et al., 2011; Cooper-Knock et al., 2012; Mahoney et al., 2012). As 
discussed previously in section 1.5.2.3, p62 is involved in substrate delivery to 
the autophagosome and so accumulations of p62 suggest a dysfunctional 
autophagy pathway (Mathew et al., 2009; Pankiv et al., 2007). Having shown 
C9orf72 interacts with a number of autophagy related proteins, loss of C9orf72 
protein in patients due to the expanded repeat could lead to a dysfunctional 
autophagy pathway and, in turn, the specific pathology associated with this 
disease. As the interacting proteins identified in this Chapter were members of 
the autophagy initiation complex, the role of C9orf72 in autophagy initiation was 
investigated more specifically. The next Chapter looks at the effect loss of 
C9orf72 could have on the autophagy pathway, investigating how C9orf72 
knock down could affect the different steps, and also what effect over 





4 C9orf72	  regulates	  the	  initiation	  of	  autophagy	  
4.1 Introduction 
The ULK1 initiation complex controls the induction of autophagy as shown in 
Figure 1.4 and 1.5 (Ganley et al., 2009; Hosokawa et al., 2009a; Jung et al., 
2009). Upon inhibition of mTOR, the ULK1 kinase becomes active, 
phosphorylating the other members of the complex, leading to further 
downstream signalling and the activation of autophagy (Hosokawa et al., 2009a; 
Jung et al., 2009; Russell et al., 2013). In chapter 3 C9orf72 was shown to 
directly interact with the autophagy initiation complex (Figs. 3.5 – 3.10) 
suggesting C9orf72 may play a role in this pathway. Since C9orf72 was 
interacting with the initiation complex and haploinsufficiency of C9orf72 may be 
involved in C9ALS/FTD, the aim of this chapter was to investigate what effect 
modulating C9orf72 protein levels would have on autophagy induction, with the 
final aim of placing C9orf72 in the pathway and describing its functional role.  
4.2 Results 
4.2.1 Loss of C9orf72 disrupts the initiation of autophagy 
To investigate the role of C9orf72 in autophagy, a number of techniques were 
employed, as described by Klionsky et al. 2012 (Klionsky et al., 2012). As a 
marker of the autophagosomes, LC3-II conversion assays were used to 
evaluate the level of autophagy induction following targeted knock down or 
overexpression of C9orf72. Firstly, LC3-II positive autophagosomes and 
lysosomes were measured via immunofluorescence assays to monitor 
autophagic flux. Secondly, LC3-II levels were monitored via immunoblot to 
determine cellular levels of autophagy. Upon autophagy induction the cytosolic 
form of LC3, LC3-I, is lipidated to form LC3-II, which is localised to the 
autphagosomes and is required for their formation (Kabeya, 2000; Kabeya et al., 
2004), see section 1.5.2.2 and Fig. 1.4. LC3-II remains membrane bound until 
autophagosome, lysosome fusion, and is then degraded along with the other 
autophagic cargos (Tanida et al., 2005). Thus quantification of LC3-II levels is 
indicative of the level of autophagy. In a final approach, other fluorescently 
labelled autophagy related proteins were monitored by immunofluorescence to 
investigate specific stages of the pathway, namely the translocation stage of 
autophagy, which is associated with autophagic induction. Details of these 
assays will be discussed below. 
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To address if C9orf72 plays a role in the initiation of autophagy, the levels of 
C9orf72 were reduced in cells with targeted siRNA and the levels of autophagy 
investigated after induction. Firstly, the effect of C9orf72 knock down on the 
level of autophagy was measured by quantifying the number of 
autophagosomes and autolysosomes by counting mCherry-EGFP-LC3 positive 
puncta by fluorescence microscopy. The mCherry-EGFP-LC3 construct allows 
for the distinction between autophagosomes and autolysosomes as the acid 
environment of the autolysosome quenches the EGFP signal, while the mCherry 
signal is unaffected. Therefore, autophagosomes fluoresce red and green, while 
the autolysosomes fluoresce only red (Pankiv et al., 2007). Therefore, 
quantifying the number of red and green puncta compared to red only puncta 
allows the quantification of autophagic flux (Klionsky et al., 2012). 
 
Hela cells treated with Ctrl or C9orf72 siRNA were transfected with mCherry-
GFP-LC3. Autophagy was induced by treatment with Torin1. In Ctrl siRNA 
treated cells, Torin1 lead to a significant increase in the level of 
autophagosomes as well as autolysosomes (Fig. 4.1A). In comparison, Torin1 
no longer increased the numbers of autophagosomes in C9orf72 siRNA treated 
cells, and the number of autolysosomes was significantly reduced (Fig. 4.1A). 
Thus loss of C9orf72 appeared to affect autophagy induction. To directly 
investigate the level of induction, HeLa cells transfected with Ctrl or C9orf72 
siRNA were treated with Torin1 in the presence of bafilomycin A1, a specific 
inhibitor of the vacuolar ATPase (V-ATPase), which inhibits acidification of the 
lysosome, preventing fusion of the autophagosome with the lysosome (Klionsky 
et al., 2008; Yamamoto et al., 1998). This therefore allows for the quantification 
of the number of autophagosomes formed specifically after induction (Tanida et 
al., 2005). In Ctrl siRNA transfected cells, these conditions lead to a significant 
increase in the number of autophagosomes (Fig. 4.1B). However, in C9orf72 
siRNA treated cells no increase in the number of autophagosomes was detected 
indicating that loss of C9orf72 prevents the correct induction of autophagy (Fig 





Figure 4.1 Loss of C9orf72 prevents autophagy induction. HeLa cells treated 
with non-targeting control (Ctrl) or C9orf72 siRNA and transfected with mCherry-
EGFP-LC3 were incubated as indicated with vehicle (Ctrl), Torin1 (250 nM; 3 h), 
Bafilomycin A1 (BafA1; 100 nM: 6 h) or combinations thereof. Autophagosomes 
(green+red) and autolysosomes (red only) were quantified per cell and are 
shown as mean±SEM from 3 replicate experiments. Statistical significance was 
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determined by one-way ANOVA with Fisher’s LSD test, * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001; N (cells) = Ctrl/Ctrl 120; Ctrl/Torin1 101; 
C9orf72/Ctrl 99; C9orf72/Torin1 106; Ctrl/BafA1 116; Ctrl/BafA1+Torin1 118; 
C9orf72/BafA1 109; C9orf72/BafA1+Torin1 106. Representative images show 
EGFP (green), mCherry (red) and merged EGFP and mCherry. Scale bar = 20 
µm. C9orf72 knock down was confirmed by RT-qPCR. 
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In a second approach, the levels of endogenous LC3-II were measured via 
immunoblot. HEK293 cells treated with either non-targeting control (Ctrl) or 
C9orf72 targeted siRNA were untreated, treated with Torin1 alone, rapamycin 
alone, bafilomycin A1 alone, bafilomycin A1 and Torin1 or bafilomycin A1 and 
rapamycin together to, again, specifically investigate induction. Although, 
autophagy was induced with rapamycin or Torin1 alone, there was no 
accumulation of LC3-II possibly due to the fact that the pathway was still able to 
progress and LC3-II was degraded (Fig. 4.2A and B). Inhibition of basal 
autophagy with bafilomycin A1 caused the accumulation of LC3-II in all samples 
(Fig. 4.2A and B). In HEK293 cells treated with Ctrl siRNA, rapamycin or Torin1 
in the presence of bafilomycin A1 led to a significant increase in the level of LC3-
II compared to bafilomycin A1 treatment alone (Fig. 4.2A and B), indicating that 
rapamycin and Torin1 were effectively inducing autophagy. However, in 
HEK293 cells treated with C9orf72 siRNA the level of LC3-II did not increase 
after rapamycin or Torin1 treatment indicating that in these cells, autophagy was 
no longer induced above basal levels (Fig. 4.2A and B). Consistent with the data 
obtained from the mCherry-EGFP-LC3 flux assay, this suggested that loss of 
C9orf72 was preventing autophagy induction. 
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Figure 4.2 Loss of C9orf72 inhibits LC3-II formation. HEK293 cells treated with 
non targeting control (Ctrl) or C9orf72 siRNA were incubated with Bafilomycin A1 
(BafA1 100 nM; 6 h), BafA1 and Torin1 (BafA1; 100nM; 6 h; Torin1; 250 nM; 3 
h) (A) or BafA1 and Rapamycin (BafA1; 100 nM; 6 h; Rapamycin; 500 nM; 6 h) 
(B) and the levels of LC3-I and LC3-II determined on immunoblot. Levels of 
LC3-II were normalised to tubulin and are shown relative to the BafA1 only 
sample (Mean±SEM; one-way ANOVA with Fisher’s LSD test, ** p ≤ 0.01, *** p 
≤ 0.001; N = 6 experiments). C9orf72 knock down was confirmed by RT-qPCR. 
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4.2.2 C9orf72 over expression induces autophagy 
As loss of C9orf72 inhibited the induction of autophagy, the effect of C9orf72 
overexpression on the autophagy pathway was investigated. HEK293 cells were 
co-transfected with EGFP-LC3 and either empty vector, Myc-C9orf72S or Myc-
C9orf72L. Monitoring the conversion of EGFP-LC3 meant autophagy was only 
assessed in cells that were co-transfected with either the empty vector control, 
C9orf72S or C9orf72L. Empty vector control cells were either untreated, treated 
with Torin1 alone, treated with bafilomycin A1 alone or treated with both Torin1 
and bafilomycin A1 together. Myc-C9orf72 transfected samples were either 
untreated, or treated with bafilomycin A1. Bafilomycin A1 treatment alone (lane 3, 
Fig. 4.3) lead to a significant accumulation of EGFP-LC3-II compared to 
untreated samples (lane 1, Fig. 4.3), and Torin1 treatment alone samples (lane 
2, Fig. 4.3). Torin1 treatment in the presence of bafilomycin A1 (lane 4, Fig. 4.3) 
significantly increased the amount of EGFP-LC3-II compared to bafilomycin A1 
treatment alone (lane 3, Fig. 4.3), indicating Torin1 was inducing autophagy 
(Fig. 4.3). Overexpression of Myc-C9orf72S or Myc-C9orf72L in the presence of 
bafilomycin A1 (lanes 6 and 8, Fig. 4.3) also significantly increased the level of 
EGFP-LC3-II compared to bafilomycin A1 treatment alone (lane 3, Fig. 4.3), 
similar to that of Torin1 treatment (lane 4, Fig. 4.3), indicating overexpression of 
C9orf72 was inducing autophagy to a similar extent to that of Torin1.  
 
In a second approach the number of EGFP-LC3 positive puncta were counted in 
cells co-transfected with empty vector, Myc-C9orf72S or Myc-C9orf72L. Empty 
vector transfected cells were treated with Torin1 to induce autophagy. As 
expected, Torin1 treatment significantly increased the number of EGFP-LC3 
puncta per cell (Fig. 4.4). Overexpression of either C9orf72S or C9orf72L also 
significantly increased the number of EGFP-LC3 puncta to a similar level to that 
of Torin1 treatment (Fig. 4.4). Thus overexpression of C9orf72 induces the 





Figure 4.3. C9orf72 induces EGFP-LC3-II. HEK293 cells were co-transfected 
with EGFP-LC3 and either empty vector, Myc-C9orf72S or Myc-C9orf72L. 24 h 
post transfection cells empty vector transfected cells were incubated with 
vehicle (Ctrl), Torin1, Bafilomycin A1 (BafA1) or both Bafilomycin A1 and Torin1. 
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Myc-C9orf72 transfected cells were incubated with vehicle (Ctrl) or BafA1 only. 
Levels of autophagy were determined by immunoblot for EGFP-LC3-I and II. 
C9orf72 expression was confirmed with anti-Myc antibodies. Levels of EGF-
LC3-II were normalised to tubulin and are shown relative to empty vector vehicle 
treated samples. (Mean±SEM; one-way ANOVA with Fisher’s LSD test, ** p ≤ 




Figure 4.4 C9orf72 induces autophagy. HeLa cells were co-transfected with 
EGFP-LC3 (green) and either empty vector (EV), Myc-C9orf72S or Myc-
C9orf72L (red). As a positive control, EV transfected cells were treated with 
Torin1 (250 nM; 3 h). Autophagy was quantified as the number of EGFP-LC3 
positive autophagosomes per cell from 3 replicate experiments. (Mean±SEM; 
one-way ANOVA with Fisher’s LSD test, **** p ≤ 0.0001, N (cells) = EV 75; 
EV+Torin1 63; C9orf72S 79, C9orf72L 85. Scale bar = 20 µm. 
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4.2.3 C9orf72 induces autophagy via the ULK1 initiation complex 
FIP200 is essential for autophagy induction (Ganley et al., 2009; Hara et al., 
2008; Hosokawa et al., 2009a; Jung et al., 2009). Loss of FIP200 can 
completely abolish autophagy, leading to the accumulation of protein 
aggregates that are associated with defective autophagy (Hara et al., 2006; 
Hara et al., 2008; Komatsu et al., 2006; Liang et al., 2010; Wei et al., 2011). 
Thus, FIP200 siRNA can disrupt the ULK1 initiation complex, inhibiting 
autophagy (Hara et al., 2008). To determine if the induction of autophagy by 
C9orf72 overexpression was via the ULK1 initiation complex, C9orf72 was 
overexpressed in cells treated with non-targeting control (Ctrl) or FIP200 siRNA. 
Autophagy induction was monitored by the conversion of co-transfected EGFP-
LC3 on immunoblot (Fig. 4.5A) or by quantifying the number of EGFP-LC3 
puncta (Fig. 4.5B). As before overexpression of C9orf72S or C9orf72L 
increased the level of EGFP-LC3-II as well as the number of EGFP-LC3 positive 
autophagosomes in Ctrl siRNA treated cells, similar to the treatment with Torin1 
(Fig. 4.5A and B). FIP200 siRNA completely prevented the induction of 
autophagy by C9orf72 overexpression in both assays (Fig. 4.5A and B). Thus 




Figure 4.5 C9orf72 induces autophagy via the ULK1 initiation complex. (A) 
HEK293 cells treated with non-targeting control (Ctrl) or FIP200 siRNA were co-
transfected with EGFP-LC3 and either empty vector control (EV), Myc-C9orf72S 
or Myc-C9orf72L. 24 h post transfection cells were treated with vehicle or BafA1 
for 6 h. Samples were lysed and subjected to SDS-PAGE and immunoblot. 
Autophagy levels were determined by immunoblot for EGFP-LC3-I and II. 
Expression of C9orf72 was confirmed using anti-Myc antibodies (* indicates 
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aspecific band). FIP200 knock down was confirmed using anti-FIP200 
antibodies. α-Tubulin was used as a loading control. (B) HeLa cells treated with 
non-targeting (Ctrl) or FIP200 siRNA were co-transfected with empty vector 
(EV), myc-C9orf72S or myc-C9orf72L (red) and EGFP-LC3 (green) to label 
autophagosomes. As positive control EV transfected cells were treated with 
Torin1 (250 nM; 3 h). Autophagy was quantified as the number of EGFP-LC3 
positive autophagosomes per cell from 3 replicate experiments (Mean±SEM; 
one-way ANOVA with Fisher’s LSD test, ** p ≤ 0.01, *** p ≤ 0.001; **** P ≤ 
0.0001, N (cells) = Ctrl/EV: 73; FIP200/EV: 76; Ctrl/EV/Torin1: 73, 
FIP200/EV/Torin1: 70; Ctrl/C9orf72L: 71; FIP200/C9orf72L: 74; Ctrl/C9orf72S: 
72; FIP200/C9orf72S: 72). Scale bar = 20 µm. FIP200 knockdown was 
confirmed by immunoblot. 
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4.2.4 Loss of C9orf72 does not affect ULK1 activation 
Under basal condition mTOR phosphorylates ULK1 at serine 757, rendering the 
initiation complex inactive (Jung et al., 2009; Kim et al., 2011), see section 
1.5.2.1 and Figs. 1.4 and 1.5. Induction of autophagy releases the ULK1 
initiation complex from mTOR resulting in loss of ULK1 Ser757 phosphorylation 
and the activation of ULK1 kinase activity (Ganley et al., 2009; Jung et al., 2009; 
Kim et al., 2011). Thus, the level of ULK1 Ser757 phosphorylation is indicative 
of the activation state of ULK1. To investigate whether loss of C9orf72 affected 
the activation of ULK1, the level of ULK1 Ser757 phosphorylation was assessed 
in HEK293 cells treated with non-targeting (Ctrl) or C9orf72 siRNA. Autophagy 
was induced with rapamycin or Torin1 and the level of ULK1 Ser757 
phosphorylation determined by using phosphospecific antibodies. Inhibition of 
mTOR with rapamycin or Torin1 led to a decrease in ULK1 Ser757 
phosphorylation in both control and C9orf72 siRNA treated cells (Fig. 4.6A and 
B), indicating that loss of C9orf72 did not prevent ULK1 activation. C9orf72 
knockdown was quantified by qPCR (Fig. 4.6C). As loss of C9orf72 inhibits 
autophagy induction, but does not affect the activation of ULK1, loss of C9orf72 





Figure 4.6 Loss of C9orf72 does not affect activation of ULK1. HEK293 cells 
treated with non-targeting control or C9orf72 siRNA were treated with vehicle, 
Torin1 (250 nM; 3 h) (A) or rapamycin (500 nM; 6 h) (B) to induce autophagy. 
Activation of ULK1 was determined via immunoblots using phopho-ULK1 (S757) 
and total ULK antibodies. Phospho-ULK1 (S757) levels were normalised to total 
ULK1 and are shown relative to the vehicle treated samples. GAPDH was used 
as a loading control. (Mean±SEM; one-way ANOVA with Fisher’s LSD test, *** p 
≤ 0.001, **** p ≤ 0.0001. (C) C9orf72 knock down was confirmed by RT-qPCR 
(Mean±SEM; one-way ANOVA with Fisher’s LSD test, ** p ≤ 0.01). (N = 3 
experiments). 
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4.2.5 C9orf72 regulates translocation of the ULK1 initiation 
complex to the phagophore via Rab1a 
Upon autophagy induction, the active ULK1 initiation complex translocates to 
the phagophore to initiate formation of the autophagosome (Hara et al., 2008), 
see section 1.5.2.1 and Fig. 1.4. Thus, the formation of ULK1, FIP200 or ATG13 
positive puncta can be monitored by immunofluorescent microscopy to assess 
translocation of the initiation complex to the phagophore (Ganley et al., 2009). 
To investigate whether C9orf72 could affect translocation of the initiation 
complex, mCherry-tagged FIP200 translocation was monitored in HeLa cells 
transfected with non-targeting (Ctrl) or C9orf72 siRNA and treated with Torin1 to 
induce autophagy. In untreated Ctrl siRNA and C9orf72 siRNA transfected cells, 
mCherry-FIP200 was diffusely distributed throughout the cytoplasm, with a small 
number of bright puncta (Fig. 4.7A). Torin1 treatment in Ctrl siRNA cells lead to 
a significant increase in the number of mCherry-FIP200 puncta, indicating 
translocation of the initiation complex after autophagy induction (Fig. 4.7A). 
However, Torin1 treatment had no effect on the number of mCherry-FIP200 
puncta in cells treated with C9orf72 siRNA, indicating that loss of C9orf72 
prevents translocation of the initiation complex (Fig. 4.7A). Thus C9orf72 is 
required for translocation of the autophagy initiation complex. The knockdown of 
C9orf72 was quantified by qPCR (Fig. 4.7B). 
 
As C9orf72 overexpression was capable of inducing autophagy, and C9orf72 
was required for translocation of the initiation complex, it was reasoned that 
increasing C9orf72 levels would actively drive translocation of the autophagy 
initiation complex to bring about the induction of autophagy as seen in Fig. 4.3 
and Fig. 4.4. To test this possibility, Hela cells were co-transfected with 
mCherry-FIP200 and either empty vector, Myc-C9orf72S or Myc-C9orf72L. 
Torin1 treatment of empty vector transfected cells significantly increased the 
number of co-transfected mCherry-FIP200 puncta compared to untreated cells 
(Fig. 4.7C). As expected, overexpression of C9orf72S or C9orf72L also 
significantly increased the number of mCherry-FIP200 puncta similar to the 





Figure 4.7 C9orf72 regulates translocation of the ULK1 complex. (A) HeLa cells 
treated with non-targeting (Ctrl) or C9orf72 siRNA were transfected with 
mCherry-FIP200. 24 h post transfection cells were treated with vehicle (Ctrl) or 
Torin1 (250 nM; 3 h) to induce autophagy. Translocation of the ULK1 complex 
was quantified as the number of mCherry-FIP200 positive puncta per cell from 3 
replicate experiments (Mean±SEM; one-way ANOVA with Fisher’s LSD test, ns: 
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not significant, **** P ≤ 0.0001; N (cells) = Ctrl/Ctrl: 65; Ctrl/Torin1: 60; 
C9orf72/Ctrl: 54; C9orf72/Torin1: 49). C9orf72 knockdown was determined by 
RT-qPCR. Scale bar = 10 µm. (B) HeLa cells were co-transfected with mCherry-
FIP200 (red) and either empty vector (EV), FLAG-C9orf72L or FLAG-C9orf72S 
(green). As positive control EV transfected cells were treated with Torin1 (250 
nM; 3 h) to induce autophagy. Translocation of the ULK1 complex was 
quantified as the number of mCherry-FIP200 positive puncta per cell from 3 
replicate experiments (Mean±SEM; one-way ANOVA with Fisher’s LSD test, *** 
P ≤ 0.001, **** P ≤ 0.0001); N (cells) = EV: 47, EV + Torin1: 31, C9orf72L: 46, 
C9orf72S: 45). Scale bar = 10µm. 
  
 155 
In yeast Ypt1 regulates the translocation ATG1, the homologue of ULK1, to the 
PAS to induce autophagy (Lynch-Day et al., 2010; Wang et al., 2013). To 
determine if the mammalian homologue of Ypt1, Rab1, was able to regulate the 
translocation of the initiation complex in mammalian cells, the translocation of 
mCherry-FIP200 in HeLa cells was investigated after depletion of Rab1a with 
targeted siRNA. Rab1a was chosen as Rab1a had previously been shown to 
regulate autophagy induction (Winslow et al., 2010). Targeted knock down of 
Rab1a by siRNA completely prevented the translocation of mCherry-FIP200 
induced by Torin1 (Fig. 4.8A), suggesting that Rab1a may regulate the 
translocation of the autophagy initiation complex in mammalian cells. To 
determine if C9orf72 acted via Rab1a to induce translocation of the initiation 
complex and induce autophagy, the effect of C9orf72 overexpression on 
mCherry-FIP200 translocation was also quantified in Rab1a depleted cells. As 
previously, overexpression of Myc-tagged C9orf72S and C9orf72L induced the 
translocation of the mCherry-FIP200 to similar levels seen with Torin1 induction 
(Fig. 4.8A). However, in cells treated with Rab1a siRNA, overexpression of Myc-
C9orf72S and Myc-C9orf72L was no longer able to induce translocation of 
mCherry-FIP200 (Fig. 4.8A). The knockdown of Rab1a was confirmed by qPCR 
(Fig. 4.8B). Thus C9orf72 required Rab1a to induce the translocation of the 





Figure 4.8 C9orf72 regulates translocation of the ULK1 initiation complex via 
Rab1a. HeLa cells treated with non-targeting (Ctrl) or Rab1a siRNA were co-
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transfected with mCherry-FIP200 (red) and empty vector (EV), myc-C9orf72L or 
myc-C9orf72S (green). As positive control EV transfected cells were treated for 
3 h with Torin1 (250 nM). Translocation of the ULK1 complex was quantified as 
the number of mCherry-FIP200 positive puncta per cell from 3 replicate 
experiments (Mean±SEM; one-way ANOVA with Fisher’s LSD test, **** P ≤ 
0.0001); N (cells) = Ctrl/EV: 81; Ctrl/EV/Torin1: 48; Ctrl/C9orf72L: 86; 
Ctrl/C9orf72S: 48; Rab1a/EV: 79; Rab1a/EV/Torin1: 68; Rab1a/C9orf72L: 78; 
Rab1a/C9orf72S: 52). Rab1a knockdown was confirmed by RT-qPCR. Scale 
bar = 10µm. 
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4.2.6 C9orf72 interacts with Rab1a 
There are 2 isoforms of Rab1, Rab1a and Rab1b, which share approximately 
92% homology (Vielh et al., 1989). Rab1 and its yeast counterpart, Ypt1, are 
required for ER to Golgi transport (Pind SN, 1994), but both have also been 
implicated in the autophagy pathway (Lipatova et al., 2012; Winslow et al., 2010; 
Zoppino et al., 2010). The data in section 4.2.5, along with the structural 
homology of C9orf72 with the DENN domain Rab GEF proteins, suggested 
C9orf72 may interact with Rab1a. Further to this, the Y2H screen conducted in 
Chapter 3 section 3.2.6 identified Rab1a as a potential C9orf72S interacting 
protein. One clone, encoding a partial Rab1a sequence (aa 46-205), was 
identified while using C9orf72S as bait. To confirm this interaction, HEK293 cells 
were co-transfected with Myc-Rab1a and either empty vector, FLAG-C9orf72S 
or FLAG-C9orf72L. FLAG-C9orf72 was immunoprecipitated with anti-FLAG 
antibodies and the immunepellets analysed by SDS-PAGE and immunoblot. 
Myc-Rab1a was found to efficiently co-immunoprecipitate with both C9orf72S 
and C9orf72L (Fig. 4.9A). 
 
To test if Rab1a was directly interacting with C9orf72 in vitro binding assays 
were performed using recombinant GST-tagged C9orf72 incubated with in vitro 
translated S35-labelled Rab1a protein. GST proteins were pulled down using 
glutathione beads and samples analysed by SDS-PAGE. Radiolabelled Rab1a 
was detected using a phosphoimager. Rab1a was found to directly interact with 
both C9orf72S and C9orf72L (Fig. 4.9B). Thus Rab1a was confirmed as a direct 




Figure 4.9 C9orf72 directly interacts with Rab1a. (A) Whole cell lysates of 
HEK293 cells co-transfected with Myc-Rab1a and either empty vector control, 
FLAG-C9orf72S or FLAG-C9orf72L were subjected to immunoprecipitation with 
anti-FLAG antibodies. Immune pellets were probed for FLAG-C9orf72 and Myc-
Rab1a on immunoblot. Blots were initially probed with 9B11 mouse anti-Myc to 
detect Myc-Rab1a. Blots were then re-probed with M2 mouse anti-FLAG to 
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detect FLAG-C9orf72. The * in the middle panel indicates Myc-Rab1a bands 
that were present after re-probing of the membrane for FLAG-C9orf72S. (B) 
C9orf72 directly interacts with Rab1a. 35S-radiolabelled recombinant Myc-Rab1a 
protein was incubated with GST, GST-C9orf72S or GST-C9orf7L immobilized 
on glutathione-coated beads. 35S-radiolabelled recombinant Myc-Rab1a protein 
was visualised by autoradiography (top panel: S.E = short exposure, L.E = long 
exposure). Coomassie-stained GST, GST-C9orf72S and GST-C9orf72L from 
the pull down are shown (bottom panel). The identities of the Coomassie protein 
bands were confirmed by mass spectrometry (* = CH60 E. coli, 60kD 
Chaperonin, # = DnaK Chaperonin E.coli). 
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4.2.7 C9orf72 mediates the interaction between Rab1a and the 
ULK1 initiation complex 
The structural homology of C9orf72 with DENN domain proteins suggested that 
C9orf72 might function as a GEF for the Rab GTPases (Levine et al., 2013; 
Zhang et al., 2012). The interaction with Rab1a, therefore suggested that the 
C9orf72 could function as a GEF for Rab1a, allowing for translocation of the 
initiation complex and the induction of autophagy. To function as a GEF, 
C9orf72 would be expected to bind preferentially to the GDP-bound version of 
Rab1a and mediate the exchange of GDP for GTP, thus activating the Rab 
GTPase.  
 
To investigate the binding affinity of C9orf72 to GDP-bound Rab1a, in vitro 
binding assays were conducted between GST-tagged C9orf72 and in vitro 
translated S35-radiolabelled Rab1a. Recombinant GST-tagged C9orf72 was 
incubated with in vitro translated S35-labelled Rab1a, S35-labelled Rab1a pre-
loaded with GDP or S35-labelled Rab1a preloaded with a non-hydrolysable 
version of GTP. GST tagged proteins were pulled down with glutathione beads 
and samples analysed by SDS-PAGE. The gel was exposed to a 
phosphoimager plate to detect S35-Rab1a. Preloading Rab1a with GDP, to 
mimic the inactive form of Rab1a, did not alter the binding with C9orf72 (Fig. 
4.11). However, preloading Rab1a with a non-hydrolysable form of GTP (GMP-
PNP), thus mimicking the active form of Rab1a, significantly increased the 
amount of Rab1a interacting with C9orf72S and C9orf72L (Fig.4.10). The 
preferential interaction between GTP-Rab1a and C9orf72 suggests that C9orf72 






Figure 4.10 C9orf72 preferentially binds GTP-bound Rab1a. 35S-radiolabelled 
recombinant Myc-Rab1a protein loaded with vehicle, GDP or GMP-PNP was 
added to GST, GST-C9orf72S and GST-C9orf72L immobilized on glutathione-
coated beads. 35S-radiolabelled recombinant Myc-Rab1a protein was visualized 
by autoradiography (top panel). Coomassie-stained GST, GST-C9orf72S and 
GST-C9orf72L in the pull-down samples are shown (bottom panel). The identity 
of the Coomassie protein bands was confirmed by mass spectrometry (* = 
CH60 E. coli, 60kD Chaperonin; Fig. S3). Relative binding of Rab1A to C9orf72 
was quantified from 3 independent experiments (Mean±SEM; one-way ANOVA 
with Fisher’s LSD test; ns, not significant; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001). 
  
 163 
In yeast, the active GTP-loaded Ypt1 is brought into contact with ATG1 by the 
action of the PAS scaffold protein, ATG11 (Lipatova et al., 2012). To investigate 
whether C9orf72 was required for the interaction of active Rab1a with the ULK1 
initiation complex, the interaction between Rab1a and ULK1 was investigated in 
HeLa cells that were treated with non-targeting (Ctrl) or C9orf72 siRNA by an in 
situ proximity ligation assay (PLA) (Soderberg et al., 2006). In PLA, cells are 
fixed and the two proteins of interest stained with primary antibodies. Secondary 
antibodies are then added, which are conjugated with complementary 
oligonucleotide probes. If the two proteins are in close enough proximity (i.e. 
less than 50 nm) the oligonucleotide probes can be ligated. This closed circle 
formation of the probes allows for rolling circle amplification, which can be 
detected by using complementary fluorescently labelled oligonucleotides. The 
signal from these fluorescent oligonucleotides can be detected by fluorescence 
microscopy (Soderberg et al., 2006). In control siRNA transfected cells, 
proximity signals were observed in all cells transfected with HA-ULK and Myc-
Rab1a, while only low numbers of proximity signals were observed in cells 
transfected with Myc-Rab1a or HA-ULK alone (Fig. 4.11). In comparison, 
C9orf72 siRNA treated cells showed significantly less proximity signals when co-
transfected with HA-ULK and Myc-Rab1a (Fig. 4.11). Thus, Rab1a interacts with 
ULK1 in a C9orf72 dependent manner.  
 
To test whether C9orf72 was indeed required for the Rab1a dependent 
induction of autophagy, the effect of constitutively active Rab1a (Rab1aQ70L) 
overexpression on mCherry-FIP200 translocation was investigated in HeLa cells 
treated with C9orf72 siRNA. Consistent with the Rab1a dependent translocation 
of the autophagy initiation complex, overexpression of constitutively active 
Rab1a (Q70L) was able to induce translocation of the autophagy initiation 
complex as measured by mCherry-FIP200 puncta formation in HeLa cells 
treated with control siRNA (Fig. 4.12A). However, in C9orf72 siRNA treated 
cells, Rab1a (Q70L) was no longer able to induce translocation of mCherry-
FIP200 (Fig. 4.12). The knockdown of C9orf72 was confirmed by RT-qPCR (Fig. 
4.12B)  
 
In conclusion these data indicate that C9orf72 acts as a Rab1a effector, 
recruiting active GTP bound Rab1a to the initiation complex to bring about 





Figure 4.11 C9orf72 regulates the interaction between Rab1a and ULK1. HeLa 
cells treated with non-targeting (Ctrl) or C9orf72 siRNA were transfected with 
HA-ULK, Myc-Rab1a or HA-ULK1 + Myc-Rab1a as indicated. Transfections 
were laced with mVenus to enable identification of transfected cells for analysis 
(green). Transfected cells were probed with both anti-HA and anti-myc 
antibodies and processed for PLA. PLA proximity signals per cell (red) were 
determined from 3 replicate experiments (Mean±SEM; one-way ANOVA with 
Fisher’s LSD test, **** P ≤ 0.0001); N (cells) = Ctrl/HA-ULK1: 125, Ctrl/Myc-
Rab1a: 149, Ctrl/HA-ULK1+Myc-Rab1a: 163, C9orf72/HA-ULK1: 136, 





Figure 4.12 C9orf72 is required for the Rab1a dependent induction of 
autophagy. HeLa cells treated with non-targeting (Ctrl) or C9orf72 siRNA were 
co-transfected with mCherry-FIP200 (red) and empty vector (EV) or myc-Rab1a 
(Q70L). Translocation of the ULK1 complex was quantified as the number of 
mCherry-FIP200 positive puncta per cell from 4 replicate experiments 
(Mean±SEM; one-way ANOVA with Fisher’s LSD test, * P ≤ 0.05, **** P ≤ 
0.0001); N (cells) = Ctrl/EV: 101; Ctrl/Q70L: 106; C9/Q70L: 42. C9orf72 
knockdown was determined by RT-qPCR. 
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4.2.8 C9orf72 depletion induces p62 accumulation 
The accumulation of p62 specific pathology in C9ALS/FTD patients is indicative 
of defective autophagy. The link between C9orf72 and autophagy induction 
therefore suggests that haploinsufficiency of C9orf72 could lead to autophagy 
deficiency in patients and the associated C9ALS/FTD pathology. To investigate 
whether loss of C9orf72 was sufficient to cause accumulation of p62, the 
accumulation of p62 were monitored by immunofluorescence in cells treated 
with non-targeting (Ctrl) siRNA or C9orf72 siRNA. In Ctrl siRNA treated cells, 
p62 was diffusely distributed throughout the cytoplasm, but was also present in 
a number of p62 cytoplasmic puncta (Fig. 4.13A). In contrast, there were 
significantly more p62 puncta in cells transfected with C9orf72 siRNA, 
suggesting that loss of C9orf72 led to the accumulation of p62 in these puncta 
or aggregates (Fig. 4.13A). Thus loss of C9orf72 is sufficient to cause the 
accumulation of p62, mimicking the pathology associated with C9ALS/FTD in 





Figure 4.13 Loss of C9orf72 induces p62 accumulation. HeLa cells treated with 
non-targeting (Ctrl) or C9orf72 siRNA were immunostained for endogenous p62. 
Accumulation of p62 was quantified by counting p62 positive puncta per cell 
from 3 replicate experiments (Mean±SEM; Mann-Whitney test, **** P ≤ 0.0001); 
N (cells) = Ctrl: 74, C9orf72: 55). C9orf72 knockdown was confirmed by RT-
qPCR. Scale bar = 10µm. 
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4.2.9 C9orf72 ALS/FTD patient derived iNeurons show defective 
autophagy 
To investigate the possibility that C9ALS/FTD patients are deficient in 
autophagy, the basal levels of autophagy were analysed in C9ALS/FTD patient 
derived iNeurons. iNeurons were generated by differentiation of induced neural 
progenitor cells from two C9ALS/FTD patients and their age and sex matched 
controls. Analysis of the C9orf72 mRNA by RT-qPCR revealed that patients had 
significantly less C9orf72 mRNA compared to controls, consistent with the idea 
that the C9orf72 repeat expansion causes haploinsufficiency of C9orf72 (Fig. 
4.14C). Such a marked reduction in C9orf72 mRNA levels in patients compared 
to controls was even greater then the knockdown achieved in many of siRNA 
experiments detailed previously. To investigate basal levels of autophagy, cells 
were either untreated or treated with bafilomycin A1 to inhibit progression of 
basal autophagy (Fig. 4.14A and B). LC3-I and LC3-II were detected in both 
controls, and both accumulated upon treatment with bafilomycin A1 (Fig 4.14A 
and B). In line with reduced levels of autophagy, LC3-I was readily detected in 
untreated in C9ALS/FTD patient cells, while LC3-II was not (Fig. 4.14A and B). 
Treatment of patient cells with bafilomycin A1 led to an accumulation of LC3-II, 
suggesting that autophagy was not completely inhibited in these cells (Fig. 
4.14A and B). However, the levels of LC3-II were significantly lower than the 
levels of LC3-II in control iNeurons (Fig. 4.14A and B). Thus there was a clear 





Figure 4.14 C9ALS/FTD patients have reduced basal autophagy. iPSC derived 
iNeurons from 2 controls (C155 and C209) and 2 confirmed C9orf72 patients 
(P183, and P201) were incubated with vehicle or BafA1 (100 nM; 6 h) to inhibit 
autophagy progression. Levels of LC3-I and LC3-II were determined on 
immunoblot. Levels of LC3-II were normalised to tubulin are shown. 
(Mean±SEM; 2-way ANOVA with Fisher’s LSD test; * p ≤ 0.05, ** p ≤ 0.01, **** p 
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≤ 0.0001, N = 4 experiments). iNeurons were prepared by Dr. Laura Ferraiuolo 




In this chapter, C9orf72 was shown to regulate the induction of autophagy by 
mediating Rab1a dependent translocation of the ULK1 autophagy initiation 
complex. 
 
The structural homology of C9orf72 with the DENN family of proteins suggested 
that C9orf72 might be a GEF for the Rab family of GTPases. In line with this, 
C9orf72 was shown to directly interact with Rab1a (Fig. 4.9). However, C9orf72 
was found to preferentially interact with the active GTP-Rab1a rather than GDP-
Rab1a, behaviour more associated with a Rab effector rather than a Rab GEF 
(Fig. 4.10). As reviewed by Grosshans et al 2006, there are multiple examples 
of Rab effector proteins binding their specific Rab (Grosshans et al., 2006). For 
example, the localisation of Rab5 to the endocytic vesicles is dependent upon 
its effector protein, Rabaptin-5, which binds GTP-Rab5 and brings it into contact 
with its partner Rab4 on endocytic vesicles (Korobko et al., 2005; Rubino et al., 
2000).  
 
In yeast, GTP bound Ypt1, the homologue of Rab1, is brought into contact with 
ATG1, the homologue of ULK1, by the action of ATG11 (Lipatova et al., 2012). 
As such, ATG11 functions as a Ypt1 effector protein. The fact that C9orf72 
carries out many of the roles performed by ATG11 suggests C9orf72 may be the 
mammalian counterpart of ATG11 in terms of function. There is also evidence 
that Rab effectors and Rab GEFs work together in feedback mechanism, 
whereby the active Rab is brought to its correct site of action by its effector and 
maintained in the active state by the continued presence of the GEF. In the case 
of Ypt1 and ATG11, the transport protein particle (TRAPP) III complex functions 
as the autophagy specific GEF for Ypt1 (Lynch-Day et al., 2010; Wang et al., 
2013). The TRAPPIII GEF complex is targeted to the PAS to maintain Ypt1 
activity, possibly by the interaction of the TRAPPIII subunit Trs85, and ATG17, 
the yeast homologue of FIP200 (Kakuta et al., 2012; Lynch-Day et al., 2010; 
Wang et al., 2013). Indeed, the importance of Trs85 in autophagy is 
demonstrated by the fact that loss of Trs85 results in a decreased autophagic 
rate (Meiling-Wesse et al., 2005; Nazarko et al., 2005). The organisation of a 
Rab GTPase, a Rab effector and a Rab GEF is also found in the case of Rab5. 
While Rabaptin-5 localises active Rab5 to the endocytic vesicles, Rabaptin-5 
can also bind and recruit the Rab5 GEF Rebex5 (Lippé et al., 2001). Thus, a 
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positive feedback loop is established, maintaining active Rab5 at the endocytic 
vesicle (Lippé et al., 2001). If C9orf72 were functioning as the mammalian 
homologue of ATG11, then the presence of a Rab1a GEF would also be 
expected to bind in this complex. 
 
In mammalian cells, the TRAPPC8 protein has been identified as a distant 
homologue of Trs85, and is also important for autophagy induction (Behrends et 
al., 2010; Choi et al., 2011). However, unlike Trs85, which is known to bind 
ATG17, TRAPPC8 has not been identified as a FIP200 interacting protein. This 
potential difference in the binding partners of Trs85 and TRAPPC8 could 
suggest other autophagy related GEFs are required for the activation of Rab1a. 
From the same study that identified the potential interaction of C9orf72 and 
FIP200, as well as the role of TRAPPC8 in autophagy, SMCR8 was also 
identified as a potential FIP200 interacting protein (Behrends et al., 2010). As 
SMCR8 was shown to interact with C9orf72 in Chapter 3, this could suggest 
that, in a similar fashion to the Ypt1-ATG11-Trs85 module, SMCR8 functions as 
the autophagy specific GEF for Rab1a, interacting with the Rab1a effector 
protein, C9orf72, as well as the autophagy initiation protein FIP200, to maintain 
active Rab1a at the site of autophagosome formation. 
 
ATG11 has a number of diverse roles in yeast. As detailed above, ATG11 
recruits a number of essential autophagy proteins to the newly forming PAS, but 
also acts as a scaffold for the formation of the autophagosome, recruiting the 
ATG9 positive membranes (He et al., 2006). Recruitment of ATG9 vesicles 
appears to be essential for autophagosome formation (Mari et al., 2010). The 
mammalian homologue of ATG9, mATG9, is located within the trans-Golgi 
network, and redistributes to LC3 positive autophagosomes upon autophagy 
induction (Young et al., 2006). Rab1a is also located within similar Golgi 
structures and loss of Rab1 was shown to disrupt the redistribution of mATG9 to 
autophagosomes (Winslow et al., 2010). Thus as C9orf72 was shown to 
regulate the translocation of Rab1a to ULK1 in this Chapter, C9orf72, via its 
interaction with Rab1a, could also regulate the translocation of mATG9-positive 
vesicles to the ULK1 initiation complex and the autophagosomes. As Golgi 
derived membranes have also been implicated in autophagosome formation 
(Yen et al., 2010), the interaction between C9orf72 and Rab1a, as well as the 
possible regulation of mATG9, could be required for the delivery of double 
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membrane structures and the formation of functional autophagosomes during 
autophagy initiation. 
 
The use of more then one method to investigate the autophagy pathway gave 
confidence that the results observed were reliable, which is standard procedure 
with such assays (Klionsky et al., 2012). The same approach was taken for 
many other experiments within this thesis. Unfortunatly, the interaction between 
Rab1a and ULK1 was only investigated by PLA. Proximity signals only indicate 
two potential binding partners are within 50 nm of each other, and do not 
confirm an actual interaction. As such this interaction should be investigated in 
more detail, potentially via co-immunoprecipitation or in vitro binding assays. 
 
Although this chapter identified C9orf72 as a Rab1a effector protein, it cannot be 
ruled out that C9orf72 is also capable of acting as a GEF for another autophagy 
related Rab. A common feature of the Rab GTPase family is the so-called Rab 
cascade whereby one activated Rab recruits a further downstream Rab (Ortiz et 
al., 2002). In this sense, while C9orf72 may be important for Rab1a recruitment 
to the ULK1 initiation complex, it may also be required for GEF activity on 
another Rab. These other targets could include other autophagy related Rabs 
as detailed in section 1.5.2.5, or those suggested to co-localise with C9orf72 in 
previous studies (Farg et al., 2014). 
 
C9orf72 is not the only Rab associated protein known to be involved in the 
pathogenesis of ALS. The Rab5 GEF Alsin (ALS2) is associated with juvenile 
onset ALS (Hadano et al., 2001a; Hadano et al., 2010; Hadano et al., 2001b). 
As mentioned above, Rab5 is classically thought to function in the endocytic 
pathway, aiding the homotypic fusion of endocytic vesicles (Lippé et al., 2001; 
Rubino et al., 2000; Topp et al., 2004). However, Rab5 is also linked to the 
autophagy pathway, regulating the formation of the Vps34 class III PI3K 
complex and also inhibiting mTORC1 (Ao et al., 2014; Dou et al., 2013; Li et al., 
2010; Ravikumar et al., 2008; Su et al., 2011). While Rab1a functions in 
translocation of the initiation complex, Rab5 appears to act further downstream, 
regulating the elongation of the autophagosome membrane (Ravikumar et al., 
2008). Mutations to Alsin, which disrupt correct GEF activity to Rab5, therefore 
also lead to dysfunctional autophagy (Otomo et al., 2011). Loss of Alsin and 
dysfunctional autophagy may therefore lead to the development of ALS. The 
role of autophagy in neuronal health is well established (Komatsu et al., 2006). 
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Beside the fact that the post-mitotic nature of neurons means they must have 
effective recycling and maintenance pathways, neural specific loss of many 
autophagy genes is has been shown to lead to neurodegeneration. Neural 
specific loss of RB1CC1 (FIP200), ATG7 or ATG5 in mice leads to 
neurodegeneration, progressive motor defects as well as the accumulation of 
cytoplasmic neural inclusion bodies (Hara et al., 2006; Komatsu et al., 2006; 
Liang et al., 2010). The cerebellum of these mice appears to be particularly 
effected by loss of these genes and the subsequent disruption to autophagy, 
suggesting a high autophagic demand by this tissue. Interestingly, C9ALS/FTD 
patients also develop p62 specific accumulations in the cerebellum suggesting 
an autophagy defect (Al-Sarraj et al., 2011; Cooper-Knock et al., 2012; 
Mahoney et al., 2012), which was replicated by C9orf72 knockdown in Fig. 4.13. 
Thus, as C9orf72 has been identified as a regulator of autophagy initiation, loss 
of C9orf72 in patients would result in a defective autophagy pathway. This is 
supported by the fact that iNeurons from C9ALS/FTD patients, who showed 
reduced C9orf72 mRNA levels, were also found to be deficient in basal levels of 
autophagy (Fig. 4.14). It would be interesting to determine whether the relative 
level of C9orf72 in patients gives any indication of disease severity, or age of 
onset. The marked reduction in C9orf72 mRNA levels in patient iNeurons 
compared to controls was consistent with previous reports (Belzil et al., 2013; 
Cooper-Knock et al., 2012; Gijselinck et al., 2012; Xi et al., 2013). However, 
whether the two patients used in this study are representative of all C9ALS/FTD 
patients remains to be seen. Whether such a significant difference between the 
level of C9orf72 mRNA in patients and the controls is always present and 
whether this leads to a worsening effect should be investigated and documented 
further. 
 
While basal autophagy in these iNeurons was investigated, the ability of these 
cells to induce autophagy above basal levels was not. Aside from the mTOR 
inhibitors used in this Chapter, the level of autophagy induction after a more 
physiologically relevant induction should be investigated, namely starvation. 
 
The evidence from the patient iNeurons supports the role of C9orf72 in 
autophagy in C9ALS/FTD as identified by the siRNA knock down studies. 
However, there is potential for off target effects when using siRNA (Fedorov et 
al., 2006). For this reason the gold standard in siRNA experiments would be to 
rescue the defect by overexpression of an siRNA-resistant form C9orf72 
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(Cullen, 2006). If the resistant over-expression construct is able to alleviate the 
defect, then one can be confident that the effect observed by knock down is 
specific. As with the previous Chapter, conducting such experiments on more 
neuronal cell populations or, better still, primary neuronal cells would greatly 





5 C9orf72	  turnover	  and	  stability	  
5.1 Introduction 
If haploinsufficiency of C9orf72 is an underlying cause of C9ALS/FTD, possibly 
by inhibition of autophagy induction (see Chapter 4), then restoring/increasing 
C9orf72 protein levels could be of therapeutic benefit. 
 
Protein levels are controlled by balancing their synthesis and breakdown, 
referred to as protein turnover. As discussed in Chapter 1, two pathways 
mediate protein degradation in eukaryotic systems: the ubiquitin proteasome 
system (UPS) and autophagy. Both UPS and autophagy-mediated degradation 
involves substrate ubiquitination. Much like phosphorylation, ubiquitination is a 
dynamic and reversible post-translational modification (Komander et al., 2009). 
The removal of ubiquitin from protein substrates is mediated by the de-
ubiquitinating enzymes (DUBs). Under physiological conditions ubiquitination 
levels are controlled by the opposing action of E3 Ubiquitin ligases and DUBs. 
Thus both classes of enzymes could be possible therapeutic targets for the 
treatment of C9orf72 haploinsufficiency. 
 
In this chapter the half-life of C9orf72 was determined and the role of the UPS 
and autophagy in its degradation investigated. Using bioinformatics approaches 
the predicted possible regulatory ubiquitination sites on C9orf72 were 
investigated and one mutated to investigate its effect on C9orf72 turnover. 
Finally, the interaction of C9orf72 and USP8 was investigated, as was the role of 
USP8 in the regulation of C9orf72 turnover. 
5.2 Results 
5.2.1. Determination of the half-life of C9orf72 
Firstly, the stability of C9orf72S and C9orf72L was characterised using 
cycloheximide (CHX) chase assays. The principle of these assays is to inhibit 
protein translation using CHX, which functions by binding to the 60S ribosome 
(Schneider-Poetsch et al., 2010) and measure protein levels over time after 
inhibition. As no new protein is synthesised after addition of CHX it is possible to 
determine the rate of degradation of a protein with the protein level at the time of 
CHX addition being 100%. Protein degradation is exponential and so to gain a 
more accurate value for protein half-life, the natural log (ln) of the calculated 
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protein levels is plotted against time to produce a straight-line curve. According 
to the laws of exponential decay, the gradient of this line is equal to the decay 
constant of the substance of interest, in this case the decay constant of C9orf72. 
This decay constant (λ) can then be used to solve the decay law equation (N = 
N0e-λt ) with respect to t1/2 or half-life, where λ is the decay constant, N is the 
amount of protein remaining at time t and N0  is the amount of protein at time 0. 
Solving this equation with respect to t1/2 gives: t1/2 = ln(2)/λ. This method of half-
life calculation was previously described (Belle et al., 2006). 
 
To determine the half-life of C9orf72, HEK293 cells were transfected with Myc-
C9orf72S or Myc-C9orf72L. 24 h post transfection protein translation was 
inhibited with CHX and the levels of C9orf72S or C9orf72L measured over time 
on immunoblots to detect the Myc tag. The half-life of C9orf72L was calculated 
as 2.29 h ± 0.37 h (mean ± SEM) (Fig. 5.1A and C). C9orf72S was found to 
have a half-life of 1.12 h ± 0.18 h (mean ± SEM) (Fig. 5.1B and C), which was 





Figure 5.1 Half-life of C9orf72. HEK293 cells were transfected with Myc-
C9orf72L (A) or Myc-C9orf72S (B). 24 h post transfection cells were treated with 
the translational inhibitor cycloheximide (CHX) for the indicated times. After 
treatments cells were lysed and subjected to SDS-PAGE and immunoblot. Blots 
were probed for Myc-C9orf72 and either GAPDH or α-Tubulin as loading 
controls. Relative levels of C9orf72L (A) and C9orf72S (B) were taken as a 
percentage and the natural log (ln) of these values plotted against time to 
produce the corresponding graphs. (C) Using the gradient of the decay curve 
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graph and the decay equation, (t1/2 = ln(2)/decay constant, the half-life of 
C9orf72L and C9orf72S was calculated across the 3 experiments. The bar 
graph shows the comparison of the half-life of C9orf72L with C9orf72S. 
(Mean±SEM; unpaired t-test, * p ≤ 0.05; N = 3 experiments). 
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5.2.2. C9orf72 is a substrate of the proteasome 
To determine whether C9orf72 was a substrate of the UPS or the autophagy 
pathway, C9orf72 CHX chase assays were conducted in the presence of the 
selective proteasome inhibitor MG132 or the autophagy inhibitor bafilomycin A1. 
  
HEK293 cells were transfected with Myc-C9orf72S or Myc-C9orf72L and 24 h 
post transfection protein translation was blocked with CHX alone, CHX in the 
presence of bafilomycin A1 or CHX in the presence of MG132. The levels of 
C9orf72 protein were measured over time on immunoblots using 9B11 anti-Myc 
antibodies to detect the Myc tag. As above, both C9orf72S and C9orf72L were 
rapidly degraded after addition of cycloheximide alone (Fig. 5.2 and 5.3). The 
addition of bafilomycin A1 during treatment with cycloheximide had no effect on 
the stability of C9orf72S (Fig. 5.2) or C9orf72L (Fig. 5.3). However, the addition 
of MG132 significantly delayed the degradation of C9orf72S (Fig. 5.2) and 
completely halted the degradation of C9orf72L during the 24h time period 





Figure 5.2 C9orf72S is a substrate of the proteasome. HEK293 cells were 
transfected with Myc-C9orf72S. 24 h post transfection cells were untreated, 
treated with cycloheximide, cycloheximide and bafilomycin A1 or cycloheximide 
and MG132 for the indicated times (h). After treatments cells were lysed and 
subjected to SDS-PAGE and immunoblot. Blots were probed for anti-Myc-
C9orf72 and α-Tubulin as a loading control. Line graph depicts mean relative 
levels of Myc-C9orf72S (normalised to α-Tubulin) at the indicated times of no-
treatment (black circles), cycloheximide treatment (red squares), cycloheximide 
and bafilomycin A1 treatment (grey triangles) or cycloheximide and MG132 
treatment (blue triangles) (Mean±SEM; two-way ANOVA with Fisher’s LSD test; 




Figure 5.3 C9orf72L is a substrate of the proteasome. HEK293 cells were 
transfected with Myc-C9orf72L. 24 h post transfection cells were untreated, 
treated with cycloheximide, cycloheximide and bafilomycin A1 or cycloheximide 
and MG132 for the indicated times (h). After treatments cells were lysed and 
subjected to SDS-PAGE and immunoblot. Blots were probed for Myc-C9orf72 
and GAPDH as a loading control. Line graph depicts mean relative levels of 
Myc-C9orf72L (normalised to GAPDH) at the indicated times of no-treatment 
(black circles), cycloheximide treatment (red squares), cycloheximide and 
bafilomycin A1 treatment (grey triangles) or cycloheximide and MG132 treatment 
(blue triangles) (Mean±SEM; two-way ANOVA with Fisher’s LSD test; ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001; N = 3 experiments). 
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5.2.3. Mutation of Lysine 14 extends the half-life of C9orf72L 
Substrates of the proteasome are targeted for degradation by addition of 
ubiquitin moieties to their lysine residues. These residues become poly-
ubiquitinated by the addition of more ubiquitin moieties to internal lysine 
residues within the initial ubiquitin molecule, most commonly at lysine 48. The 
size and type of these ubiquitin chains plays a critical role in the fate of the 
protein. Tetra ubiquitination of a substrate linked through lysine 48 appears to 
be the minimum signal for degradation of a substrate by the proteasome 
(Thrower et al., 2000). 
 
C9orf72 contains 26 lysine residues as detailed in Fig. 5.4. To analyse which of 
these lysines was the most likely to be ubiquitinated, the C9orf72L protein 
sequence was entered into the ubiquitination site prediction software, UbPred. 
UbPred uses a database consisting of 266 experimentally verified ubiquitination 
sites to predict potential ubiquitination sites within a target sequence of interest 
(Radivojac et al., 2010). Of all possible lysines UbPred identified lysine 14 as 













Figure 5.4 UbPred predicted ubiquitination sites of C9orf72L. The C9orf72L 
amino acid sequence was entered into the UbPred ubiquitination site prediction 
software. All 26 lysine residues are indicated with lysine 14 marked in blue. 
Lysine 14 was scored with medium confidence as a potential ubiquitination site. 
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Table 5.1: C9orf72L lysine residues and UbPred scores 
Residue Score Ubiquitinated 
14 0.79  Yes   Medium confidence 
22 0.61 No 
48 0.47 No 
83 0.61 No 
90 0.53 No 
141 0.41 No 
148 0.4 No 
156 0.52 No 
191 0.55 No 
243 0.44 No 
246 0.29 No 
261 0.38 No 
273 0.59 No 
285 0.52 No 
316 0.39 No 
378 0.51 No 
388 0.32 No 
408 0.52 No 
414 0.3 No 
422 0.18 No 
424 0.09 No 
425 0.14 No 
428 0.22 No 
434 0.48 No 
454 0.41 No 
456 0.27 No 
  
Label Score range Sensitivity Specificity 
Low confidence 0.62 ≤ s ≤ 0.69 0.464 0.903 
Medium confidence 0.69 ≤ s ≤ 0.84 0.346 0.950 
High confidence 0.84 ≤ s ≤ 1.00 0.197 0.989 
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Lysine (K) to arginine (R) mutation is a common method to prevent 
ubiquitination of a protein (Rodriguez et al., 2000; Rufini et al., 2011). Therefore, 
to investigate whether ubiquitination on lysine 14 was involved in C9orf72 
degradation via the proteasome, the lysine 14 residue was mutated to arginine 
and the half-life of C9orf72L K14R determined in CHX chase assays. The 
cloning of C9orf72L K14R is detailed in section 2.2.1.6. 
 
HEK293 cells were transfected with either Myc-C9orf72L or Myc-C9orf72L 
K14R. 24 h post transfection protein translation was inhibited using CHX and the 
levels of C9orf72 protein were measured over time on immunoblots. The half-life 
of C9orf72L is this experiment was calculated as 3.2 h ± 0.29 h (mean ± SEM) 
(Fig. 5.5), similar to the value calculated in previously (Fig. 5.1A). The K14R 
mutation significantly extended the half-life of C9orf72L to 5.46 h ± 0.02 h (mean 
± SEM; Fig. 5.5) suggesting that K14 ubiquitination is involved in C9orf72 





Figure 5.5 Mutation of lysine 14 extends the half-life of C9orf72L. HEK293 cells 
were transfected with Myc-C9orf72L or Myc-C9orf72L K14R. 24 h post 
transfection cells were treated with cycloheximide for the indicated times. After 
treatment cells were lysed and subjected to SDS-PAGE and immunoblot. Blots 
were probed for Myc-C9orf72L and GAPDH as a loading control. Decay curve 
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depicts mean relative levels of C9orf72L (red circles) and C9orf72 K14R (blue 
squares) at the indicated times of cycloheximide treatment. Bar chart depicts the 
comparison of the half-life of C9orf72L or C9orf72 K14R. (Mean±SEM; unpaired 
t-test, * p ≤ 0.05; N = 2 experiments). 
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5.2.4. C9orf72 interacts with USP8 
The Y2H screen conducted in Chapter 3 identified USP8 as a possible 
interaction partner of C9orf72S (Table 3.2). USP8, also known as Ubiquitin-
specific protease Y (UBPy), is a ubiquitin isopeptidase of the USP family of 
cysteine proteases and is particularly abundant in the brain and testis (Gnesutta 
et al., 2001; Naviglio et al., 1998). USP8 has been shown to interact with a 
number of proteins substrates including the Ras nucleotide exchange factor 
CDC25, TrkA and NRDP1, leading to their subsequent deubiquitination (Ceriani 
et al., 2015; Gnesutta et al., 2001; Wu et al., 2004). USP8 depletion in cells 
leads to increased global ubiquitination and enlargement of MVBs and 
endosomal structures. (Row et al., 2006). Thus USP8 may function to regulate 
the ubiquitination and stability of C9orf72. 
 
To confirm the interaction between C9orf72 and USP8, co-immunoprecipitation 
experiments were conducted. HEK293 cells were co-transfected with EGFP or 
EGFP-USP8 and either empty vector, Myc-C9orf72S or Myc-C9orf72L. C9orf72 
was isolated using anti-Myc antibodies and immune pellets analyzed by SDS-
PAGE and immunoblot. C9orf72 was specifically enriched in the 
immunoprecipitated samples. EGFP did not co-immunoprecipitate with either 
C9orf72 isoform, while EGFP-tagged USP8 specifically co-immunoprecipitated 






Figure 5.6 C9orf72 interacts with USP8. Whole cell lysates of HEK293 cells co-
transfected with empty vector, Myc-C9orf72S or Myc-C9orf72L and either EGFP 
or EGFP-USP8 were subjected to immunoprecipitation with rabbit anti-Myc 9106 
antibodies. Immune pellets were probed for Myc-C9orf72 with mouse anti-Myc 
9B11 antibodies and EGFP and EGFP-USP8 using mouse JL8 anti-GFP 
antibodies on immunoblot. Blots were initially cut at approximately 75 – 100 
kDa. The top section was probed with mouse JL8 mouse anti-GFP antibodies 
(top panel) and the lower section probed with 9B11 mouse anti-Myc antibodies 
(middle panel). This lower section was then re-probed with JL8 mouse anti-JL8 
antibodies to detect GFP control (bottom panel). The * indicates the Myc-




5.2.5. USP8 extends the half-life of C9orf72L 
To investigate whether USP8 regulates the stability of C9orf72 by 
deubiquitination, the half-life of C9orf72 was investigated in cells overexpressing 
USP8 using CHX chase assays. 
 
HEK293 cells were co-transfected with Myc-C9orf72L or Myc-C9orf72S and 
either EGFP or EGFP-USP8. 24 h post transfection protein translation was 
inhibited with CHX and the levels of C9orf72 measured over time on 
immunoblots. USP8 overexpression caused an increase in C9orf72S and 
C9orf72L protein levels at time 0, indicating that USP8 can stabilize and 
increase C9orf72 protein levels (Fig. 5.7 and 5.8). This was confirmed in the 
half-life analysis.  
 
The half-life of C9orf72L co-transfected with only the EGFP control was 
calculated as 2.82 h ± 0.1 h (mean ± SEM) (Fig 5.7), similar to the half-life 
calculated in Fig. 5.1 and 5.5. USP8 overexpression significantly increased the 
half-life of C9orf72L to 5.87 h ± 0.64 h (mean ± SEM) (Fig. 5.7) suggesting that 
USP8 is able to stabilize C9orf72L possibly by deubiquitinating C9orf72L and 
preventing its degradation by the proteasome. The half-life of C9orf72S co-
transfected with EGFP control was more than double that seen in cells 
transfected with only Myc-C9orf72S (2.86 h v 1.12 h; see Fig. 5.1B and C). 
Nevertheless, as was the case for C9orf72L, USP8 overexpression significantly 
increased the half-life of C9orf72S from 2.86 h ± 0.05 (mean ± SEM) to 3.45 h ± 
0.22 h (mean ± SEM) (Fig. 5.8). 
  





Figure 5.7 USP8 extends the half-life of C9orf72L. HEK293 cells were co-
transfected with Myc-C9orf72L and either EGFP or EGFP-USP8. 24 h post 
transfection cells were treated with cycloheximide (CHX) for the indicated times. 
After treatments cells were lysed and subjected to SDS-PAGE and immunoblot. 
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Blots were probed for Myc-C9orf72L, EGFP, EGFP-USP8 and GAPDH as a 
loading control. Decay curve depicts ln of relative percentages of Myc-C9orf72L 
(red circles) or Myc-C9orf72L in the presence of USP8 (blue squares) at the 
indicated times of cycloheximide treatment. Bar chart depicts the comparison of 
the half-life of C9orf72L alone or in the presence of USP8 overexpression. 





Figure 5.8 USP8 extends the half-life of C9orf72S. HEK293 cells were co-
transfected with Myc-C9orf72S and either EGFP or EGFP-USP8. 24 h post 
transfection cells were treated with cycloheximide (CHX) for the indicated times. 
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After treatments cells were lysed and subjected to SDS-PAGE and immunoblot. 
Blots were probed for Myc-C9orf72S, EGFP, EGFP-USP8 and α-Tubulin as a 
loading control. Decay curve depicts ln of relative percentages of Myc-C9orf72S 
(red circles) or Myc-C9orf72S in the presence of USP8 (blue squares) at the 
indicated times of cycloheximide treatment. Bar chart depicts the comparison of 
the half-life of C9orf72S alone or in the presence of USP8 overexpression. 




This chapter has identified C9orf72 as a substrate of the proteasome and 
implicates K14 ubiquitination and the DUB USP8 as regulators of C9orf72 
turnover.  
 
The involvement of C9orf72 in autophagy initiation detailed in Chapter 4, 
therefore suggests that USP8, via its regulation of C9orf72, could also be 
involved in autophagy regulation. USP8 has previously been implicated in 
endocytic trafficking events, mediating the stability of the endosomal protein, 
hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) binding 
protein (Hbp), which is involved in growth factor receptor degradation via the 
endosome (Kato et al., 2000). USP8 appears to be localized to the endosomal 
compartment by the interaction of its N-terminal microtubule interacting and 
transport (MIT) domain with the CHMP family of proteins of the ESCRT 
machinery (Row et al., 2007). Endosomal enlargement resulting from USP8 
knockdown suggests loss of USP8 leads to disruption of endocytic trafficking 
events and degradation (Row et al., 2006). 
 
The catalytic activity of USP8 is regulated by Src-dependent phosphorylation 
(Meijer et al., 2013; Mizuno et al., 2007). The phosphorylation status of USP8 
also regulates the binding of 14-3-3 proteins, which negatively regulate the 
catalytic activity of USP8, potentially by changing the conformation of the USP8 
active site (Meijer et al., 2013; Mizuno et al., 2007). 14-3-3ζ has been shown to 
negatively regulate autophagy by binding the PI3K, Vps34 (Pozuelo-Rubio, 
2011). Upon autophagy initiation 14-3-3ζ dissociates from Vps34, allowing for 
progression of autophagy (Pozuelo-Rubio, 2011). Thus in a similar fashion, 
autophagy induction could also release 14-3-3 from USP8, leading to activation 
of USP8 and the deubiquitination of C9orf72. By preventing the turnover of 
C9orf72 and increasing C9orf72 protein levels, this may facilitate the ULK1-
Rab1a interaction and the induction of autophagy as described in Chapter 4. 
USP8 is further implicated in autophagy due to its interaction with Nbr1, a 
ubiquitin scaffold protein that functions in a similar way to p62 (Waters et al., 
2009).  
 
USP8 is also implicated in mitophagy by regulating Parkin ubiquitination; de-
ubiquitination of Parkin by USP8 allows for the correct recruitment of Parkin to 
 198 
dysfunctional mitochondria, thus mediating their clearance by the PINK1/Parkin 
pathway and mitophagy (Durcan et al., 2014). The data presented in this 
Chapter directly links C9orf72, which regulates the initiation of autophagy 
(Chapter 4) with a known regulator of mitophagy. As C9orf72 was shown to 
interact with the mitochondrial Cox6C protein (Chapter 3), it may be that 
C9orf72 delivers USP8 to mitochondria, via its interaction with Cox6C, to allow 
for the effective stabilisation of Parkin and efficient mitophagy. Thus in a positive 
feedback mechanism, USP8 could deubiquitinate and stabilise C9orf72, leading 
to an increase in C9orf72 levels, which allows for the increased recruitment of 
USP8 to the mitochondria via the interaction of C9orf72 and Cox6C. C9orf72 
could therefore be the regulator of USP8 delivery to the mitochondrial network. If 
the interaction of C9orf72 with Cox6C were promoted under conditions of 
mitochondrial depolarisation then C9orf72 would increase the delivery of USP8 
to depolarised mitochondria to increase the stabilisation of Parkin, and the 
induction of mitophagy.  
 
The ability for C9orf72 to function as the homologue of ATG11 (Chapter 4) is 
also relevant for the role of C9orf72 and USP8 in mitophagy. Upon the induction 
of mitophagy in yeast, ATG11 localises to the mitochondria, via its interaction 
with ATG32, and recruits the mitochondrial fission machinery to bring about 
isolation of the damaged organelles from the mitochondrial network (Mao et al., 
2013). Thus, if C9orf72 is able to function as ATG11, then C9orf72 may be 
involved in isolation of damaged mitochondria from the network via the 
interaction with Cox6C and the recruitment of USP8, and ultimately the ULK1 
initiation complex. 
 
The idea of stabilising C9orf72 or modulating C9orf72 levels is particularly 
interesting in terms of treatment for C9ALS/FTD. If indeed the autophagy defect 
associated with loss of C9orf72 described in this thesis is a contributing factor to 
disease, then modulating C9orf72 stability and half-life could be one method to 
increase C9orf72 protein levels. This Chapter shows that ubiquitination is 
important for the regulation of C9orf72. Consequently both E3 ligases and DUBs 
are candidates to help modulate C9orf72 protein levels. Increasing the activity of 
a DUB could prove to be more complicated than inhibiting the action of an E3 
ligase. Furthermore, as there are fewer DUBs relative to the E3 ligases, DUBs 
may be considered to be more promiscuous in terms of protein targets. 
Therefore, increasing DUB activity could have more detrimental off target effects 
 199 
that targeting an E3 ligase with a specific protein target. For example, while 
increasing the activity of USP8 in C9ALS/FTD patients may help to restore 
C9orf72 protein levels and the induction of autophagy, this could also promote 
an increase in mitophagy and the aberrant clearance of healthy mitochondria. 
Unfortunately, a candidate E3 ligase for C9orf72 was not identified during this 
thesis. Analysis of the C9orf72 sequence should be conducted to identify 
possible recognition motifs for the different E3 ligases that may be responsible 
for C9orf72 ubiquitination and clearance by the proteasome. 
 
Although the data presented in this Chapter indicate that C9orf72 is indeed 
ubiquitinated, further work would be required to confirm this. Co-
immunoprecipitation experiments between a tagged ubiquitin construct and 
C9orf72 would allow this. Alternatively mass spectrometry analysis of C9orf72 
immunoprecipitates would highlight all potential ubiquitination sites (Udeshi et 
al., 2013). These experiments would also indicate whether C9orf72 K14R is 
unable to be ubiquitinated as would be predicted. 
 
While cycloheximide is commonly used to investigate protein turnover, 
radioactive pulse chase assays may provide a more accurate estimate of half-
life (Simon and Kornitzer, 2014). The use of radioactive pulse chase allows the 
investigation of turnover without global disruptions to cellular protein translation 
caused by cycloheximide. The inhibition of translation by cycloheximide may 
also lead to an artificially extended half-life due to the fact that all protein 
translation is inhibited, including any relevant E3 ligases that may be 
responsible for ubiquitination of C9orf72. Furthermore regulatory feedback loops 
may prevent further protein degradation and maintain certain cellular pools of 







A hexanucleotide repeat expansion of GGGGCC in C9orf72 is the most 
common genetic defect associated with ALS and FTD. As detailed in section 
1.7, there are multiple possible mechanisms by which this expansion may cause 
disease, but it has been shown to correlate with reduced C9orf72 expression, 
suggesting C9orf72-associated ALS/FTD may be a result of C9orf72 
haploinsufficiency (Belzil et al., 2013; Cooper-Knock et al., 2012; DeJesus-
Hernandez et al., 2011). As reduced C9orf72 protein may therefore contribute to 
disease, it is important to determine the cellular function of C9orf72 to aid 
understanding of disease pathogenesis. 
 
The aim of this thesis was to discover the cellular function of C9orf72. As a 
method to indicate possible function, the interaction partners of C9orf72 were 
investigated. The p62 specific pathology associated with C9ALS/FTD indicated 
that C9orf72 might be involved in the autophagy pathway. Searches of the 
literature highlighted FIP200 as a potential binding partner of C9orf72, which led 
to the investigation of C9orf72 and the autophagy initiation complex. These data 
presented in Chapter 3 strongly linked C9orf72 to the autophagy pathway. 
Parallel to this, two unbiased approaches were conducted to identify novel 
interacting proteins: a mass spec screen conducted on immunoprecipitated 
C9orf72L and a Y2H screen conducted using C9orf72S and C9orf72L as bait. 
These different approaches were able to identify a number of novel C9orf72 
interacting partners, which were confirmed by co-immunoprecipitation studies. 
 
Chapter 4 investigated what effect altering C9orf72 protein levels could have on 
the autophagy pathway. Knock down of C9orf72 with targeted siRNA led to an 
inhibition of autophagy, specifically at the stage of induction (Figures 4.1 and 
4.2). These data fitted with the binding data obtained in Chapter 3, which 
showed C9orf72 was interacting with the autophagy initiation complex (Figures 
3.5-3.10). Further in depth analysis of the autophagy pathway showed that 
C9orf72 was important for translocation of the ULK1 complex, and that loss of 
C9orf72 inhibited translocation and thus the induction of autophagy (Figures 4.1, 
4.2, 4.5, and 4.7). Conversely, overexpression of C9orf72 was able to actively 
induce autophagy (Figures 4.3, 4.4 and 4.7). 
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This ability of C9orf72 to regulate autophagy induction via the ULK1 initiation 
complex was Rab1a dependent (Figure 4.8). Analysis of the interaction of 
C9orf72 with Rab1a identified C9orf72 as an effector of Rab1a biology, with 
C9orf72 mediating the interaction between active GTP-bound Rab1a and ULK1, 
thus facilitating the translocation of the initiation complex to the PAS to initiate 
autophagosome formation (Figures 4.9-4.11).  
 
The clinical relevance of this data linking loss of C9orf72 to reduced autophagy 
induction was investigated in C9ALS/FTD patient iNPC derived iNeurons, which 
showed reduced levels of basal autophagy compared to controls (Figure 4.14). 
Thus, these data were in support of the idea that haploinsufficiency of C9orf72 
may be a contributing factor to the development of C9ALS/FTD due to the 
decreased levels of autophagy. The data showing that knock down of C9orf72 
was also able to replicate the p62 aggregation seen in patients supported this 
idea (Figure 4.13). 
 
Thus increasing C9orf72 protein levels could be therapeutic. The aim of Chapter 
5 was to investigate the stability of the C9orf72 protein. The data presented here 
identified C9orf72 as a substrate of the ubiquitin proteasome system (Figure 5.2 
and 5.3). Analysis of the C9orf72 amino acid sequence highlighted lysine 
residue 14 as a potential ubiquitination site (Figure 5.4 and Table 5.1). Mutation 
of lysine 14 was able to increase the stability of C9orf72L, suggesting C9orf72 
was ubiquitinated at this residue (Figure 5.5). The Y2H data presented in 
Chapter 3 identified the DUB USP8 as a potential C9orf72S interacting protein. 
Here it was shown that USP8 was indeed an interacting partner of C9orf72S 
and C9orf72L and that USP8 was able to increase the stability of C9orf72, 
increasing the half-life of both C9orf72 isoforms (Figure 5.6, 5.7 and 5.8). 
 
6.2 Defective autophagy and ALS/FTD 
The data reported in this thesis places C9orf72 at the initiation stage of 
autophagy, showing that loss of C9orf72 leads to defective autophagy induction 
and the accumulation of p62 positive structures, similar to the pathology 
specifically associated with C9ALS/FTD (Al-Sarraj et al., 2011; Cooper-Knock et 
al., 2012). Several groups have reported reduced C9orf72 mRNA in C9ALS/FTD 
patients and reduced C9orf72 protein frontal cortex of C9ALS/FTD patients has 
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also been described (Waite et al., 2014). Consequently, the data presented in 
this thesis suggest haploinsufficiency of C9orf72 could result in the development 
of C9ALS/FTD in part due to the defect in autophagy initiation. This is 
summarised in figure 6.1.  
 
The model predicts that loss of function C9orf72 prevents the delivery of active 
GTP-Rab1a to the ULK1 initiation complex. Without active Rab1a the ULK1 
initiation complex then fails to translocate to the site of autophagosome 
formation. Without functional autophagosomes, autophagy receptors cannot 
target their ubiquitinated substrates, thus leading to their accumulation, which 
may be toxic to the cell. Thus this thesis has identified the molecular mechanism 
by which reduced C9orf72 leads to defective autophagy and potentially the 





Figure 6.1 The role of C9orf72 in autophagy initiation. (A) Under normal 
conditions, C9orf72 binds to the autophagy initiation complex (1). The Rab1a 
protein is activated by the action of an unknown GEF, forming GTP-Rab1a (2). 
Via its interaction with Rab1a and ULK1, C9orf72 mediates the interaction 
between these two proteins allowing for translocation of the autophagy initiation 
complex to the phagophore. C9orf72 may also bind the Rab1a GEF to maintain 
active GTP-Rab1a at its site of action (3). Once at the phagophore the initiation 
complex promotes the further downstream signalling events leading to formation 
and elongation of the autophagosome. During this time, substrates are delivered 
to the autophagosome by the action of autophagy receptor proteins such as p62 
and OPTN (4). Autophagosomes may then be translocated before fusing with 
the lysosome (5). Finally, the acid hydrolases degrade the contents of the 
autolysosome (6). (B) In C9ALS/FTD, haploinsufficiency of C9orf72 may result 
in reduced C9orf72 protein (7). Without C9orf72 at the ULK1 complex, active 
GTP-Rab1a cannot be recruited to the initiation complex (8). Without the Rab1a-
ULK1 interaction the initiation complex cannot translocate to the phagophore 
and so autophagosome formation decreases (9). Without the formation of the 
autophagosomes, the autophagic substrates accumulate, as they cannot be 
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cleared. This leads to further aggregates and accumulations possibly leading to 
cellular toxicity and cell death (10). 
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As discussed in Chapter 1, Rab proteins play a number of vital roles in 
autophagy induction. The interaction between Rab1a and C9orf72 identifies 
C9orf72 as the second Rab associated protein linked to the development of 
ALS. Alsin (ALS2) is a Rab5 GEF (Topp et al., 2004), with loss of function 
mutations known to cause juvenile onset ALS (Hadano et al., 2001a; Hadano et 
al., 2001b). While Rab1a appears to regulate translocation of the ULK1 initiation 
complex, Rab5 acts via the Vps34-Atg6/Beclin 1 complex to regulate 
autophagosome formation (Ravikumar et al., 2008), suggesting both C9orf72 
and Alsin regulate trafficking events in the autophagy pathway. Loss of function 
mutations in Alsin therefore result in the inactivation of Rab5 and the inhibition of 
autophagosome formation leading to the development of ALS. Indeed, loss of 
Alsin has been shown to exacerbate motor dysfunction in a SOD1 mouse model 
of ALS, possibly due to the accumulation of autophagic substrates (Hadano et 
al., 2010). Thus regulation of autophagy and particularly Rab biology may be a 
common contributing factor to the development of ALS. 
 
The neuronal cytoplasmic inclusions of ubiquitin and hyperphosphorylated TDP-
43 are hallmarks of ALS and FTD (Arai et al., 2006; Neumann et al., 2006). 
These inclusions are also suggestive of defective autophagy as ubiquitinated 
protein aggregates are readily cleared via autophagy (Filimonenko et al., 2010; 
Pankiv et al., 2007). There is also further evidence linking this hallmark of 
disease to autophagy. Firstly, TDP-43 has been shown to be a substrate of 
autophagy, with autophagy induction enhancing the clearance of mutant TDP-43 
and increasing cell survival in ALS neuronal models (Barmada et al., 2014). 
Secondly, TDP-43 aggregate formation may involve p62 as well as HDAC6, 
both of which are considered receptors for autophagy substrates (Brady et al., 
2011; Cohen et al., 2015). Furthermore, TDP-43 has been shown to regulate 
expression of HDAC6, with loss of functional TDP-43 down regulating HDAC6 
expression (Fiesel et al., 2010). Mutant TDP-43 may therefore establish a toxic 
feed forward mechanism whereby aggregates of mutant TDP-43, lead to loss of 
functional TDP-43 subsequently downregulating HDAC6 expression and 
therefore disrupting its own autophagic clearance. 
 
Impaired and defective autophagy has also been implicated in other cases of 
non-C9orf72 ALS and FTD, as discussed in section 1.6. The study of familial 
inherited forms of ALS and FTD indicates many of the disease associated gene 
products are involved in the autophagy process. Figure 6.2, which includes the 
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effects of C9orf72 haploinsufficiency, highlights the steps of autophagy that are 
affected. For example, optineurin, p62 and Tbk1, all of which are mutated in 
certain cases of FALS and FTD (Freischmidt et al., 2015; Ito et al., 2011; Rubino 
et al., 2012; Teyssou et al., 2013), are all involved in autophagy substrate 
recognition and delivery to the autophagosome (Matsumoto et al., 2015; Pankiv 
et al., 2007; Pilli et al., 2012; Wong and Holzbaur, 2014). These disease-
associated mutations, which lead to loss of functional protein, result in reduced 
substrate delivery to autophagosomes, increased aggregate formation and the 
development of disease (Freischmidt et al., 2015; Ito et al., 2011; Rubino et al., 
2012; Teyssou et al., 2013; Wong and Holzbaur, 2014). Interestingly, patients 
harbouring both C9orf72 repeat expansions and p62 mutations have recently 
been described, possibly suggesting that the two mutations act synergistically to 
affect disease pathogenesis (Almeida et al., 2015).  
 
Furthermore, several ALS/FTD related genes are linked to autophagosome 
maturation. For example, mutations to Ubiquilin-2 cause a subset of ALS and 
FTD cases (Deng et al., 2011; Osaka et al., 2015). Ubiquilin-2 is thought to 
function in autophagosome maturation due to its ability of co-localising with p62, 
optineurin and ULK1 positive vesicles (N'Diaye et al., 2009b; Osaka et al., 2015; 
Rothenberg et al., 2010). Mutant Ubiquilin-2 disrupts the localisation of 
optineurin; again suggesting a synergistic effect between these two ALS/FTD 
associated mutations (Osaka et al., 2015). Loss of VCP leads to accumulation 
of p62, ubiquitin and LC3-II positive structures (Ju et al., 2009; Tresse et al., 
2010), suggesting that the accumulation and aggregate formation seen in VCP 
F155H ALS and Paget’s disease of bone and FTD (Johnson et al., 2010; Ju et 
al., 2009) is due to accumulations of immature autophagosome structures. 
Similarly, loss of FIG4 leads to accumulations of p62 and LC3-II in FIG4-/- mice 
(Chow et al., 2007). Loss of function mutations in FIG4 account for 
approximately 1-2% of FALS cases, supporting the idea that loss of 
autophagosome maturation or clearance is a contributing factor to the 
development of ALS. 
 
The discovery of TMEM106B as a known modifier of C9ALS/FTD supports the 
idea that C9orf72 regulates autophagy initiation (Gallagher et al., 2014; Van 
Blitterswijk et al., 2014). TMEM106B is a transmembrane protein that localises 
to the endo-lysosomal compartment and has been implicated in lysosomal 
biology (Brady et al., 2013; Stagi et al., 2014). How TMEM106B modifies 
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C9ALS/FTD is unknown, but the identification of a known lysosomal protein as a 
modifier of C9ALS/FTD suggests that lysosomal biology, and therefore 
autophagy, are potential pathways at play, supporting the outcome of this thesis. 
Single nucleotide polymorphisms within TMEM106B appear to regulate 
expression and turnover of this protein (Nicholson et al., 2013). There is 
conflicting evidence for the effect of TMEM106B levels on lysosomal function. 
On one hand overexpression of TMEM106B has been reported to disrupt 
lysosomal function (Brady et al., 2013), while on the other, increased levels are 
reported to improve lysosomal function and stress signalling (Stagi et al., 2014). 
Thus as a modifier of C9ALS/FTD the levels of TMEM106B may contribute to an 
autophagy related defect associated with reduced C9orf72 and therefore 





Figure 6.2 Impact of ALS associated genes on the autophagy pathway. As 
described above, loss of C9orf72 prevents correct translocation of the initiation 
complex, inhibiting autophagy induction. Mutation to the autophagy receptor 
proteins such as p62, OPTN, and their activator Tbk1, may lead to reduced 
substrate delivery to the autophagosome resulting in increased aggregate 
formation. Mutations to Fig4, VCP and Alsin are all likely to disrupt formation of 
the lysosome leading to a failure to clear autophagic substrates. ALS associated 
mutations to Dynactin or SOD1 may disrupt the retrograde transport of 
autophagosomes, a step known to be important for autophagosome lysosome 
fusion. A number of ALS genes are thought to impact on the autophagosome 
lysosome fusion event. Spatacsin mutations may impact on lysosome 
biogenesis thus disrupting lysosome fusion, while the mutation to CHMP2B may 
affect maturation of the autophagosomes and the final fusion with the lysosome. 
TMEM106B is a genetic modifier of C9ALS/FTD and is involved in lysosomal 
biology. Mutations or SNPs within TMEM may negatively impact lysosomal 
biology thus exacerbating C9ALS/FTD. 
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It is well established that loss of neuronal autophagy can result in neuronal 
degeneration. The neural specific knockout of essential autophagy genes in 
mice, such as ATG7, ATG5 and Rb1cc1 (FIP200), leads to neuronal 
degeneration, progressive motor defects, such as reduced coordinated 
movement, and increased neuronal cytoplasmic inclusion body formation (Hara 
et al., 2006; Komatsu et al., 2006; Liang et al., 2010). Interestingly, the 
cerebellum appears to be particularly susceptible to loss of autophagy in these 
models, suggesting a high autophagic demand (Komatsu et al., 2006; Liang et 
al., 2010). The specific p62 positive, TDP-43 negative, structures characteristic 
of C9ALS/FTD are also largely associated with the cerebellum and 
hippocampus (Al-Sarraj et al., 2011; Cooper-Knock et al., 2012; Mahoney et al., 
2012). These p62 positive accumulations in the cerebellum are also seen with 
neuron specific knockout of FIP200 (Liang et al., 2010). Such a bono fide defect 
in neuronal autophagy giving rise to a similar pathology to that of C9ALS/FTD 
supports the idea that defective autophagy is factor in the development of 
C9ALS/FTD. 
 
In the only reported C9orf72 knockout mouse model, developed by Koppers et 
al. 2015, neuronal specific ablation of C9orf72 did not lead to motor neuron 
degeneration (Koppers et al., 2015), suggesting that, unlike ATG7, ATG5 or 
FIP200, C9orf72 is not essential for neuronal autophagy in mice. While there 
may be redundancy of the C9orf72 gene in mice, C9orf72 may be involved at a 
more specific level of autophagy initiation. Dysregulated innate immunity and 
inflammation have been implicated in the pathogenesis of ALS (Goldknopf et al., 
2006; Zhang et al., 2009). Whether defective or prolonged inflammation is found 
in these C9orf72 knockout mice is yet to be established, but ULK1 activation has 
been shown to reduce the inflammatory response, preventing sustained, 
aberrant inflammation (Konno et al., 2013a). Indeed, suppression of autophagy 
has been shown to increase the inflammatory response (Yoshizaki et al., 2012). 
In support of this, SNPs that increase ATG16L1 turnover and degradation are 
strongly linked to Crohn’s disease, a type of inflammatory bowl disease (Murthy 
et al., 2014). Thus, one could speculate that without functional C9orf72, the 
correct action of ULK1 may be perturbed, leading to prolonged and harmful 
inflammation. Autophagy defects or neuronal p62 accumulations have not been 
investigated in these C9orf72 knockout mice. However, C9orf72 knockout did 
result in reduced body weight, a feature that is also found in the ATG7-/- mice 
(Komatsu et al., 2006). Knock-out of ATG7 in hypothalamic agouti-related 
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peptide neurons also leads to significantly reduced body weight (Kaushik et al., 
2011). This suggests that reduced body weight in these C9orf72 neural specific 
knockout mice could be related to defective autophagy.  
 
Aside from C9orf72 haploinsufficiency there are two other possible mechanisms 
of disease associated with C9ALS/FTD: toxic RNA foci formation and aberrant 
DPR protein production. The production of aggregating DPR proteins from the 
repeat expansion has been shown to be toxic in a number of models. The 
arginine containing DPR proteins, poly-GR and poly-PR, are particularly toxic 
when overexpressed in a Drosophila model (Mizielinska et al., 2014), while the 
poly-GA species are toxic to primary cortical neurons (May et al., 2014). These 
DPR protein species are also a component of the p62 positive inclusions in 
C9ALS/FTD patients (Mann et al., 2013), suggesting that, similar to p62, their 
accumulation is could be due to defective autophagic clearance. If DPR proteins 
are considered substrates of the autophagy pathway this could put a greater 
burden on the autophagy system. There is therefore the potential for a 
synergistic effect between the production of DPRs and haploinsufficiency of 
C9orf72. This hypothesis is outlined in figure 6.2. With an already defective 
autophagy pathway, caused by C9orf72 haploinsufficiency, increased 
autophagic substrate production would exacerbate the problem. Inflicting further 
pressure on the autophagy pathway would promoting further aggregate 
formation and ultimately lead to cellular toxicity and possibly cell death. In this 
case the DPR proteins and haploinsufficiency of C9orf72 could function in a two 
hit scenario, where individually they may not have the potential to cause 
disease, but together their effects are cumulative, leading to the development of 
C9ALS/FTD. 
 
A number of mouse models have been developed to investigate the effect of the 
C9orf72 hexanucleotide repeat expansion (Chew et al., 2015; Hukema et al., 
2014; O'Rourke et al., 2015; Peters et al., 2015). These models are able to 
replicate the RNA nuclear inclusions, TDP-43 positive inclusions, ubiquitinated 
aggregates, DPR proteins aggregation (Chew et al., 2015; Hukema et al., 2014; 
O'Rourke et al., 2015; Peters et al., 2015) and in some cases cortical neuronal 
loss (Chew et al., 2015). However, there are no reports of motor neuron loss, 
muscle wasting, paralysis or other classical ALS phenotypes (Chew et al., 2015; 
Hukema et al., 2014; O'Rourke et al., 2015; Peters et al., 2015). Crucially these 
models do not report the presence of specific p62 positive, TDP-43 negative, 
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inclusions in the cerebellum and hippocampus, the phenotype most strongly 
linked to C9ALS/FTD. While these models mimic many features of C9ALS/FTD, 
it also suggests that the repeat expansion alone does not completely replicate 
the C9ALS/FTD pathology or phenotype. It would be predicted that, due to the 
function of C9orf72 outlined in this thesis, the knockout model of C9orf72 is the 
most likely to develop the p62 pathology, as well as other autophagy related 
defects. It would be interesting to determine which phenotypes are specifically 
associated with haploinsufficiency, DPR protein production or RNA foci 
formation. One would predict that a model that is able to reproduce all three 
mechanisms would more fully replicate C9ALS/FTD. 
 
As the C9orf72 repeat expansion is the most common genetic cause of ALS and 
FTD, this, along with the evidence from other ALS associated mutations, 
therefore supports the idea that defective autophagy is a common and important 
pathogenic mechanism associated with the development of ALS and FTD.  
6.3 Consequences for the treatment of ALS/FTD 
The range of evidence for the three mechanisms associated with C9orf72 ALS 
suggests the three are likely to be non mutually exclusive. However, having 
identified the cellular function of the C9orf72 protein, it is important to recognise 
that if haploinsufficiency is a mechanism of disease then mediating C9orf72 
levels, or modulating the autophagy pathway, has the potential to be a 
therapeutic target in the treatment of C9orf72 ALS/FTD. Autophagy treatments 
have already been suggested to be beneficial in the treatment of ALS (Barmada 
et al., 2014; Castillo et al., 2013). However, simply inducing autophagy in 
C9ALS/FTD may not be beneficial due to the role of C9orf72 at autophagy 
initiation. On the other hand, treatments that could enhance autophagy via a 
different route would certainly be an attractive possible therapy for C9ALS/FTD, 
as would the modulation of endogenous C9orf72 protein levels. As described in 
Chapter 5, C9orf72 is a substrate of the UPS with USP8 possibly functioning as 
the deubiquitinating enzyme responsible for stabilising C9orf72. Therefore 
targeting proteins such as USP8 could act as a therapeutic target to increase 
C9orf72 protein levels and ameliorate disease. Alternatively, determining the E3 
ubiquitin ligase responsible for C9orf72 ubiquitination, possibly at lysine 14, 
could also provide a method of regulating C9orf72 levels. Identification of a 
small molecule inhibitor of an E3 ligase is possibly a more realistic target 
compared to finding an activator of a DUB, as E3 inhibitors are already in clinical 
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trials for the treatment of some cancers (Patel and Player, 2008). By inhibiting 
the action of the E3 ligase, endogenous levels of C9orf72 would be increased; 
potentially ameliorating the problems associated with decreased C9orf72 protein 
levels. Targeting the E3 ligase may prove a more attractive target due to the 
specificity of E3 ligases to their substrate compared to that of the DUBs. 
 
As discussed in section 6.2, variants of TMEM106B are known modifiers of 
FTLD and C9ALS/FTD (Gallagher et al., 2014; Van Blitterswijk et al., 2014; 
Vass et al., 2011). Understanding how these variants modulate risk of C9orf72 
may provide potential targets for the treatment of C9ALS/FTD and FTLD. 
Identification of other genetic modifiers of C9ALS/FTD could be investigated in a 
similar fashion. 
6.4 C9orf72 as an effector of Rab biology 
Secondary structural analysis has revealed C9orf72 to have structural homology 
with the DENN domain family of proteins, which are GEFs for the Rab GTPases 
(Levine et al., 2013; Zhang et al., 2012). In line with this evidence C9orf72 was 
shown to co-localise with a number of Rab proteins (Farg et al., 2014). In this 
thesis, C9orf72 was shown to directly interact with Rab1a, consistent with the 
idea that C9orf72, as a DENN domain protein, could be a GEF for the Rab 
GTPases. However, in vitro binding assays conducted in Chapter 4 revealed 
that C9orf72 had a higher affinity for the active GTP-bound Rab1a (Fig. 4.10), a 
concept more in line with a Rab effector protein (Grosshans et al., 2006). Rab 
effector proteins preferentially bind GTP-bound Rabs and target them to their 
site of action (Grosshans et al., 2006). In some cases, these effectors are also 
capable of binding the GEF associated with the Rab, meaning the active Rab is 
targeted to its correct site of action by the effector and also kept active by the 
presence of the GEF (Horiuchi et al., 1997; Korobko et al., 2005; Lipatova et al., 
2012). This scenario of a Rab module comprising of a GEF, and effector and a 





Figure 6.3 The Rab module. 1) The Rab GTPases cycle from an inactive GDP 
bound state to an active GTP-bound state. The exchange of GDP for GTP is 
mediated by the guanine nucleotide exchange factors (GEFs). The intrinsic 
GTPase activity of the Rabs can be enhance by GTPase activating proteins 
(GAPs) promoting the hydrolysis of GTP to GDP, thus inactivating the Rab 
GTPase. 2) Rab effectors bind active GTP-Rabs to bring them to their site of 
action. Rab effectors are also capable of binding the GEF responsible for Rab 
activation, meaning the active Rab is brought to its site of action and maintained 
in an active state by the presence of the GEF. This Rab module therefore 
comprises a GEF, an effector and a Rab GTPase. 3) The active Rab module is 
targeted to its site of action, (a cellular compartment, a membrane or a complex) 
via the interaction of the effector. Localisation of the correct Rab and the correct 
site leads to downstream effects and pathway activation. 4) Without an effector 
protein the Rab module is not established. 5) The active Rab cannot be targeted 




The yeast Rab1a homologue, Ypt1, regulates the translocation of the ULK1 
homologue, ATG1, to the PAS, allowing for autophagosome formation (Lipatova 
et al., 2012; Wang et al., 2013). Data presented in Chapter 4 showed Rab1a 
has a similar role in mammalian cells, as Rab1a was required for translocation 
of the ULK1 initiation complex upon autophagy induction (Figure 4.8). C9orf72 
was shown to mediate the interaction between Rab1a and ULK1 (Figure 4.11). 
Thus by binding active, GTP-bound Rab1a, C9orf72 is able to mediate the 
further downstream interaction with ULK1, therefore leading to translocation of 
the autophagy initiation complex and the induction of autophagy. The interaction 
between GTP-loaded Ypt1 and ATG1 in yeast is mediated by the ATG11 
protein; however, in mammalian systems there is no known homologue of 
ATG11 (Lipatova et al., 2012). The data presented here show that, much like 
ATG11, C9orf72 is required for the interaction of ULK1 and Rab1a, by binding 
GTP-loaded Rab1a and ULK1. These data suggest C9orf72 may be functioning 
as the mammalian homologue of ATG11. ATG11 is thought to interact with 
Ypt1, as well as the Ypt1 GEF complex and Ypt1 activator, TRAPPIII, on ATG9 
positive membranes, mediating the interaction of this complex with ATG1 
(Lipatova et al., 2012). This module is then targeted to the PAS either by the 
interaction of ATG11 with ATG17, the yeast homologue of FIP200, or by the 
interaction of TRAPPIII subunit, Trs85, with ATG17 (Lipatova et al., 2012; 
Lynch-Day et al., 2010; Wang et al., 2013). The delivery of this complex to the 
PAS brings about the interaction of ATG1 and ATG17, Ypt1 with ATG1, as well 
as delivery of ATG9 positive membranes to the PAS, all of which are essential 
for the formation of the autophagosome (Kakuta et al., 2012; Lipatova et al., 
2012; Lynch-Day et al., 2010; Wang et al., 2013). Again similarly to yeast 
ATG11, the data presented here show that C9orf72 is also able to bind FIP200, 
supporting the idea that C9orf72 may be functioning as the mammalian 
homologue of ATG11, by binding GTP-loaded Rab1a and bringing it into contact 
with the ULK1 initiation complex. This is detailed in Figure 6.1. By binding the 
initiation complex as well as the GTP-bound Rab1a, C9orf72 mediates the 
interaction between active Rab1a and ULK1. This allows the correct 
translocation of the autophagy initiation complex to the phagophore, and thus 
the formation of the autophagosome. Loss of C9orf72 prevents active GTP-
bound Rab1a from binding ULK1, therefore preventing the translocation of the 
initiation complex and preventing the formation of the autophagosome. By 
preventing autophagosome formation, autophagy is effectively inhibited. 
Autophagy receptor proteins such as p62 still bind their associated substrates, 
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but the lack of newly formed autophagosomes prevents their clearance. This in 
turn leads to the accumulation of ubiquitin and p62 positive aggregates. 
 
TRAPPC8 has been identified as the mammalian homologue of Trs85 (Choi et 
al., 2011; Zong et al., 2011), the subunit that targets the TRAPPIII GEF complex 
to Ypt1 in yeast (Lipatova et al., 2012; Lynch-Day et al., 2010). While TRAPPC8 
has been shown to be important for autophagy induction (Behrends et al., 
2010), no direct TRAPPIII GEF complex able to active Rab1a in mammalian 
cells has been identified (Huang et al., 2011). In yeast, Trs85 is able to bind 
Ypt1 as well ATG17 at the PAS, but also co-localises with ATG11 (Lipatova et 
al., 2012; Lynch-Day et al., 2010; Wang et al., 2013). If C9orf72 were taken to 
function in a similar way to ATG11, then one would expect a GEF protein to 
interact with C9orf72, FIP200 as well as Rab1a, which would be responsible for 
the activation of Rab1a. The same study that identified C9orf72 as a possible 
FIP200 interacting protein also found SMCR8 to be the most likely interactor of 
FIP200 (Behrends et al., 2010). Interestingly, SMCR8 was then further identified 
as a novel DENN domain protein in the same study that identified C9orf72 as a 
potential DENN protein (Zhang et al., 2012). A mass spec screen conducted by 
Dr Mathew Walsh within the department suggested SMCR8 was also a binding 
partner of C9orf72L (Figure 3.11 and table 3.1). Having confirmed the C9orf72 
and SMCR8 interaction by co-immunoprecipitation experiments (Figure 3.12), it 
is not inconceivable to imagine that through its interaction with C9orf72 and its 
likely interaction with FIP200, SMCR8 could function as a GEF for Rab1a, in a 
similar method to TRAPPIII in yeast. Future work would seek to address this. 
Thus in an arrangement similar to that seen in yeast, C9orf72 may function in a 
Rab1a module, with C9orf72 as the effector, Rab1a as the GTPase and SMCR8 
as the GEF, regulating the initiation stages of autophagy. 
 
This module type arrangement of a GEF, an effector and a Rab GTPase is 
commonly seen with Rab biology. For example, the Rab5 GEF Rabex5 is in 
complex with Rab5 and the Rab5 effector, Rabaptin5, meaning active Rab5 is 
brought to its site of action by the effector and maintained in an active state by 
the GEF, ensuring efficient endosomal trafficking (Horiuchi et al., 1997). In 
yeast, transport of secretory vesicles required for exocytosis requires the Rab 
GTPase Sec4p, which associates with its effector Sec15p and its exchange 
factor Sec2p to ensure correct and efficient activity during exocytosis (Medkova 
et al., 2006). 
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With the exception of Cox6C, C9orf72 appears to interact with all identified 
binding partners through its N-terminal domain, shown in Chapter 1 to 
correspond to the u-DENN region of the full DENN domain (Figure 1.8). The u-
DENN region of DENN domain proteins appears to be important in GEF 
cascade pathways, as it may mediate the interaction between other Rab 
proteins without necessarily facilitating GDP/GTP exchange. In the case of the 
Rab6 GEF, Rab6IP1, the u-DENN domain of Rab6IP1 is likely the region 
required for Rab11 binding (Miserey-Lenkei et al., 2007). By interacting with 
GTP-bound Rab11 as well as acting as a GEF for Rab6, Rab6IP1 can mediate 
the interaction between the late endosomes and the Golgi (Marat et al., 2011; 
Miserey-Lenkei et al., 2007). Another example of the uDENN region involved in 
Rab binding and GEF cascade formation is the Rab3 GEF, DENN/MADD. The 
u-DENN region of DENN/MADD, also known as Rab3-GEP, interacts with GTP-
bound Rab3, which is found on synaptic vesicles, potentially to mediate motor 
dependent transport of Rab3 positive vesicles (Marat et al., 2011; Niwa et al., 
2008). In terms of the cascade, DENN/MADD then acts as a functional GEF for 
the Rab27 (Figueiredo et al., 2008; Yoshimura et al., 2010), which, similar to 
Rab3, is involved in exocytosis. The requisite for a DENN protein to function in a 
GEF cascade appears to be the ability to bind an active GTP-bound Rab, 
effectively functioning as an effector protein, before coming into contact with its 
actual Rab target. This situation has obvious similarities with the action of 
C9orf72 described here. By binding GTP-Rab1a and mediating the interaction 
with the ULK1 initiation complex, perhaps C9orf72 is able to function as a GEF 
for another autophagy related Rab, such as Rab5 or Rab7 (Ao et al., 2014; 
Blümer et al., 2013; Ravikumar et al., 2008; Su et al., 2011). It would be of 
interest to dissect the pathway further and identify the possible Rab requiring 
C9orf72 for activation. Thus, via its u-DENN region, C9orf72 could be 
functioning in a GEF cascade involving Rab1a.  
6.5 C9orf72 and mitophagy 
Mitochondrial quality control and removal of dysfunctional mitochondria is 
essential to maintain a healthy mitochondrial network (Poole et al., 2008; 
Whitworth and Pallanck, 2009). The mitochondrial localised serine/threonine 
kinase PTEN-induced kinase 1 (PINK1) and the E3 ubiquitin ligase Parkin are 
the main regulators of mitophagy. USP8 been identified as a de-ubiquitinating 
enzyme for Parkin, mediating removal of K6-linked ubiquitin and promoting 
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Parkin recruitment to depolarised mitochondria (Durcan et al., 2014). The 
interaction of C9orf72 with USP8, detailed in Chapter 5, and its proposed role in 
autophagy induction, therefore links C9orf72 to mitophagy. A potential role of 
C9orf72 in mitochondrial biology is further supported by its interaction with 
Cox6C, as identified in Chapter 3. Considering the evidence presented in 
Chapter 4, showing C9orf72 regulates the delivery of active Rab1a to the ULK1 
complex, C9orf72 could function as an adaptor protein in other cellular 
situations. Via its interaction with Cox6C, C9orf72 could aid in the delivery of 
USP8 to the mitochondria thereby enhancing the ability of USP8 to 
deubiquitinate Parkin and promote mitophagy of dysfunctional mitochondria. It 
could also be that C9orf72 binds Cox6C more readily after mitochondrial 
depolarisation allowing for enhanced recruitment of USP8 to damaged 
mitochondria and therefore more efficient mitophagy. The PINK1/Parkin 
pathway essentially functions to isolate dysfunctional mitochondria and therefore 
the autophagy machinery is still required for their removal. Thus, as C9orf72 
was shown to regulate translocation of the ULK1 initiation complex, C9orf72 
may be involved in the recruitment of the autophagy machinery to dysfunctional, 
isolated, mitochondria. The concept of C9orf72 functioning as the ATG11 
homologue discussed in section 6.4 supports this idea. ATG11 has been shown 
to have an important role in mitophagy (Mao et al., 2013), binding to the 
mitochondrial associated protein ATG32 and aiding in recruitment of the 
mitochondrial fission machinery and also the core autophagy proteins to the 
mitochondrial surface (Aoki et al., 2011; Kondo-Okamoto et al., 2012; Mao et al., 
2013). 
 
As with autophagy, Rab proteins are also involved in mitophagy. Rab7 and 
Rab32 have both been implicated in autophagosome formation and specifically 
mitophagy (Alto et al., 2002; Hirota and Tanaka, 2009; Yamano et al., 2014). 
Thus, via its DENN homology, C9orf72 may act as a GEF for these mitophagy 
related Rabs, promoting the clearance of dysfunctional mitochondria.  
 
Mitochondrial dysfunction in the pathogenesis of ALS is well documented (De 
Vos et al., 2007; Menzies et al., 2002). Beyond the predicted autophagy 
dysfunction described here, haploinsufficiency of C9orf72 could therefore, also 
promote mitochondrial dysfunction providing a further insult to neurons and 
potentially contributing to disease pathogenesis. 
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6.6 Future directions 
This thesis has identified the role of C9orf72 in autophagy. However, 
understanding this function of C9orf72 has also raised further questions and 
ideas that should be addressed. These are outlined in this section. 
 
Data presented in Chapter 5 suggested USP8 was a DUB enzyme for C9orf72. 
Future work should make use of co-immunoprecipitation experiments between 
C9orf72 and tagged ubiquitin, firstly to show that C9orf72 is ubiquitinated and 
that, secondly, USP8 is able to deubiquitinate C9orf72. Similar methods should 
be employed to investigate whether the K14 residue is indeed a ubiquitination 
site. Studies should also be undertaken to identify the E3 ligase responsible for 
C9orf72 ubiquitination. Many E3 ligases rely on consensus sequences within 
their target protein for binding. Analysis of the C9orf72 sequence may yield 
potential sites specific for certain E3 ligases. Potential E3 ligases would then be 
confirmed by interaction studies. Identification of the E3 ligase could then form 
part of the basis for investigating methods to modulate C9orf72 levels, with the 
idea of alleviating the problems caused by C9orf72 haploinsufficiency by 
inhibiting the E3 ligase responsible for C9orf72 degradation.  
 
The interaction of C9orf72 with USP8 also suggests a potential role in 
mitophagy, as discussed in section 6.5. As mitochondrial morphology defects 
and mitochondrial dysfunction is observed in ALS, future experiments should 
assess the effect alterations in C9orf72 protein levels can have on these 
aspects of mitochondrial biology. C9orf72 was also speculated to deliver USP8 
to dysfunctional mitochondria possibly via its interaction with Cox6C. Therefore 
the interaction of USP8 and Cox6C with C9orf72 should be investigated after 
depolarisation of the mitochondrial network to determine whether these 
interactions are promoted under such conditions and whether they are required 
for efficient mitochondrial clearance by mitophagy. 
 
Future work should seek to assess the subcellular localisation of C9orf72 in 
more detail. Fractionation experiments would help to determine if C9orf72 is 
present within the mitochondrial fraction supporting the idea that C9orf72 could 
be interacting with Cox6C within the mitochondrial environment. 
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The data obtained from the C9orf72 patient derived iNeurons in Chapter 4 
suggests a defect in basal autophagy. If reduced C9orf72 levels caused this 
defect then overexpression of C9orf72 could act as a rescue. Viral transduction 
of these iNeurons with C9orf72 construct would be one method of delivering a 
functional C9orf72 gene. Rescuing the autophagy defect by overexpression of 
C9orf72 would support the idea that modulating C9orf72 levels in patients would 
be an attractive therapy for the treatment of C9ALS/FTD. 
 
Further work would be required to confirm the existence of the C9orf72-Rab1a 
module. The yeast ATG11-Ypt1 module also comprises the GEF complex, 
TRAPPIII. It is speculated here that SMCR8 could function as the Rab1a GEF, 
mainly due to the predicted interaction with FIP200 (Behrends et al., 2010), a 
characteristic of the yeast module, but also its interaction with C9orf72. Future 
work should establish if SMCR8 has the ability to interact with Rab1a and also 
whether SMCR8 is able to promote GDP-GTP exchange on Rab1a. 
 
Identifying C9orf72 as part of the Rab1a module raises the possibility that 
C9orf72 is functioning as the mammalian homologue of ATG11. 
Complementation experiments in ATG11-/- yeast could help to identify C9orf72 
as the definitive homologue of ATG11. Expression of beclin-1 in the vps30 
mutant yeast can rescue the associated autophagy defect (Liang et al., 1999). It 
would be interesting to see whether expression of C9orf72 in ATG11-/- yeast 
would be sufficient to rescue the associated autophagy defects. 
 
The interaction of C9orf72 with GTP-bound Rab1a suggests C9orf72 is a Rab1a 
effector. However, C9orf72 could also function in a GEF cascade, activating 
another downstream autophagy related Rab. Future work should determine 
whether C9orf72 has the potential to act as a GEF for another Rab protein. GDP 
release assays could be conducted to determine this. Possible candidates 
would include known autophagy related Rabs such as Rab5, Rab7, Rab32 and 
Rab33B (Ao et al., 2014; Dou et al., 2013; Gutierrez et al., 2004; Hirota and 
Tanaka, 2009; Itoh et al., 2008; Jäger et al., 2004; Ravikumar et al., 2008). 
 
Rab1 is known to be Golgi associated (Jin et al., 1996; Pind SN, 1994). In Rab 
biology, the Rab GTPases are located within a specific membrane compartment 
by their specific prenylation motif (Gomes et al., 2003). In relation to Rab1a and 
C9orf72, this suggests that C9orf72 could be responsible for the delivery of 
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Rab1a, within its Golgi derived membranes, to the ULK1 initiation complex to 
bring about autophagosome formation. Golgi derived membranes have been 
suggested as the precursor to autophagosome membrane (Geng et al., 2010; 
Yen et al., 2010). In line with this, ATG9 positive membranes are required for 
autophagosome formation (Chan et al., 2009; Young et al., 2006) and ATG9 is 
located within the Golgi network (Winslow et al., 2010; Yen et al., 2010; Young 
et al., 2006). In this case, C9orf72 could be responsible for the delivery of Golgi 
membrane compartments required for the formation of the autophagosome. 
ATG11 appears to be responsible for this activity in yeast (He et al., 2006). To 
investigate whether C9orf72 is required for Golgi-derived membrane delivery to 
the autophagosome, the inclusion of Golgi related proteins in newly synthesised 
membranes could be investigated after C9orf72 targeted siRNA. The effect of 
C9orf72 siRNA on ATG9-positive membrane distribution should also be 
investigated, as Rab1a siRNA was shown to disrupt the localisation of ATG9 to 
LC3 positive vesicles (Winslow et al., 2010). 
 
Upon activation, ULK1 phosphorylate a number of targets, including its initiation 
complex partners FIP200 and ATG13, as well as further downstream targets 
such as Beclin-1 (Alers et al., 2011; Ganley et al., 2009; Jung et al., 2009; 
Russell et al., 2013). Recently, a consensus motif for the ULK1 phosphorylation 
site has been identified. ULK1 has a preference for serine residues surrounded 
by hydrophobic residues, particularly at the -3, +1 and +2 sites in relation to the 
serine target (Egan et al., 2015). This gives the general consensus motif as 
(L/M,X,X,S,Z,Z), where X appears to be any amino acid and Z is any aliphatic or 
hydrophobic amino acid, including methionine (Egan et al., 2015). Serine 189 
within C9orf72 appears to be a potential candidate as an ULK1 target site. The -
3 position is taken by leucine, while position +1 is taken by methionine, both of 
which fit the suggested consensus motif (Egan et al., 2015). Further to this, 
position -1 is taken by serine, which also appears beneficial to the ULK1 
recognition motif. This raises the possibility that, like the other ULK1 interacting 
proteins FIP200 and ATG13 (Alers et al., 2011; Jung et al., 2009), C9orf72 
could also be a target of activated ULK1 phosphorylation upon autophagy 
induction. Future work could utilise in vitro kinase assays to determine whether 
C9orf72 is a substrate of ULK1 and, if so, whether the serine 189 residue is 
particularly important for this phosphorylation. 
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Throughout this thesis experiments have been conducted on both the short and 
long isoforms of C9orf72. In many cases, both C9orf72S and C9orf72L were 
shown to bind the same protein partners, or indeed have the same effect. As 
C9orf72S essential lacks the majority of the DENN domain as well as the entire 
dDENN domain (See Fig 1.8), future work should investigate the differential 
actions of C9orf72S and C9orf72L, such as whether C9orf72S is a functional 
GEF as it lacks the C-terminal region. Other Rab GEF proteins are known to 
dimerize for efficient GEF activity, possibly via their longin  (uDENN) domains 
(Nordmann et al.). Thus, as C9orf72S contains the longin domain, it may have 
the potential to interact and dimerize with C9orf72L. This interaction should be 
investigated further. 
 
As described in Chapter 3, endogenous FIP200, ULK1 and ATG13 were found 
to co-immunoprecipitate with C9orf72. However, endogenous bands of FIP200, 
ULK1 and ATG13 of different molecular weights also co-immunoprecipitated. It 
was speculated that the bands of FIP200 and ULK1, could be phosphorylated 
species, in response to ULK1 activation. Thus the identities of these other 
species should be investigated, to confirm whether they are phosphorylate 
forms. Alternatively, these endogenous co-immunoprecipitation experiments 
could be conducted after Torin1 treatment of the cells to activate ULK1. The 
lower molecular weight band of ATG13 was speculated to be a splice variant. 
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